Podcasts about puretech

In this exclusive interview, Mohawk's Charles DiSano reveals how North Carolina manufacturing helps power the company's American made growth strategy. Discover why retailers are turning to Mohawk's tariff-free flooring solutions in PureTech, RevWood and Pergo Elements that deliver confidence in an uncertain market.

On a beaucoup parlé cette semaine des rappels dans le secteur automobile : Stellantis a rappelé en France 68.000 voitures produites entre 2022 et 2024 en raison d'un défaut sur des buses de refroidissement de jet d'huile de ses moteurs PureTech. Renault a également rappelé plus de 15.000 R5 électriques à propos d'une "potentielle impossibilité de démarrer". Ces rappels sont de plus en plus fréquents. L'un des plus retentissants reste le "Diesel gate" un véritable scandale industriel et sanitaire. De 2009 à 2015, le groupe Volkswagen a été accusé d'avoir réduit frauduleusement les émissions polluantes de certains modèles, lors des tests d'homologation...

Que se passe-t-il encore chez Stellantis ? Le constructeur automobile rappelle 68.000 voitures produites entre 2022 et 2024, cette fois en raison d'un défaut sur des buses de refroidissement de jet d'huile de ses moteurs PureTech. Ce rappel concerne des modèles compacts : 57.000 Citroën C3, 2.500 Peugeot 208 et 8.700 Opel Corsa équipés d'un moteur 1.2 PureTech de 82 chevaux. Écoutez les explications de Renaud Kayanakis, directeur associé chez SIA, expert du marché automobile. Ecoutez L'invité pour tout comprendre avec Yves Calvi du 25 février 2025.

Au programme ce samedi : PureTech, airbags Takata : que risque Stellantis ? Les usines de batteries asiatiques en Europe respectent-elles les règles ? Notre parc automobile vieillissant est-il en bon état ?

Esto es un extracto de la Tertulia de AutoFM que se emite cada jueves en Onda Cero. En este episodio de AutoFM, analizamos en detalle una importante medida de Stellantis: el lanzamiento de una plataforma de reclamaciones para los propietarios de vehículos equipados con los motores PureTech. Esta herramienta, puesta en marcha el pasado 16 de enero de 2025, permitirá gestionar reembolsos con carácter retroactivo para la reparación de averías relacionadas con estos motores, y ya está disponible en España y Francia, con planes de ampliación internacional. ¿Qué motores están afectados? 1.0 y 1.2 PureTech atmosféricos (2012-2022): Problemas con la correa de distribución. 1.2 PureTech turbo (2014-2018, primera generación): Consumo excesivo de aceite debido a fallos en los segmentos de los pistones. 1.2 PureTech turbo (2018-2023, segunda generación): Problemas de consumo de aceite por un fallo en el separador de aceite. ¿Cómo reclamar? La plataforma https://stellantis-support.com/ permite registrar reclamaciones por reparaciones realizadas entre el 1 de enero de 2022 y el 18 de marzo de 2024, siempre que se cumplan estos requisitos: El vehículo esté cubierto por una garantía ampliada de 10 años o 175.000 km. Las revisiones se hayan realizado según las recomendaciones del fabricante. Diagnósticos y reparaciones efectuados en talleres oficiales del grupo. Ampliación de garantías Desde marzo de 2024, Stellantis amplió la garantía para cubrir los costes al 100% en reparaciones relacionadas con el consumo anómalo de aceite y problemas de correa de distribución en generaciones previas de motores PureTech. ¿Cuál es el origen del problema? La raíz de las averías está en la rápida degradación del aceite que baña la correa de distribución en condiciones de conducción urbana, lo que provoca desgaste prematuro y fallos graves, como obstrucciones en los filtros de lubricación y la rotura del motor. Acciones legales Los afectados no han tardado en tomar medidas: más de 6.000 miembros de la Asociación de Afectados Stellantis (AFESTEL) han iniciado demandas colectivas. Solo en Vigo, ya se han admitido a trámite 15 de las 112 primeras demandas, que buscan indemnizaciones de más de 1,1 millones de euros. En este episodio, exploramos cómo esta situación está afectando a miles de conductores y qué implica para el futuro de Stellantis y sus motores PureTech. ¡No te lo pierdas! Todos los podcast: https://www.podcastmotor.es Twitter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ YouTube: https://www.youtube.com/@AutoFM Contacto: info@autofm.es

Stellantis et l'indemnisation des moteurs PureTech, les avantages de l'autoconsommation électrique… Rattrapez l'actualité économique du jour avec notre podcast 120 secondes. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

#trump #puretech #cocheelectrico Desde los estudios centrales de ONDACERO Madrid Sur te acercamos las últimas noticias del motor, pruebas de los últimos modelos que llegan al mercado, consejos y recomendaciones y seguridad vial. Nos puedes escuchar en directo en ONDACERO Madrid Sur y ONDACERO Jaén. Analizamos las siguientes noticias: • Adiós a las ayudas para la compra de coches eléctricos, el Gobierno no saca adelante la prórroga del Moves 3 • Conocemos la opinión de Raúl Morales , Director de Comunición de Faconauto por esta crisis que se avecina en la compra de vehículos electrificados. • Trump llega a la Casablanca y no le importa nada el automóvil eléctrico. • Confirmado: Stellantis se hará cargo de las reparaciones de los motores Puretech que hayan sufrido sus clientes desde 2022 • Buzón del Oyente: - Nuestro Oyente Rafa nos pide que le guiemos en la compra de un hibrido enchuable de hasta 55.000€. • Bombazo: LeapMotor se plantea fabricar un coche en la planta de Stellantis ubicada en Zaragoza • Seguridad Vial: •¿Qué ha pasado con una niña olvidada en un autobus escolar? • SEAT imparable en 2024; el Arona es el SUV urbano líder en España y la marca crece un 7,5% a nivel global • Nuevo MG Cyberster 2025: precios, gama, equipamientos y ofertas en España • Dunlop es vendida a Falken. • Salmoral Media y Dr. Gasari. Eventos del motor para marcas y para aficionados - III Ruta Solidaria by Gasari Drivers Club - Viaje a Marruecos con el Doctor Gasari El equipo de gala que ha acompañado en este programa ha sido: Fernando Rivas, José Lagunar, Mario de Loading Cars, David Navarro de Gasari Drivers Club e Ivan Mingo del periódico El Debate En la sección de TotalEnergies, conocemos más a fondo las últimas normativas de lubricación de Volvo Trucks y los fluidos recomendados para sus vehículos. Todos los podcast: https://www.podcastmotor.es Twitter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ YouTube: https://www.youtube.com/@AutoFM Contacto: info@autofm.es

In deze aflevering van Z 7 op 7:Stellantis – de autobouwer van onder meer Citroën en Peugeot – lanceert een online platform waar consumenten schade kunnen melden die ze hebben geleden met de PureTech-motor of de AdBlue-tank van hun wagen.Europa blijft openstaan voor wereldwijde samenwerkingen. Dat zei Europees Commissievoorzitter Von der Leyen tijdens haar toespraak op het Wereld Economisch Forum in Davos.Amerikaans president Trump voert vanaf 1 februari een invoerheffing van 25 procent in op producten uit Mexico en Canada. Opvallend is dat China en Europa vooralsnog worden ontzien. Z 7 op 7 is de nieuwe dagelijkse podcast van Kanaal Z en Trends. Elke ochtend, vanaf 5u30 uur luistert u voortaan naar een selectie van de meest opmerkelijke nieuwsverhalen, een frisse blik op de aandelenmarkten en een scherpe duiding bij de economische en politieke actualiteit door experts van Kanaal Z en Trends.Start voortaan elke dag met Z 7 op 7 en luister naar wat echt relevant is voor uw business, onderneming, carrière en geld.

Esto es un extracto de la tertulia de AUTOFM que se emite cada jueves en Onda Cero y se sube a este canal de podcast todos los lunes. En este episodio de AutoFM analizamos una de las noticias más impactantes de los últimos tiempos en la industria del automóvil: la dimisión sorpresa de Carlos Tavares como CEO de Stellantis. Un anuncio que ha sacudido a la automoción europea y que deja muchas preguntas sobre el futuro del gigante automotriz. Exploramos las razones detrás de esta decisión inesperada, repasamos el legado de Tavares al frente de Stellantis, incluyendo la polémica gestión de los motores PureTech y la transición hacia la movilidad eléctrica, y debatimos sobre los retos inmediatos que enfrenta la compañía bajo la dirección interina de John Elkann. Además, hablamos sobre el papel crucial de la plataforma STLA Small en la estrategia de electrificación de Stellantis, que será recordada como uno de los últimos proyectos impulsados bajo el mandato de Tavares. ¡No te pierdas este episodio cargado de análisis y actualidad! Puedes seguirnos en nuestra web: https://www.podcastmotor.es Twiter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ Youtube: https://www.youtube.com/channel/UC57czZy-ctfV02t_PeNXCAQ Contacto: info@autofm.es

“Stellantis anuncia que el Consejo de Administración de la Compañía ha aceptado hoy la dimisión de Carlos Tavares como CEO con efecto inmediato”. ÁMSTERDAM, 1 de diciembre de 2024. Cae el último defensor a ultranza de los coches eléctricos. Un personaje que ha metido a muchas marcas en un verdadero callejón sin salida… y que en 2022 cobró más de 23 millones de euros… He reflexionado mucho antes de hacer este video, que quizás no sea muy del estilo de los habituales en GH, donde hablamos mucho de historia, de tecnología, de competición, de curiosidades, de clásicos… pero no podía dejar pasar una cosa así… Y es que, en el fondo de este viejo aficionado, sigue latiendo el corazón de un periodista… Para mi esta dimisión representa el cambio de un ciclo… o, dicho de otro modo: ¡A ver si los demás se dan cuenta de que éste no es el camino! ¿Qué camino ha marcado el hombre de los 23 millones de euros de sueldo? Vamos a hacer una relación y luego vamos a entrar en detalle. Pero antes permitidme una reflexión previa en un vídeo en el que habrá muchas reflexiones. La nota de prensa continúa diciendo que “El proceso de nombramiento del nuevo consejero delegado permanente está muy avanzado y concluirá en el primer semestre de 2025”. ¿Hacen falta 6 meses para cerrar esta crisis?… mal vamos. De momento, de forma interina, la empresa será dirigida por John Elkann. Primero, es una constatación de la crisis absoluta de la industria europea. Segundo, insisto de nuevo en que esto es una opinión, demuestra que Stellantis ha sido y es una mezcla de marcas insostenible. Tercero, la mala gestión de la crisis de los motores “PureTech” o como ya los llama la mayoría “Pudretech”. Y cuarto y último, lo digo en la entradilla, con Tavares se va el "último irreductible" de la electrificación. Porque a estas alturas, en la patronal europea, Tavares era el único que defendía el límite 2035. Entremos en detalle. Me gustan los refranes, como el que dice “entre todos la mataron y ella sola se murió”, que va al pelo aplicado a la industria europea. Y es que las medidas de los políticos para mi han sido enormemente desacertadas, pero las soluciones adoptadas por las marcas lo han sido más aún si cabe. Estos nuevos CEO que cobran millonadas han sido “blanditos” y no han negociado bien con los organismos oficiales y con la UE. ¡Qué tiempos en los que las marcas defendían no sus intereses, sino los intereses de sus clientes! Cuando los políticos marcaban los objetivos, pero los fabricantes decidían cuál era el camino a seguir más adecuado. Y luego está China… los fabricantes europeos dicen que su pérdida de competitividad frente a los fabricantes chinos viene dada por el coste de la energía y de la mano de obra… y seguro que es cierto…. en parte. Pero, os hago otra reflexión: ¿Cómo va a competir contra tus proveedores? China fabrica el 80 por ciento de la producción mundial de baterías para coches… es difícil competir con alguien que es a la vez rival y proveedor… Este video se ha “colado”, por pura cuestión de actualidad, a uno que hemos grabado sobre la plataforma “Tipo 4” uno de los primeros proyectos con verdadero éxito de ahorro de costes. El video se titulará “Alfa 164, Fiat Croma, Lancia Thema y Saab 9000, tan iguales tan distintos”. Os invito a verlo. ¿El motivo? Este video demuestra que la economía de escala es posible sin que las marcas pierdan su identidad. En mi opinión la mezcla de marcas italianas, americanas, alemanas y francesas en un mismo grupo no ha funcionado… Como os decía, entras en un concesionario y ves un Alfa casi al lado de un Citroën, un Lancia o un Opel… o un DS, que se ha quedado a medio camino de lo premium. ¿No sería mejor que cada marca pudiera enfocar su desarrollo en función de sus propias estrategias de desarrollo, diseño y objeticos comerciales? De “PureTech” a “Pudretech”. No, no han sido rápidos en Stellantis solucionando esta grave crisis. Y es que hablamos de mucho, muchísimos motores… a ver, si para nombrar un nuevo CEO necesitan 6 meses, para solucionar el problema de cientos de miles de motores pueden necesitar… siglos. Todo el mundo, incluidos los fabricantes de coches, pueden equivocarse. Aunque hay errores y errores… ¿a qué ingeniero le pareció una buena idea poner una correa que es básicamente de goma en baño de aceite? En Stellantis han tardado mucho en darse cuenta, mucho en reaccionar y las propuestas que han dado a sus clientes no siempre han sido adecuadas… un desastre para los clientes y también para la reputación de las marcas. Tavares era el "último irreductible" defensor de la electrificación con fecha límite en 2035. Y no, no porque fuese un ecologista convencido, era una huida hacia adelante… Porque después de crear un monstruo empresarial, de parar todo el desarrollo de los motores diésel y gasolina, de no apostar decididamente por los híbridos que son los actuales reyes del mercado y de invertir un dineral en electrificación... pues no ha estado dispuesto a cambiar el paso… Lo cierto es que Stellantis y su líder se han ido quedando cada vez más solos. En verano, la Asociación Europea de Fabricantes de Automóviles solicitó a la UE que pospusiera los nuevos objetivos de emisiones de 2025. Pues… adivina quien lanzó un comunicado apoyando la normal actual. La conclusión es que espero y deseo que esta dimisión, que como en la obra de Gabriel García Márquez era la “Crónica de una muerte anunciada”, suponga un cambio de ciclo. De hecho, su contrato acababa en 2026. A ver si llega una renovación de las personas y las ideas de quienes deciden el futuro de la industria europea del automóvil. En el caso de Stellantis, el problema no es el presente. A fin de cuentas, la compañía presentó unos resultados en 2023 de 18.525 millones de euros, un 11% más que el año anterior… Pero los resultados de algunas marcas, la situación en el mercado americano y creo que sus posicionamientos respecto a las normativas europeas han hecho que el consejo de directivo de Stellantis le haya puesto en una situación complicada y haya preferido renunciar. Respecto al resto de la industria, me considero ecologista, pero hay que buscar soluciones realistas y globales. ¿Por qué digo esto? Porque las emisiones de gases de efecto invernadero de la UE, sobre el total mundial, era del 7,3% en 2021 y ha seguido descendiendo. China era el responsable del 32% y sigue creciendo…. La fuente de estos datos es la propia UE y Naciones Unidas. Y podríamos seguir hablando de grandes contaminantes, como la industrias, los barcos o los aviones… Sí, soy ecologista, pero tomemos medidas realistas, eficaces y justas, no medidas que solo sirven para el “postureo” y que destruyen industrias, riqueza y puestos de trabajo.

Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company's pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bharatt and Eric share their professional journeys and key insights, emphasizing the importance of simplicity and unwavering commitment to impactful ideas. The episode delves into the story behind Karuna Therapeutics, highlighting the challenges of obtaining funding and skepticism from the industry before its success with a groundbreaking schizophrenia drug. Bharatt and Eric underline the importance of patient-centered innovation and reflect on the lessons learned, including overcoming obstacles with persistence. They also discuss the need for more efficient pathways in drug development and share a glimpse into PureTech's upcoming projects. Biography: Bharatt Chowrira, PhD, JD, is the chief executive officer and a member of the board of directors at PureTech. Dr. Chowrira has been a member of the PureTech management team since March 2017, leading various departments including Operations, Finance and Business Development. Dr. Chowrira plays a key role in the Founded Entity fundraisings and provide strategic guidance as a Board member to many Founded Entities, including co-founding Seaport Therapeutics. Prior to joining PureTech, he held various leadership roles including Chief Executive Officer, President, Chief Operating Officer and General Counsel in multiple biotech companies over the past 30+ years, including Auspex Pharmaceuticals Inc., which was acquired by Teva Pharmaceuticals for $3.5 billion and Sirna Therapeutics that was acquired by Merck for $1.1 billion and as a Vice President at Merck & Co. Dr. Chowrira received a JD from the University of Denver's Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India. Eric Elenko, PhD, is the president at PureTech where he has led the development of a number of programs, including three that have received US FDA approvals (EndeavorRx, Plenity and Cobenfy). Dr. Elenko plays a key role in the Founded Entity drug discovery and fundraisings, including co-founding Seaport Therapeutics. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

Heute sprechen wir über den Citroën Aircross: Der Hybrid 136 erweitert das elektrifizierte Angebot des C5 Aircross. Zwei Motoren der neuen Generation (Elektro und Benzin), können zusammen oder getrennt arbeiten. Die neue Antriebstechnologie ermöglicht das Anfahren, Manövrieren (z. B. beim Einparken) und das Fahren bei niedriger Geschwindigkeit im Stop & Go-Verkehr bis zu 30 km/h im rein elektrischen Modus. Darum geht es diesmal!Dass die Hybridtechnologie effizient und benutzerfreundlich ist, dürfte sich mittlerweile herumgesprochen haben. Und es gibt nicht mehr allzu viele Hersteller, die darauf verzichten. Sei es die konventionelle Hybridtechnologie, oder aber auch Plug-in Hybriden. Beide Antriebstechnologien hat Citroën im Programm. Wir haben uns für den Test des Citroën C5 Aircross als Hybrid 136 entschieden.Power und Drive!    Der C5 Aircross Hybrid 136 trägt den Zusatz ë-DSC6, weil er serienmäßig ein 6-Gang Doppelkupplungsgetriebe an Bord hat. Das ë schreibt sich übrigens mit einem Trema, das sind die beiden Pünktchen auf dem kleinen e, die auch im Namen Citroën zu finden sind. Und die 136 steht, sie dürfen einmal raten, für die PS-Zahl. In Kilowatt ausgedrückt sprechen wir dann von 100, aber 136 im Namen sieht natürlich besser aus. Außerdem – seien wir mal ehrlich –, wer von uns spricht von Kilowatt, für uns ältere Menschen heißt es nach wie vor PS. Darunter können wir uns was vorstellen. Im Fall des C5 Aircross setzt Citroën auf eine 48 V Hybridtechnologie, bei der sich eine 48 V Batterie während bestimmter Fahrphasen selbst auflädt und die so den Benzinmotor unterstützt. Ein permanentmagnetischer Synchron-Elektromotor mit einer Leistung von 21 kW (28 PS) ermöglicht es, den C5 Aircross bei geringem Drehmomentbedarf, bei niedrigen Geschwindigkeiten, beim Manövrieren oder Abbremsen rein-elektrisch anzutreiben, zudem unterstützt er den Benzinmotor beim Anfahren. Beim Verzögern wirkt er als Generator, um die Batterie aufzuladen, was gleichzeitig den Verschleiß der Bremsen verringert. Die exakten Daten des Fahrzeugs dürfen Sie ausnahmsweise mal selbst nachlesen, dazu fehlt mir hier jetzt leider die Zeit. Ich möchte nämlich noch über die Preise des Fahrzeugs sprechen.Die Kosten!Und diese Preise gehen bei 25.350, – Euro für den PureTech 130 Stop & Start mit Sechsgang-Schaltgetriebe los, sie enden bei 50.810,– Euro für den Plug-In-Hybrid 225 Stop & Start ë-EAT8 mit 8-Gang Automatik. Unser Testfahrzeug, der Hybrid 136 ë-DSC6 kostet je nach Ausstattung zwischen 30.480, – und – 37.380, – Euro.Alle Fotos: © Citroen/PSA/Stellantis   Diesen Beitrag können Sie nachhören oder downloaden unter:

ROMA (ITALPRESS) - Cresce la famiglia della nuova C3. In attesa di quella ibrida, entro fine anno, Citroen lancia la versione a benzina a 14.990 euro, quasi 9mila in meno del modello base alimentato dal propulsore elettrico. E' equipaggiata con il motore PureTech 100 Start&Stop da milledue centimetri cubici e 100 cavalli, abbinato a un cambio manuale a 6 rapporti. Le l'emissioni sono di 126 grammi di CO2 per chilometro. Molte le innovazioni, come il sistema di sospensioni con ammortizzatori idraulici progressivi, che offre una percezione su strada molto più fluida. A ridurre l'effetto delle buche anche i sedili avvolgenti grazie a uno schiuma aggiuntiva spessa un centimetro. tvi/gtr

In this episode, host Shikha Jain, MD, speaks with Aparna Parikh, MD, about cancer and GI malignancies in the global health space, circulating tumor DNA in the field of oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Parikh 1:07 •    The interview 2:08     •    What was your path into medicine, cancer care and GI oncology? 2:35 •    Tell us about what you do in the global health space and what your thoughts are on colon cancer and GI malignancies in the global health space. 8:07 •    Why are we seeing so many more young people being diagnosed with colon cancer in the US and internationally? 12:24 •    Do you think US lifestyle and Western diets compared to the rest of the world have contributed to the rise of early colon cancer diagnoses?  15:04 •    How can physicians talk about lifestyle, diet and environmental/social determinants of health that impact a cancer diagnosis? 17:52 •    Can you provide a brief overview of what is circulating tumor DNA (ctDNA) and liquid biopsy, and how are we using it in this space? 19:44 •    Jain and Parikh on ctDNA as an innovation can be transformative in the field of GI oncology.  24:06 •    What are your predictions for GI oncology in the next ten to twenty years?  26:06 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:44 •    How to contact Parikh 30:57 •    Thanks for listening 31:57 Aparna Parikh, MD, is a GI oncologist at the MGH Cancer Center where she directs the colorectal research program and young adults CRC program. She is an associate professor at Harvard Medical School and an international expert in CRC and liquid biopsies. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Parikh can be reached via email aparna.parikh@mgh.harvard.edu. Disclosures: Jain reports no relevant financial disclosures. Parikh reports equity in C2i Genomics XGenomes Cadex and Parithera. Advisor/consultant for Abbvie, AZ, Bayer, Biofidelity, Checkmate Pharmaceuticals, CVS, Delcath, Eli Lilly, FMI, Guardant, Hookipa, Illumina, Inivata, Mirati, Pfizer, Saga, Seagen, Taiho, Scare Inc, Science For America, and Value Analytics Lab. She receives fees from Up to Date.  She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on Steering Committee for Exilixis. She has received research funding to the Institution from BMS, Daiichi Sankyo, Erasca, Genentech, Mirati, Novartis, PMV Pharmaceuticals, Plexxicon, PureTech, Takeda and Syndax. 

Drs. Shaalan Beg and Aparna Parikh discuss the role of ctDNA as a powerful prognostic biomarker for GI cancers, along with its impact on risk stratification and the detection of recurrence. They highlight key studies in ctDNA that were featured at the 2024 ASCO GI Cancers Symposium, including COBRA, GALAXY, and BESPOKE in CRC, as well as the promise of ctDNA testing in the preoperative detection of iCCA. TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Shaalan Beg, your guest host for the ASCO Daily News Podcast today. I am an adjunct associate professor at UT Southwestern's Harold Simmons Comprehensive Cancer Center in Dallas. On today's episode, we will be discussing the emergence of circulating tumor DNA (ctDNA) technology in GI cancers. I am delighted to be joined by Dr. Aparna Parikh, an assistant professor of medicine at Harvard University and the director for colorectal medical oncology at the Massachusetts General Hospital Cancer Center, where she also serves as the medical director of the Young Adult Colorectal Cancer Center. Dr. Parikh will share her insights on key research on this hot topic in GI oncology that was featured at the recent ASCO Gastrointestinal Cancers Symposium.  Our full disclosures are available in the transcripts of this episode, and disclosures related to all episodes of the podcast are available at asco.org/DNpod.  Dr. Parikh, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much, Dr. Beg.  Dr. Shaalan Beg: In recent years, it has become evident that liquid biopsy and other emerging ctDNA technologies are changing how we treat GI cancers, and colorectal cancer (CRC) is in the forefront of this space. Before we dive into key studies, can you briefly highlight for our listeners how ctDNA is advancing the field and how it can influence the care that we deliver to our patients in the future? Dr. Aparna Parikh: Absolutely, ctDNA is certainly a hot topic. What we have learned over the years is that ctDNA has emerged across many solid tumor types as one of the most powerful, if not the most powerful, prognostic biomarker we have to date. ctDNA has improved risk stratification. We have learned a lot about the role in what is called minimal or molecular residual disease in patients with early-stage disease, and ctDNA being a biomarker of recurrence for those patients, with ctDNA, we have a better understanding of tumoral heterogeneity, both spatially and temporally, getting a better glimpse of what is happening in a given patient with multiple metastases, as well as genomic evolution of tumors over time. So certainly many, many roles and areas where ctDNA is emerging. Dr. Shaalan Beg: This was a hot topic at the 2024 ASCO GI Cancers Symposium, and we're going to take a deep dive into some of the abstracts that were presented. Let's start with the COBRA study, which is the NRG-GI005. That was Abstract 5 at the ASCO GI Cancers Symposium, and the GALAXY study, which was Abstract 6 at the symposium. So, the COBRA study reported results of ctDNA as a predictive biomarker in adjuvant chemotherapy for people with colon cancer. At a high level, it was a negative study, but there are some important lessons for us to learn. Similarly, in the GALAXY study, investigators from Japan presented an updated analysis on the correlation of ctDNA dynamics with outcomes in colorectal cancer with minimal residual disease. How do you synthesize all this information and help the listeners understand our current state for ctDNA applications in colorectal cancer? Dr. Aparna Parikh: Yeah. Let's take the COBRA study first. Let's talk a little bit about the design of COBRA. COBRA was intended to look at patients that were resected, stage 2 colorectal cancer patients, or colon cancer patients who were 2A. These are patients where the treating physician would, at the outset, decide that there was no adjuvant chemotherapy indicated. These are patients where active surveillance would be entirely appropriate as the standard of care. Patients were randomized to arm 1, which was active surveillance, or randomized to arm 2, which was assay-directed therapy. If there were ctDNA positive in arm 2, then they were given chemotherapy, FOLFOX or CAPOX. And if they were “ctDNA not detected,” then they would also go on to active surveillance.   And so, the plan was that nearly 1,500 patients are to be recruited, and at the time of this data cut, they had around 630-some patients. The primary objective was to look at the clearance rates of ctDNA between the ctDNA-positive cohorts, remember, the chemotherapy and the active surveillance cohorts at 6 months. They had around a 5% detection rate of ctDNA patients. Ultimately, that was around 16 patients. The reason that the study shut down was that what they found was that in the surveillance arm, the arm that was not getting any treatment, they had a ctDNA clearance of 43% versus 11% in the chemotherapy arm. They had an interim analysis to look at the clearance rate between the 2 arms, and what was surprising to the investigators and the community was what was happening in terms of clearance. Why do we have a 43% clearance rate in patients that were not getting anything? And so, because of that, the study was shut down as it did not meet its prespecified interim look at clearance in those 2 arms.   Many things came up in terms of learnings from COBRA. Number one was the characteristics of the assay. And so, you take an assay in a low-risk patient population that has a fixed specificity, and when your baseline prevalence of recurrence is so low, for example, in low-risk stage 2 patients, your composite predictive value is very susceptible to small changes in that specificity. And so, your PPV is going to be a lot lower in a low-risk patient population than a higher-risk patient population. The COBRA study used an older version of a tumor-uninformed assay, so it definitely called into question some characteristics of the assay. Is one-time-point clearance sufficient, and is that the right endpoint? We have seen now, including the GALAXY study that we'll talk about here, previously reported just spontaneous clearance happening in 5%, 10% of patients. The question with that spontaneous clearance is: Was it actually clearance, or was chemotherapy just perhaps in a low ctDNA shedding state? Are you just suppressing the ctDNA below the level of limited detection?  And then in this study, the clearance draw was actually done in the chemotherapy arm right before the last cycle of chemotherapy, again to that point of, are you just suppressing the ctDNA with chemotherapy? There is also stochastic sampling error that can happen in patients with very low residual tumor volume. So, I think this is a disappointing study in the sense that it is still a really important question. There are still 2A patients that recur, but maybe [this was] not the right test, or maybe single-time-point testing wasn't enough. And so, lots of lessons to be learned from this study in terms of test and design, but hopefully more to come. I think certainly stage 2 patients remain an area where I think, hopefully, ctDNA still plays a factor for those patients.  Dr. Shaalan Beg: And how was the patient population for the GALAXY study? That was Abstract 6, compared to the COBRA study. Could you summarize those findings for us?  Dr. Aparna Parikh: Yeah, so GALAXY was part of a large study in Japan that includes an observational cohort plus therapeutic cohorts as well. And so, GALAXY was just further reporting of the observational cohort. So unlike COBRA, which is a low-risk, stage 2 study that was actually asking that interventional question: Can you use it to guide therapy? The GALAXY and the updated GALAXY just continues to show more clinical validity data rather than clinical utility data. And it was nearly 3,000 patients, pan stages. Again, the lion's share were stage 2 and 3 patients, but there were also stage 1 and stage 4 patients as well. And what they showed was that ctDNA is undoubtedly prognostic. They showed very consistent Kaplan-Meier curves, which we've seen time and time again, where if you're ctDNA-positive, you don't do as well.  What they showed was, not surprisingly, with longer-term follow-up – this is 24-month follow up, so longer-term follow up than was published in their paper last year – was that when you test at one time point, so landmark testing, the sensitivity of detecting recurrence was around 48%, and that fell from the publication last year which was around 58%, 59%, which is not surprising as you follow more people. I think single time point testing soon after surgery may miss those late recurrences, but it's still prognostic and showed a specificity of around 94%.   They also continued to show that if you continued to test with serial testing, your sensitivity improves, but what was really interesting and new, what they presented this time, was a clearance analysis. And showing, again, comparable to COBRA, in many ways, in the sense that clearance can be a little bit finicky, especially at one time point, is what they showed is that patients who had sustained clearance, and these are patients that had at least two time points with their ctDNA remained to be negative, they did very well. But if you had transient clearance, and again, the definition was a little bit broad, at least having one negative and then one positive, those patients ultimately, at 24 months, the curves came together with the no clearance curve. So initially, they did better than the people that didn't have any clearance. But if you transiently cleared at two years, the curves came back together.   And what was interesting is that in those patients that sort of transiently clear by 9 to 12 months, 80% of those are actually having a rapid return of ctDNA. And so this begs the question of was chemotherapy just suppressing that ctDNA or maybe if you have a better test you could have actually improved it.  These were some of the updated, interesting learnings from GALAXY, which remains incredibly prognostic. And then the concept of clearance, which I think we have to look into a little bit more as a field, and understanding that maybe just one time point clearance isn't sufficient.  Dr. Shaalan Beg: Yeah, and one of the most important applications for ctDNA can be its ability to inform adjuvant chemotherapy. Its ability to not only identify more people who may benefit from chemotherapy, but maybe even identify people who don't need chemotherapy. And along those lines, Abstract 9, the BESPOKE study, looked to understand the role of ctDNA-based detection of molecular residual disease to inform adjuvant therapy for stage 2 and 3 colorectal cancer. And they presented interim data at the GI ASCO this year. What were your takeaways from this study? Dr. Aparna Parikh: Exactly. Beyond the prognostic implications, I think what was really interesting was that there was the initial data looking at the benefit of adjuvant chemotherapy. So, what they did was they said, “Okay. We're going to take the MRD-positive patients and look at the benefit of adjuvant chemotherapy and then the benefit of adjuvant chemotherapy in the MRD-negative patients.” And again, remember, this is a prospective observational study, so it's not looking at negative and positive to guide therapy, but it's just looking prospectively and observationally at how those patients are doing. But what they showed again is that indeed, in the adjuvant chemotherapy group, the benefit of adjuvant chemotherapy again with the follow-up to date on the study was different in the MRD-positive patients.  First of all, I guess taking a step back, the DFS in the ctDNA-negative patients at 2 years was very good. So negative patients had over 98% 2-year DFS in both the adjuvant chemotherapy and observational group. And there was no real difference between adjuvant or not. But in the positive patients, not surprisingly, the DFS was worse. But what was reassuring to see is that you can make an impact with adjuvant chemotherapy in the positive patients. And the difference in DFS between the positive and negative patients, with adjuvant or not, was 42% versus 12.5%, in the observational patients. So, it is benefitting the patients who are positive so it does give us more data that, again, at least in the positive patients, you may be able to reverse the recurrences there with adjuvant chemotherapy. And maybe if you're negative, eventually, we'll get to a point of de-escalation of care. Again, keeping in mind the kinds of sensitivity limitations as well.  Dr. Shaalan Beg: Wonderful. And one of the other malignancies in the GI space where precision therapies and molecular biomarkers are making a huge difference are intrahepatic cholangiocarcinoma. Genomic profiling using ctDNA is increasingly being used in this population to inform precision oncology approaches and determine mechanisms of resistance to targeted therapies as well. In Abstract 528, investigators looked at the role of preoperative ctDNA testing for resectable intrahepatic cholangiocarcinoma. What are your thoughts on that study?  Dr. Aparna Parikh: Yeah, it's such an important area, as you mentioned, in the metastatic space – FGFR, IDH1, all these alterations that are emerging in intrahepatic cholangios. This was a very small study, it was preoperative, and so the tumor was intact, and around 14 patients. They used a tumor-informed approach just for detection and quantification of ctDNA. So this was not a study that was looking at a next-generation sequencing approach where you're going to actually be able to detect the alterations, but it's actually looking for the detection and quantification of ctDNA rather than genomic characterizations. And patients had about a month or so where they had their baseline blood detected. And I think what was reassuring to say was that ctDNA was actually detected in all the patients with the primary tumor intact, except for one patient who was a very low-risk stage 1A patient. There was some correlation, against a small number of patients, between the concentration of ctDNA in patients that had the lower stage and then the higher stage groups. Small numbers were actually hard to characterize and correlate with recurrence or mortality, but at least, some correlation with pathologic tumor size, they were able to because it was a bespoke panel and you're sampling the tissue and then looking in the blood, IDH1 and 2 were mutations that were tracked based on the genomic profiling and a couple of the patients were able to have their IDH mutations tracked.  So it gives us a sense, a little bit, that ctDNA, we know has a lot of variable shedding across disease states and tumor locations, but gives us some promise that it is reliably detected with the tumor-informed approach, at least preoperatively in cholangios. So may again open some more opportunities for MRD testing in cholangiocarcinoma as well.  Dr. Shaalan Beg: Thank you. That's a wonderful review of ctDNA applications in gastrointestinal cancers from the 2024 ASCO GI Cancers Symposium. Thank you, Dr. Parikh, for sharing your valuable insights with us on the podcast today. Dr. Aparna Parikh: Thank you so much for having me. Dr. Shaalan Beg: Thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Shaalan Beg @ShaalanBeg Dr. Aparna Parikh @aparna1024   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals   Dr. Aparna Parikh: Consulting or Advisory Role (An Immediate Family Member): PMV Consulting or Advisory Role: Checkmate Pharmaceuticals, Guardant Health, Foundation Medicine, Abbvie, Value Analytics Labs, Bayer, Taiho Oncology, Delcath, Seagen, CVS, SAGA Diagnostics, Scarce, Illumina, UpToDate, Takeda, AstraZeneca, Takeda, Pfizer, Kahr, Xilio Therapeutics, Sirtex Research Funding: PMV Pharma, Erasca, Inc, Syndax Research Funding (Institution): Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo, Karkinos Other Relationship: C2i Genomics, Xgenomes, Parithera, Cadex

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have a jam-packed episode with the latest news and trends in the industry. Let's dive in!In the pharmaceutical industry, drugmakers are facing five important questions in 2024. These include competition in obesity, the next era of oncology, and the impact of a contentious drug pricing law. Pfizer had a difficult year in 2023, but we had the opportunity to hear from Albert Bourla, the company's CEO, about their plans for the future. PureTech's Daphne Zohar is also making waves with her neuroscience startups. Despite layoffs in the biotech industry, recent deal-making and stock market momentum have brought some optimism. Biotech mergers and acquisitions are picking back up, with $45 billion worth of deals announced in the past six weeks. We also have sponsored content about leveraging artificial intelligence in patient support and real-world data in clinical trials.Switching gears to healthcare, hospitals are facing slim operating margins and experts predict they will focus on trimming unnecessary expenses and investing strategically in labor. The Department of Health and Human Services has published an updated provider conscience rule, balancing religious freedom rights with patients' access to care. The Federal Trade Commission has reached a settlement with a data broker to protect patients' privacy. Sutter Health has appointed a new CFO, Raju Iyer, who will be responsible for financial planning. And don't forget about FedEx Office's sponsored content on how high-quality printed materials can boost patient relationships.In biotech news, Myrobalan has raised $24 million to advance its neurorestorative drugs for neurological disorders. Alcon has reported promising data from a Phase III trial for its drops to treat dry eye disease. Taco Bell is hosting a Las Vegas fan experience ahead of Super Bowl LVIII, showcasing new products and partnerships. Walmart+ has enlisted TV personality Andy Cohen for its "Quitter's Day" campaign. Honda has launched its "Chasing Greatness" campaign featuring indie artist Bishop Briggs. And we have the top 50 content marketing brands and eight predictions for 2024 in the marketing industry.Two biotech companies, 4D Molecular Therapeutics and Arbor Biotechnologies, have announced a collaboration to develop treatments for central nervous system diseases. We also discuss the potential of artificial intelligence in drug discovery and development. And we wrap up with news on pharmaceutical companies using tactics to maintain high drug prices, Clarivate's "drugs to watch" list for 2024, and various acquisitions and layoffs in the biopharma industry.Abzena is offering a new application note for its Thiobridge™ technology in ADC development, highlighting improved stability and efficacy. Medtronic is focused on delivering durable revenue and profit growth, while Dexcom plans to launch a new CGM device. Amazon has launched a chronic condition management portal, and Walgreens has settled a drug pricing dispute with Humana. Nonprofit hospitals and health systems are financially stable despite declining operating margins. And digital health funding reached its lowest level since 2019.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more news and updates in the industry. Remember, we give you only what's important to hear!

For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it's like to struggle and survive in this rough-and-tumble industry.  Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

On this week's episode of Biotech Hangout hosts Daphne Zohar, Tim Opler, Josh Schimmer, Chris Garabedian, John Maraganore and Ethan Perlstein discuss the latest industry news including takeaways and sentiment from the recent Jefferies, Stifel, American Heart Association and ACR conferences. They also discuss Ajinomoto acquiring Forge Biologics ($620M), Crispr and Vertex MHRA approval in the UK, Verve data and Novo Nordisk's SELECT trial details. They hosts discuss Astellas' acquisition of Propella ($175M) and the differences between Propella and PureTech's lymphatic-focused technologies, on the back of PureTech's Phase 2 data. Other topics include three merger agreements: Graphite Bio/ Lenz Therapeutics, Q32 Bio/Homology Medicines and Selecta Biosciences/ Cartesian Therapeutics, adcomm for Merck's inhibitor for chronic cough and more. *This episode aired on November 17, 2023

Tous les matins RMC S'engage Avec Vous : toute l'équipe de Guillemette Franquet se mobilise pour vous aider à résoudre vos problèmes et porter vos combats. Une adresse pour nous contacter : rmcavecvous@rmc.fr.

Selon plusieurs enquêtes journalistiques et le site "Que Choisir", environ 200.000 propriétaires de véhicules essence seraient concernés par des soucis liés au moteur 1.2 Puretech. Un moteur commercialisé par les constructeurs du groupe Stellantis. Ce dernier équipe notamment des Citroën et des Peugeot, deux marques que Maylis a achetées. Elle a dû se débarrasser de sa Peugeot 308 suite à une casse de moteur. Et aujourd'hui, elle a de nouveau ce problème avec sa Citroën C3. La jeune mère de famille doit faire changer l'entièreté de son moteur, ce qui lui reviendrait à environ 2.000 euros. Tous les jours, retrouvez en podcast les meilleurs moments de l'émission "Ça peut vous arriver", sur RTL.fr et sur toutes vos plateformes préférées.

Recorded on 10/10/23 TD Cowen analyst Yaron Werber speaks with Daphne Zohar, founder and CEO of PureTech, and Brad Loncar, founder of BiotechTV about their unique experiences as biotech entrepreneurs. Daphne discusses the innovative “hub and spoke” model she pioneered with PureTech, while Brad describes his transition from biotech investor to communicator and his long-term vision for BiotechTV. Both showcase the benefits of taking an unorthodox approach, finding where their differentiation can be leveraged to fill an unmet need, and having the conviction/dedication to actualize their goals. For Disclosures, click here bit.ly/3cPHkNW

Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it's like to struggle and survive in this rough-and-tumble industry. 

Flavour, an integral part of our daily lives, takes center stage at Besmoke. They understand the pivotal role that complex, clean, balanced, and bold flavours play in making your products truly stand out. Thepassion lies in bringing these flavours to life, enhancing any application they touch.Since the inception in 2004, they have been on a relentless quest to redefine smoked food ingredients. Huw has pioneered state-of-the-art patented technology, which removes a staggering 95% of carcinogenic PAHs (Polycyclic Aromatic Hydrocarbons) from smoke. This innovation has allowed them to craft fresh, complementary, and well-rounded flavours. They've even engineered smoke volatiles to transform the culinary landscape, offering clean grill flavours, umami-enhancing taste modifiers, and reductions in salt and sugar content, among other innovations.Now, let's dive into the remarkable benefits of Besmoke:Authentic smoke and grill flavours that elevate your culinary creations.A revolutionary process that eliminates over 95% of PAHs, ensuring a natural, clean, and safe experience.Say goodbye to acrid smoke tar – the technology removes it entirely.They're committed to sustainability and promoting healthier choices.The product journey began with the introduction of our SmokeCreate™ range, utilising traditional smoking techniques to produce rich, deep, and irresistibly savoury ingredients.But the true essence of Besmoke lies in their PureTech™ lineup. This collection harnesses the power of the patented technology to deliver balanced smoke, grill, or umami flavours in their purest form. It's a game-changer, allowing them to enhance flavour profiles and reduce salt and sugar levels while maintaining quality and purity.The story of Besmoke is woven with the passion and dedication of the founder, Huw Griffiths. His fascination with flavour science ignited in 2004 when he embarked on smoking garlic in an old tin ballot box. Endless experimentation led to the creation of high-quality smoked garlic that gained popularity at delis and food markets across the country. With the addition of smoked salt and smoked pepper, Besmoke was born.In our conversation with Huw Griffiths, we delve into:Huw's personal journey and career.The core mission of the Besmoke brand.The inspiration that drove Huw to enter the FMCG sector.What sets Besmoke's products apart in the market.Defining moments that have shaped the brand's significant growth in the FMCG sector.Unexpected pivots or adaptations made along the journey.Exciting developments on the horizon for the Besmoke brand.Join us as we explore the fascinating world of flavour and innovation with Huw Griffiths.Contact Harlands Accountants / The Evolving Accountant Tweet us at @Harlands_NE Give us a follow on LinkedIN Give us a Like on Facebook Email us at host@theevolvingaccountant.co.uk Don't forget to leave us a review Thanks for listening!

Viajamos hasta Málaga para acompañar a Peugeot en sus Peugeot e-Lion days. Que no es otra cosa que poder conducir y conocer todas las novedades de los vehículos electrificados más acúlales de la firma francesa. La estrella de la jornada fue el nuevo motor eléctrico que incorpora en suv compacto Peugeot E 2008. El Peugeot e-2008 es el único modelo que presenta cambios en su mecánica en comparación con el modelo anterior. La marca francesa ha comenzado a incorporar un nuevo motor eléctrico más potente, dejando atrás el antiguo motor de 100 kW (equivalente a 136 CV). El nuevo sistema de propulsión eléctrica combina un motor de 115 kW (equivalente a 156 CV) con una batería de mayor capacidad. La batería anterior de 50 kWh ha sido reemplazada por una nueva batería de 54 kWh de capacidad neta. Esto se traduce en un aumento en el rango de conducción, pasando de los anteriores 345 km a los actuales 406 km. El Peugeot e-2008 viene de serie con un cargador de 7,4 kW, pero existe la opción de sustituirlo por un cargador trifásico de 11 kW. La batería del vehículo puede cargarse a una velocidad máxima de 100 kW y el tiempo de carga es similar al modelo anterior: del 20 % al 80 % se realiza en 30 minutos utilizando tomas de carga ultrarrápida, en 4 horas y 40 minutos en un Wall Box de 7,4 kW, y en una toma doméstica convencional de 3,2 kW, la carga se completa en 11 horas y 10 minutos. La segunda jornada de pruebas la comenzamos probando la tecnología micro híbrida de 48 voltios que llega a los Peugeot 3008 y 5008. Estos dos vehículos SUV introducen la innovadora tecnología Peugeot 48 V Hybrid, que destaca por incluir un nuevo motor de gasolina tricilíndrico turbo de 1.2 litros PureTech, con una potencia de 136 CV. Este motor cuenta con una distribución por cadena y utiliza el Ciclo Miller para mejorar su eficiencia. Además, se ha incorporado una nueva caja de cambios electrificada de doble embrague y 6 velocidades, conocida como e-DCS6, que cuenta con un motor eléctrico de imanes permanentes capaz de generar hasta 21 kW (equivalente a 28 CV) y un par motor de 55 Nm. Estos vehículos también disponen de una batería de 48 V, la cual se recarga durante la conducción y está ubicada debajo del asiento del conductor. Otra gran novedad que tuvimos la ocasión de conducir y que estará posicionada en la categoría más económica y que ya se encuentra disponible en otros modelos como el 308. Estamos hablando del modelo Híbrido de 180 CV, el cual combina un motor de gasolina de 150 CV con otro motor eléctrico de 110 CV y una batería de 12,4 kWh (similar a la utilizada en otros vehículos híbridos enchufables). Con esta configuración, se logra una autonomía de aproximadamente 60 km en modo de cero emisiones. Además, este vehículo mantiene una capacidad de carga en corriente alterna (CA) de 7,4 kW, lo que nos permite cargar la batería por completo en menos de 2 horas utilizando una toma de corriente de potencia similar. Para cerrar la jornada probamos el tope de gama deportivo entre las berlinas, el Peugeot 508 PSE (Peugeot Sport Enginereed). Este vehículo de tipo híbrido enchufable, además de contar con un motor eléctrico, está equipado con un motor de gasolina de 200 CV y una segunda unidad eléctrica de 83 kW en la parte posterior del tren, ofreciendo un rendimiento global de 360 caballos de fuerza y tracción en todas las ruedas. Presenta y dirige: Fernando Rivas https://twitter.com/rivasportauto Redacción Seguridad y Economía: https://www.linkedin.com/in/joselagunar/ Redacción: Antonio R. Vaquerizo https://twitter.com/Antortxa Web Peugeot: https://www.peugeot.es/ Alberto Morla: https://www.linkedin.com/in/alberto-morla-santos-495808164/ Kike Ruiz: https://www.linkedin.com/in/enriqueruiz77/ Puedes seguirnos en nuestra web: https://www.podcastmotor.es Twiter: https://twitter.com/AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ Youtube: https://www.youtube.com/channel/UC57czZy-ctfV02t_PeNXCAQ Contacto: info@autofm.es

#cochesfiables #fiabilidad #microhibridos #kiario #tesla Desde los estudios centrales de ONDACERO Madrid Sur te acercamos las últimas noticias del motor, pruebas de los últimos modelos que llegan al mercado, consejos y recomendaciones y seguridad vial. Nos puedes escuchar en directo en ONDACERO Madrid Sur y ONDACERO Jaén. Analizamos las siguientes noticias: • Noruega era el paraíso del coche eléctrico, hasta que se recortaron las ayudas: las ventas han caído a nivel de 1962 • El Kia Rio sigue el mismo camino que el Ford Fiesta y dice adiós al mercado europeo • ¿Qué podemos hacer si vamos conduciendo y nos empezamos a encontrar mal? • Los Peugeot 3008 y 5008 estrenan motores 1.2 PureTech microhíbridos • Confirmado el debut del Mazda CX-80 en Europa a finales de 2023 • No vamos a poder comprar coches nuevos gasolina o diésel a partir de 2035: Europa se mantiene firme en su prohibición • Ford despedirá a 3.800 trabajadores en Europa, la planta de Almussafes se libra gracias al coche eléctrico • La encuesta de calidad de JD Power sitúa a Lexus y Kia como las marcas más fiables y posiciona a Tesla abajo en la clasificación • Llega al mercado el exclusivo MINI Cooper SE Cabrio 2023, el 100% eléctrico descapotable de Mini. El equipo de gala que ha acompañado en este programa especial ha sido: Fernando Rivas y José Lagunar y Javier Hernando. Como invitado especial: - Nacho Rabadán Director General de CEEES. Confederación Española de Empresarios de Estaciones de Servicios. Intentando dirigir a estos profesionales del motor, Antonio R. Vaquerizo. En la sección de TotalEnergies descubrimos como cambiar el aceite de las cajas de cambios automáticas. Puedes seguirnos en nuestra web: https://autofm.es/ y https://www.podcastmotor.es Twitter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ YouTube: https://www.youtube.com/channel/UC57czZy-ctfV02t_PeNXCAQ Contacto: info@autofm.es

Malý trojvalec, automat s 8 stupňami, všetko fajn. A potom zrazu, dačo! Veď si vypočujte. #opel #astra #automobilovypodcast

Air and water quality in the home is something that should be front-of-mind for us all. Thankfully, companies like RePure have brought solutions to market that make it easy to do it right. Learn what they do, how they do it, and how to improve air and water quality by utilizing their products and resources in this episode of Connecting Tech+Design with RePure President, Michael Don Ham — who is also WELL AP certified, a member of the WELL Faculty, and a Fitwel Ambassador. For interior designers, architects, and technology integration professionals, this episode offers valuable insights as well as new market opportunities. Download and tune in today! To learn more about RePure, visit www.puretech-alliance.com and www.linkedin.com/company/52175681/admin, and to connect with Michael Don Ham, go to www.linkedin.com/in/michael-d-ham.

In this episode, Ayesha talked about the FDA approval of Ferring Pharmaceuticals' fecal matter-based therapy Rebyota for the treatment of recurrent C. difficile infections. While fecal matter transplants (FMT) have been a standard of care for recurrent CDIs, despite not having formal approval, Rebyota has become the first FDA approved FMT-based treatment for CDIs. Hear more about the drug and its approval in this episode. Ayesha also discussed a new CBD oral capsule being developed by PureTech Health for the treatment of epilepsy and potentially other indications as well. The drug will be going up against Jazz Pharma's Epidiolex, which was first approved in 2018 for the treatment of seizures associated with rare types of epilepsy. Hear about the advantages of an oral capsule formulation of CBD, including lower costs and not requiring the use of sesame oil.Read the full articles here:FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C. Difficile InfectionPureTech Reveals New CBD Pill to Rival Jazz's EpidiolexFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

El programa de hoy lo podemos calificar como de histórico porque vamos a hablar de la primera vez que Fiat produce coches en España y lo hace concretamente en la factoría del Grupo Stellantis en Vigo. Concretamente el primer Fiat que se hace en Vigo fue una Fiat eDobló que se produjo en Enero de 2022. En esas instalaciones ya se fabrican hasta cinco marcas distintas. Y es que en en la fábrica inaugurada en 1958 y donde históricamente han salido todos los modelos de Citroen que recordamos ahora también se producen vehículos de Peugeot, Opel, Vauxhall (para el Reino Unido), Toyota y, ahora Fiat. En total unos 16 Modelos diferentes coches de los que 12 tiene versión EV completamente eléctrica. Y es que el Grupo Stellantis es líder en electrificación en España. No en vano1 de cada 4 coches electrificados que se venden en España lo fabrica Stellantis. Con todos estos modelo no hace nada más que reforzar el compromiso del grupo de llegar a 2038 neutro en carbono en toda la cadena de valor. Aunque en 2030 ya quieren tener una reducción del 50% en esas emisiones de carbono. Por la constante progresión del grupo se están desarrollando desde ya hasta 4 plataformas nuevas para la futuro construcción de vehículos eléctricos. Cada una especializada en sectores clave como la movilidad urbana eficiente, los vehículos premium, los coches deportivos o los de gran capacidad y prácticos. De la factoría del Grupo Stellantis en Vigo salen casi medio millón de coches algunos años como fue el pasado 2021. Porque sin las restricciones de los semiconductores, pandemias, guerras o demás incidencias son capaces de fabricar 2.300 coches. Algo que es la única fábrica en España que lo consigue. Para todo ello en la factoría de Stellantis hay 6.400 empleados que se multiplican por 5 si hablamos de la industria de componentes y servicios que lo rodean. Dando trabajo a 125 proveedores de componentes que la rodean. Con estos datos es fácil adivinar que Stellantis Vigo es la fábrica con mayor número de coches construidos al año de España, mientras que Stellantis Zaragoza es la tercera (por detrás de Martorell del Grupo Volkswagen). A todo esto se suma Stellantis Madrid con unos 75.000 coches al año lo que dan una pista de la dimensión del grupo para nuestro país. En este programa vamos a hablar también de la nueva Fiat Dobló que se fabrica sobre la plataforma modular EMP2 que se desarrolló en 2015 y que llegó a la fábrica en 2018. Una plataforma que luego se fue mejorando llegando la electrificación hasta ella. El primer coche en utilizarla con algún tipo de electrificación fue el Peugeot 2008. Es bueno que sepamos que el peso de la electrificación en el sector de los industriales ligeros que es muy importante pues el 20 por ciento de las furgonetas que se hacen en Vigo son eléctricas ya. Un éxito de esta factoría gallega pues pese a que un motor eléctrico tiene menos piezas que un motor de combustión a la hora de la fabricación el eléctrico tiene más trabajo. Desde 1995 en Vigo ya se hizo un trabajo para montar una Citroen C15 eléctrica hasta 2021 que un Peugeot 2008 fue el primero en salir de la línea de montaje como vehículo eléctrico. Antes se llevaba a una nave distinta el coche y allí se montaba como eléctrico. La Dobló completa la gama eléctrica de Fiat que viene a jugar al segmento de ventas más grande del mercado con un 40% de cuota. Se denomina segmento C de furgonetas eléctricas tanto para el transporte de personas como de mercancías. A partir de ahora toda la gama de Fiat Professional está electrificada. Ya tienen más de 1.000 pedidos de Fiat Dobló tanto en combustión como en eléctricas. De hecho Stellantis tiene en el segmento C eléctrico una cuota de mercado del 92 % con todas sus marcas. Además Stellantis es líder absoluto de industriales ligeros con un 38% de cuota en lo que va de año. Siendo un 40% su cuota en vehículos de bajas emisiones. La Fiat Dobló llegó al mercado en 2000 y ahora es ya su quinta generación. Dispone de 4 siluetas y 2 longitudes que van desde los 4,4 a los 4,75 metros. Y con capacidades de 3,3 a 3,8 metros cúbicos en su longitud estándar a los 3,9 a 4,4 metros cúbicos en la versión Maxi. MOTORES: · Diésel 1.5 BlueHDI con acabados de 130 y 100 caballos · Gasolina 1.2 Puretech de 110 caballos MOTOR ELÉCTRICO · Potencia de 100 kW (136cv) con batería de iones litio de 50 kWh y una autonomía homologada WLTP de 285 km. Con una capacidad de carga en DC de hasta 100kw y en AC de hasta 7,4 KW pero se puede opcionalmente hasta 11 kw. Lleva de serie un cable de carga modo 3 incluido. Dispone de 3 asientos delanteros con oficina móvil que se monta bajando el asiento del medio. Además bajando los dos asientos de pasajeros delanteros puedes conseguir un espacio extra de 0,5 metros de longitud. En otro orden de cosas hay una versión combi N1 para pasajeros y carga jugando con la posición de la mampara. Se clasifica como mixto adaptable. El diseño sin grandes estridencias es robusto y protector, muy sobrio con los parachoques en negro, barras de techo y llantas de hasta 17 pulgadas. Dispone además de una más que interesante versión de 7 plazas. Con 5 plazas el maletero es de hasta 770 litros. Si abatimos todos los asientos nos queda un gran suelo plano. Dispone de acceso al maletero levantando el cristal del portón solo. Por dentro la versión del pasajero puede añadir un techo flotante panorámico muy grande y más espacio para dejar objetos y la pantalla multimedia es de 8 pulgadas y el cuarto de instrumentos es de 10 pulgadas con tecnología compatible con Appel Car Play y Android Auto. Para la configuración de la versión furgón hay diferentes packs de personalización que son: Pack Carga, Pack Confort y Funcionalidad, Pack Seguridad y Pack ADAS o Estilo. Mientas que para la configuración de la versión de pasajeros son: Pack Style, Pack Comfort y Pack Técnico. En cuanto al precio la cuota para los furgones son 229 euros al mes más IVA para la eléctrica y para la de combustión igual pero la eléctrica con más entrada. La cuota para la versión de pasajeros son 249 euros con IVA a 36 meses con 3 años de mantenimiento y cargador de regalo. Un gran equipamiento en materia de seguridad con hasta 17 ADAS. De lo mejor de su segmento. Ahora se está fabricando a tope y se está haciendo stock para tratar de que los plazos de entrega sean los mínimos. Quieren estar por debajo de los 6 meses siempre. De hecho de momento se está tirando del stock que viene de las fabricadas en Turquía. Fernando Rivas: https://www.linkedin.com/in/fernando-rivas-4965681a8/ Jose Antonio León Capitán: https://www.linkedin.com/in/jaleoncapitan/ Puedes seguirnos en nuestra web: https://www.podcastmotor.es Twiter: https://twitter.com/AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ Youtube: https://www.youtube.com/channel/UC57czZy-ctfV02t_PeNXCAQ Contacto: info@autofm.es

Leonard S. Johnson is the Founder and CEO of AIEDC, a 5G Cloud Mobile App Maker and Service Provider with Machine Learning to help small and midsize businesses create their own iOS and Android mobile apps with no-code or low-code so they can engage and service their customer base, as well as provide front and back office digitization services for small businesses. Victoria talks to Leonard about using artificial intelligence for good, bringing the power of AI to local economics, and truly democratizing AI. The Artificial Intelligence Economic Development Corporation (AIEDC) (https://netcapital.com/companies/aiedc) Follow AIEDC on Twitter (https://twitter.com/netcapital), Instagram (https://www.instagram.com/netcapital/), Facebook (https://www.facebook.com/Netcapital/), or LinkedIn (https://www.linkedin.com/company/aiedc/). Follow Leonard on Twitter (https://twitter.com/LeonardSJ) and LinkedIn (https://www.linkedin.com/in/leonardsjohnson84047/). Follow thoughtbot on Twitter (https://twitter.com/thoughtbot) or LinkedIn (https://www.linkedin.com/company/150727/). Become a Sponsor (https://thoughtbot.com/sponsorship) of Giant Robots! Transcript: VICTORIA: This is The Giant Robots Smashing Into Other Giant Robots Podcast, where we explore the design, development, and business of great products. I'm your host, Victoria Guido. And with us today is Leonard S. Johnson or LS, Founder and CEO AIEDC, a 5G Cloud Mobile App Maker and Service Provider with Machine Learning to help small and midsize businesses create their own iOS and Android mobile apps with no-code or low-code so they can engage and service their customer base, as well as provide front and back office digitization services for small businesses. Leonard, thanks for being with us today. LEONARD: Thank you for having me, Victoria. VICTORIA: I should say LS, thank you for being with us today. LEONARD: It's okay. It's fine. VICTORIA: Great. So tell us a little more about AIEDC. LEONARD: Well, AIEDC stands for Artificial Intelligence Economic Development Corporation. And the original premise that I founded it for...I founded it after completing my postgraduate work at Stanford, and that was 2016. And it was to use AI for economic development, and therefore use AI for good versus just hearing about artificial intelligence and some of the different movies that either take over the world, and Skynet, and watch data privacy, and these other things which are true, and it's very evident, they exist, and they're out there. But at the end of the day, I've always looked at life as a growth strategy and the improvement of what we could do and focusing on what we could do practically. You do it tactically, then you do it strategically over time, and you're able to implement things. That's why I think we keep building collectively as humanity, no matter what part of the world you're in. VICTORIA: Right. So you went to Stanford, and you're from South Central LA. And what about that background led you to pursue AI for good in particular? LEONARD: So growing up in the inner city of Los Angeles, you know, that South Central area, Compton area, it taught me a lot. And then after that, after I completed high school...and not in South Central because I moved around a lot. I grew up with a single mother, never knew my real father, and then my home life with my single mother wasn't good because of just circumstances all the time. And so I just started understanding that even as a young kid, you put your brain...you utilize something because you had two choices. It's very simple or binary, you know, A or B. A, you do something with yourself, or B, you go out and be social in a certain neighborhood. And I'm African American, so high probability that you'll end up dead, or in a gang, or in crime because that's what it was at that time. It's just that's just a situation. Or you're able to challenge those energies and put them toward a use that's productive and positive for yourself, and that's what I did, which is utilizing a way to learn. I could always pick up things when I was very young. And a lot of teachers, my younger teachers, were like, "You're very, very bright," or "You're very smart." And there weren't many programs because I'm older than 42. So there weren't as many programs as there are today. So I really like all of the programs. So I want to clarify the context. Today there's a lot more engagement and identification of kids that might be sharper, smarter, whatever their personal issues are, good or bad. And it's a way to sort of separate them. So you're not just teaching the whole group as a whole and putting them all in one basket, but back then, there was not. And so I just used to go home a lot, do a lot of reading, do a lot of studying, and just knick-knack with things in tech. And then I just started understanding that even as a young kid in the inner city, you see economics very early, but they don't understand that's really what they're studying. They see economics. They can see inflation because making two ends meet is very difficult. They may see gang violence and drugs or whatever it might end up being. And a lot of that, in my opinion, is always an underlining economic foundation. And so people would say, "Oh, why is this industry like this?" And so forth. "Why does this keep happening?" It's because they can't function. And sometimes, it's just them and their family, but they can't function because it's an economic system. So I started focusing on that and then went into the Marine Corps. And then, after the Marine Corps, I went to Europe. I lived in Europe for a while to do my undergrad studies in the Netherlands in Holland. VICTORIA: So having that experience of taking a challenge or taking these forces around you and turning into a force for good, that's led you to bring the power of AI to local economics. And is that the direction that you went eventually? LEONARD: So economics was always something that I understood and had a fascination prior to even starting my company. I started in 2017. And we're crowdfunding now, and I can get into that later. But I self-funded it since 2017 to...I think I only started crowdfunding when COVID hit, which was 2020, and just to get awareness and people out there because I couldn't go to a lot of events. So I'm like, okay, how can I get exposure? But yeah, it was a matter of looking at it from that standpoint of economics always factored into me, even when I was in the military when I was in the Marine Corps. I would see that...we would go to different countries, and you could just see the difference of how they lived and survived. And another side note, my son's mother is from Ethiopia, Africa. And I have a good relationship with my son and his mother, even though we've been apart for over 15 years, divorced for over 15 years or so or longer. But trying to keep that, you can just see this dichotomy. You go out to these different countries, and even in the military, it's just so extreme from the U.S. and any part of the U.S, but that then always focused on economics. And then technology, I just always kept up with, like, back in the '80s when the mobile brick phone came out, I had to figure out how to get one. [laughs] And then I took it apart and then put it back together just to see how it works, so yeah. But it was a huge one, by the way. I mean, it was like someone got another and broke it, and they thought it was broken. And they're like, "This doesn't work. You could take this piece of junk." I'm like, "Okay." [laughs] VICTORIA: Like, oh, great. I sure will, yeah. Now, I love technology. And I think a lot of people perceive artificial intelligence as being this super futuristic, potentially harmful, maybe economic negative impact. So what, from your perspective, can AI do for local economics or for people who may not have access to that advanced technology? LEONARD: Well, that's the key, and that's what we're looking to do with AIEDC. When you look at the small and midsize businesses, it's not what people think, or their perception is. A lot of those in the U.S. it's the backbone of the United States, our economy, literally. And in other parts of the world, it's the same where it could be a one or two mom-and-pop shops. That's where that name comes from; it's literally two people. And they're trying to start something to build their own life over time because they're using their labor to maybe build wealth or somehow a little bit not. And when I mean wealth, it's always relative. It's enough to sustain themselves or just put food on the table and be able to control their own destiny to the best of their ability. And so what we're looking to do is make a mobile app maker that's 5G that lives in the cloud, that's 5G compliant, that will allow small and midsize businesses to create their own iOS or Android mobile app with no-code or low-code, basically like creating an email. That's how simple we want it to be. When you create your own email, whether you use Microsoft, Google, or whatever you do, and you make it that simple. And there's a simple version, and there could be complexity added to it if they want. That would be the back office digitization or customization, but that then gets them on board with digitization. It's intriguing that McKinsey just came out with a report stating that in 2023, in order to be economically viable, and this was very recent, that all companies would need to have a digitization strategy. And so when you look at small businesses, and you look at things like COVID-19, or the COVID current ongoing issue and that disruption, this is global. And you look at even the Ukrainian War or the Russian-Ukrainian War, however you term it, invasion, war, special operation, these are disruptions. And then, on top of that, we look at climate change which has been accelerating in the last two years more so than it was prior to this that we've experienced. So this is something that everyone can see is self-evident. I'm not even focused on the cause of the problem. My brain and the way I think, and my team, we like to focus on solutions. My chairman is a former program director of NASA who managed 1,200 engineers that built the International Space Station; what was it? 20-30 years ago, however, that is. And he helped lead and build that from Johnson Center. And so you're focused on solutions because if you're building the International Space Station, you can only focus on solutions and anticipate the problems but not dwell on them. And so that kind of mindset is what I am, and it's looking to help small businesses do that to get them on board with digitization and then in customization. And then beyond that, use our system, which is called M.I.N.D. So we own these...we own patents, three patents, trademarks, and service marks related to artificial intelligence that are in the field of economics. And we will utilize DEVS...we plan to do that which is a suite of system specifications to predict regional economic issues like the weather in a proactive way, not reactive. A lot of economic situations are reactive. It's reactive to the Federal Reserve raising interest rates or lowering rates, Wall Street, you know, moving money or not moving money. It is what it is. I mean, I don't judge it. I think it's like financial engineering, and that's fine. It's profitability. But then, at the end of the day, if you're building something, it's like when we're going to go to space. When rockets launch, they have to do what they're intended to do. Like, I know that Blue Origin just blew up recently. Or if they don't, they have a default, and at least I heard that the Blue Origin satellite, if it were carrying passengers, the passengers would have been safe because it disembarked when it detected its own problem. So when you anticipate these kinds of problems and you apply them to the local small business person, you can help them forecast and predict better like what weather prediction has done. And we're always improving that collectively for weather prediction, especially with climate change, so that it can get to near real-time as soon as possible or close a window versus two weeks out versus two days out as an example. VICTORIA: Right. Those examples of what you call a narrow economic prediction. LEONARD: Correct. It is intriguing when you say narrow economic because it wouldn't be narrow AI. But it would actually get into AGI if you added more variables, which we would. The more variables you added in tenancies...so if you're looking at events, the system events discretion so discrete event system specification you would specify what they really, really need to do to have those variables. But at some point, you're working on a system, what I would call AGI. But AGI, in my mind, the circles I run in at least or at least most of the scientists I talk to it's not artificial superintelligence. And so the general public thinks AGI...and I've said this to Stephen Ibaraki, who's the founder of AI for Good at Global Summit at the United Nations, and one of his interviews as well. It's just Artificial General Intelligence, I think, has been put out a lot by Hollywood and entertainment and so forth, and some scientists say certain things. We won't be at artificial superintelligence. We might get to Artificial General Intelligence by 2030 easily, in my opinion. But that will be narrow AI, but it will cover what we look at it in the field as cross-domain, teaching a system to look at different variables because right now, it's really narrow. Like natural language processing, it's just going to look at language and infer from there, and then you've got backward propagation that's credit assignment and fraud and detection. Those are narrow data points. But when you start looking at something cross-domain...who am I thinking of? Pedro Domingos who wrote the Master Algorithm, which actually, Xi Jinping has a copy of, the President of China, on his bookshelf in his office because they've talked about that, and these great minds because Stephen Ibaraki has interviewed these...and the founder of Google Brain and all of these guys. And so there's always this debate in the scientific community of what is narrow AI what it's not. But at the end of the day, I just like Pedro's definition of it because he says the master algorithm will be combining all five, so you're really crossing domains, which AI hasn't done that. And to me, that will be AGI, but that's not artificial superintelligence. And artificial superintelligence is when it becomes very, you know, like some of the movies could say, if we as humanity just let it run wild, it could be crazy. VICTORIA: One of my questions is the future of AI more like iRobot or Bicentennial Man? LEONARD: Well, you know, interesting. That's a great question, Victoria. I see most of AI literally as iRobot, as a tool more than anything, except at the end when it implied...so it kind of did two things in that movie, but a wonderful movie to bring up. And I like Will Smith perfectly. Well, I liked him a lot more before -- VICTORIA: I think iRobot is really the better movie. LEONARD: Yeah, so if people haven't seen iRobot, I liked Will Smith, the actor. But iRobot showed you two things, and it showed you, one, it showed hope. Literally, the robot...because a lot of people put AI and robots. And AI by itself is the brain or the mind; I should say hardware are the robots or the brain. Software...AI in and of itself is software. It's the mind itself. That's why we have M.I.N.D Machine Intelligence NeuralNetwork Database. We literally have that. That's our acronym and our slogan and everything. And it's part of our patents. But its machine intelligence is M.I.N.D, and we own that, you know; the company owns it. And so M.I.N.D...we always say AI powered by M.I.N.D. We're talking about that software side of, like, what your mind does; it iterates and thinks, the ability to think itself. Now it's enclosed within a structure called, you know, for the human, it's called a brain, the physical part of it, and that brain is enclosed within the body. So when you look at robots...and my chairman was the key person for robotics for the International Space Station. So when you look at robotics, you are putting that software into hardware, just like your cell phone. You have the physical, and then you have the actual iOS, which is the operating system. So when you think about that, yeah, iRobot was good because it showed how these can be tools, and they were very, in the beginning of the movie, very helpful, very beneficial to humanity. But then it went to a darker side and showed where V.I.K.I, which was an acronym as well, I think was Virtual Interactive Kinetic technology of something. Yeah, I believe it was Virtual Interactive Kinetic inference or technology or something like that, V.I.K.I; I forgot the last I. But that's what it stood for. It was an acronym to say...and then V.I.K.I just became all aware and started killing everyone with robots and just wanted to say, you know, this is futile. But then, at the very, very end, V.I.K.I learned from itself and says, "Okay, I guess this isn't right." Or the other robot who could think differently argued with V.I.K.I, and they destroyed her. And it made V.I.K.I a woman in the movie, and then the robot was the guy. But that shows that it can get out of hand. But it was intriguing to me that they had her contained within one building. This wouldn't be artificial superintelligence. And I think sometimes Hollywood says, "Just take over everything from one building," no. It wouldn't be on earth if it could. But that is something we always have to think about. We have to think about the worst-case scenarios. I think every prudent scientist or business person or anyone should do that, even investors, I mean, if you're investing something for the future. But you also don't focus on it. You don't think about the best-case scenario, either. But there's a lot of dwelling on the worst-case scenario versus the good that we can do given we're looking at where humanity is today. I mean, we're in 2022, and we're still fighting wars that we fought in 1914. VICTORIA: Right. Which brings me to my next question, which is both, what are the most exciting opportunities to innovate in the AI space currently? And conversely, what are the biggest challenges that are facing innovation in that field? LEONARD: Ooh, that's a good question. I think, in my opinion, it's almost the same answer; one is...but I'm in a special field. And I'm surprised there's not a lot of competition for our company. I mean, it's very good for me and the company's sense. It's like when Mark Zuckerberg did Facebook, there was Friendster, and there was Myspace, but they were different. They were different verticals. And I think Mark figured out how to do it horizontally, good or bad. I'm talking about the beginning of when he started Facebook, now called Meta. But I'm saying utilizing AI in economics because a lot of times AI is used in FinTech and consumerism, but not economic growth where we're really talking about growing something organically, or it's called endogenous growth. Because I studied Paul Romer's work, who won the Nobel Prize in 2018 for economic science. And he talked about the nature of ideas. And we were working on something like that in Stanford. And I put out a book in 2017 of January talking about cryptocurrencies, artificial intelligence but about the utilization of it, but not the speculation. I never talked about speculation. I don't own any crypto; I would not. It's only once it's utilized in its PureTech form will it create something that it was envisioned to do by the protocol that Satoshi Nakamoto sort of created. And it still fascinates me that people follow Bitcoin protocol, even for the tech and the non-tech, but they don't know who Satoshi is. But yeah, it's a white paper. You're just following a white paper because I think logically, the world is going towards that iteration of evolution. And that's how AI could be utilized for good in an area to focus on it with economics and solving current problems. And then going forward to build a new economy where it's not debt-based driven or consumer purchase only because that leaves a natural imbalance in the current world structure. The western countries are great. We do okay, and we go up and down. But the emerging and developing countries just get stuck, and they seem to go into a circular loop. And then there are wars as a result of these things and territory fights and so forth. So that's an area I think where it could be more advanced is AI in the economic realm, not so much the consumer FinTech room, which is fine. But consumer FinTech, in my mind, is you're using AI to process PayPal. That's where I think Elon just iterated later because PayPal is using it for finance. You're just moving things back and forth, and you're just authenticating everything. But then he starts going on to SpaceX next because he's like, well, let me use technology in a different way. And I do think he's using AI on all of his projects now. VICTORIA: Right. So how can that tech solve real problems today? Do you see anything even particular about Southern California, where we're both at right now, where you think AI could help predict some outcomes for small businesses or that community? LEONARD: I'm looking to do it regionally then globally. So I'm part of this Southern Cal Innovation Hub, which is just AI. It's an artificial intelligence coordination between literally San Diego County, Orange County, and Los Angeles County. And so there's a SoCal Innovation Hub that's kind of bringing it together. But there are all three groups, like; I think the CEO in Orange County is the CEO of Leadership Alliance. And then in San Diego, there's another group I can't remember their name off the top of my head, and I'm talking about the county itself. So each one's representing a county because, you know. And then there's one in Northern California that I'm also associated with where if you look at California as its own economy in the U.S., it's still pretty significant as an economic cycle in the United States, period. That's why so many politicians like California because they can sway the votes. So yeah, we're looking to do that once, you know, we are raising capital. We're crowdfunding currently. Our total raise is about 6 million. And so we're talking to venture capitalists, private, high net worth investors as well. Our federal funding is smaller. It's just like several hundred thousand because most people can only invest a few thousand. But I always like to try to give back. If you tell people...if you're Steve Jobs, like, okay, I've got this Apple company. In several years, you'll see the potential. And people are like, ah, whatever, but then they kick themselves 15 years later. [laughs] Like, oh, I wish I thought about that Apple stock for $15 when I could. But you give people a chance, and you get the word out, and you see what happens. Once you build a system, you share it. There are some open-source projects. But I think the open source, like OpenAI, as an example, Elon Musk funds that as well as Microsoft. They both put a billion dollars into it. It is an open-source project. OpenAI claims...but some of the research does go back to Microsoft to be able to see it. And DeepMind is another research for AI, but they're owned by Google. And so, I'm also very focused on democratizing artificial intelligence for the benefit of everyone. I really believe that needs to be democratized in a sense of tying it to economics and making it utilized for everyone that may need it for the benefit of humanity where it's profitable and makes money, but it's not just usurping. MID-ROLL AD: As life moves online, brick-and-mortar businesses are having to adapt to survive. With over 18 years of experience building reliable web products and services, thoughtbot is the technology partner you can trust. We provide the technical expertise to enable your business to adapt and thrive in a changing environment. We start by understanding what's important to your customers to help you transition to intuitive digital services your customers will trust. We take the time to understand what makes your business great and work fast yet thoroughly to build, test, and validate ideas, helping you discover new customers. Take your business online with design‑driven digital acceleration. Find out more at tbot.io/acceleration or click the link in the show notes for this episode. VICTORIA: With that democratizing it, is there also a need to increase the understanding of the ethics around it and when there are certain known use cases for AI where it actually is discriminatory and plays to systemic problems in our society? Are you familiar with that as well? LEONARD: Yes, absolutely. Well, that's my whole point. And, Victoria, you just hit the nail on the head. Truly democratizing AI in my mind and in my brain the way it works is it has opened up for everyone. Because if you really roll it back, okay, companies now we're learning...we used to call it several years ago UGC, User Generated Content. And now a lot of people are like, okay, if you're on Facebook, you're the product, right? Or if you're on Instagram, you're the product. And they're using you, and you're using your data to sell, et cetera, et cetera. But user-generated content it's always been that. It's just a matter of the sharing of the economic. That's why I keep going back to economics. So if people were, you know, you wouldn't have to necessarily do advertising if you had stakeholders with advertising, the users and the company, as an example. If it's a social media company, just throwing it out there, so let's say you have a social media...and this has been talked about, but I'm not the first to introduce this. This has been talked about for over ten years, at least over 15 years. And it's you share as a triangle in three ways. So you have the user and everything else. So take your current social media, and I won't pick on Facebook, but I'll just use them, Facebook, Instagram, or Twitter. Twitter's having issues recently because Elon is trying to buy them or get out of buying them. But you just looked at that data, and then you share with the user base. What's the revenue model? And there needs to be one; let me be very clear. There has to be incentive, and there has to be profitability for people that joined you earlier, you know, joined the corporation, or become shareholders, or investors, or become users, or become customers. They have to be able to have some benefit, not extreme greater than everyone else but a great benefit from coming in earlier by what they contributed at the time. And that is what makes this system holistic in my opinion, like Reddit or any of these bloggers. But you make it where they use their time and the users, and you share it with the company and then the data and so forth, and whatever revenue economic model you have, and it's a sort of a three-way split. It's just not always equal. And that's something that I think in economics, we're still on a zero-sum game, I win, you lose sort of economic model globally. That's why there's a winner of a war and a loser of a war. But in reality, as you know, Victoria, there are no winners of any war. So it's funny, [laughs] I was just saying, well, you know, because of the economic mode, but Von Neumann, who talked about that, also talked about something called a non-zero-sum game when he talked about it in mathematics that you can win, and I can win; we just don't win equally because they never will match that. So if I win, I may win 60; you win 40. Or you may win 60, I win 40, and we agree to settle on that. It's an agreement versus I'm just going to be 99, and you'll be 1%, or I'm just going to be 100, and you're at 0. And I think that our economic model tends to be a lot of that, like, when you push forth and there needs to be more of that. When you talk about the core of economics...and I go way back, you know, prior to the Federal Reserve even being started. I just look at the world, and it's always sort of been this land territorial issue of what goods are under the country. But we've got technology where we can mitigate a lot of things and do the collective of help the earth, and then let's go off to space, all of space. That's where my brain is focused on. VICTORIA: Hmm. Oh yeah, that makes sense to me. I think that we're all going to have to evolve our economic models here in the future. I wonder, too, as you're building your startup and you're building your company, what are some of the technology trade-offs you're having to make in the stack of the AI software that you're building? LEONARD: Hmm. Good question. But clarify, this may be a lot deeper dive because that's a general question. And I don't want to...yeah, go ahead. VICTORIA: Because when you're building AI, and you're going to be processing a lot of data, I know many data scientists that are familiar with tools like Jupyter Notebooks, and R, and Python. And one issue that I'm aware of is keeping the environments the same, so everything that goes into building your app and having those infrastructure as code for your data science applications, being able to afford to process all that data. [laughs] And there are just so many factors that go into building an AI app versus building something that's more easy, like a web-based user form. So just curious if you've encountered those types of trade-offs or questions about, okay, how are we going to actually build an app that we can put out on everybody's phone and that works responsibly? LEONARD: Oh, okay. So let me be very clear, but I won't give too much of the secret sauce away. But I can define this technically because this is a technical audience. This is not...so what you're really talking about is two things, and I'm clear about this, though. So the app maker won't really read and write a lot of data. It'll just be the app where people could just get on board digitalization simple, you know, process payments, maybe connect with someone like American Express square, MasterCard, whatever. And so that's just letting them function. That's sort of small FinTech in my mind, you know, just transaction A to B, B to A, et cetera. And it doesn't need to be peer-to-peer and all of the crypto. It doesn't even need to go that level yet. That's just level one. Then they will sign up for a service, which is because we're really focused on artificial intelligence as a service. And that, to me, is the next iteration for AI. I've been talking about this for about three or four years now, literally, in different conferences and so forth for people who haven't hit it. But that we will get to that point where AI will become AI as a service, just like SaaS is. We're still at the, you know, most of the world on the legacy systems are still software as a service. We're about to hit AI as a service because the world is evolving. And this is true; they did shut it down. But you did have okay, so there are two case points which I can bring up. So JP Morgan did create something called a Coin, and it was using AI. And it was a coin like crypto, coin like a token, but they called it a coin. But it could process, I think, something like...I may be off on this, so to the sticklers that will be listening, please, I'm telling you I may be off on the exact quote, but I think it was about...it was something crazy to me, like 200,000 of legal hours and seconds that it could process because it was basically taking the corporate legal structure of JP Morgan, one of the biggest banks. I think they are the biggest bank in the U.S. JPMorgan Chase. And they were explaining in 2017 how we created this, and it's going to alleviate this many hours of legal work for the bank. And I think politically; something happened because they just pulled away. I still have the original press release when they put it out, and it was in the media. And then it went away. I mean, no implementation [laughs] because I think there was going to be a big loss of jobs for it. And they basically would have been white-collar legal jobs, most specifically lawyers literally that were working for the bank. And when they were talking towards investment, it was a committee. I was at a conference. And I was like, I was fascinated by that. And they were basically using Bitcoin protocol as the tokenization protocol, but they were using AI to process it. And it was basically looking at...because legal contracts are basically...you can teach it with natural language processing and be able to encode and almost output it itself and then be able to speak with each other. Another case point was Facebook. They had...what was it? Two AI systems. They began to create their own language. I don't know if you remember that story or heard about it, and Facebook shut it down. And this was more like two years ago, I think, when they were saying Facebook was talking, you know, when they were Facebook, not Meta, so maybe it was three years ago. And they were talking, and they were like, "Oh, Facebook has a language. It's talking to each other." And it created its own little site language because it was two AI bots going back and forth. And then the engineers at Facebook said, "We got to shut this down because this is kind of getting out of the box." So when you talk about AI as a service, yes, the good and the bad, and what you take away is AWS, Oracle, Google Cloud they do have services where it doesn't need to cost you as much anymore as it used to in the beginning if you know what you're doing ahead of time. And you're not just running iterations or data processing because you're doing guesswork versus, in my opinion, versus actually knowing exactly specifically what you're looking for and the data set you're looking to get out of it. And then you're talking about just basically putting in containers and clustering it because it gets different operations. And so what you're really looking at is something called an N-scale graph data that can process data in maybe sub seconds at that level, excuse me. And one of my advisors is the head of that anyway at AGI laboratory. So he's got an N graph database that can process...when we implement it, we'll be able to process data at the petabyte level at sub-seconds, and it can run on platforms like Azure or AWS, and so forth. VICTORIA: Oh, that's interesting. So it sounds like cloud providers are making compute services more affordable. You've got data, the N-scale graph data, that can run more transactions more quickly. And I'm curious if you see any future trends since I know you're a futurist around quantum computing and how that could affect capacity for -- LEONARD: Oh [laughs] We haven't even gotten there yet. Yes. Well, if you look at N-scale, if you know what you're doing and you know what to look for, then the quantum just starts going across different domains as well but at a higher hit rate. So there's been some quantum computers online. There's been several...well, Google has their quantum computer coming online, and they've been working on it, and Google has enough data, of course, to process. So yeah, they've got that data, lots of data. And quantum needs, you know, if it's going to do something, it needs lots of data. But then the inference will still be, I think, quantum is very good at processing large, large, large amounts of data. We can just keep going if you really have a good quantum computer. But it's really narrow. You have to tell it exactly what it wants, and it will do it in what we call...which is great like in P or NP square or P over NP which is you want to do it in polynomial time, not non-polynomial, polynomial time which is...now speaking too fast. Okay, my brain is going faster than my lips. Let me slow it down. So when you start thinking about processing, if we as humans, let's say if I was going to process A to Z, and I'm like, okay, here is this equation, if I tell you it takes 1000 years, it's of no use to us, to me and you Victoria because we're living now. Now, the earth may benefit in 1000 years, but it's still of no use. But if I could take this large amount of data and have it process within minutes, you know, worst case hours...but then I'll even go down to seconds or sub-seconds, then that's really a benefit to humanity now, today in present term. And so, as a futurist, yes, as the world, we will continue to add data. We're doing it every day, and we already knew this was coming ten years ago, 15 years ago, 20 years ago, even actually in the '50s when we were in the AI winter. We're now in AI summer. In my words, I call it the AI summer. So as you're doing this, that data is going to continue to increase, and quantum will be needed for that. But then the specific need...quantum is very good at looking at a specific issue, specifically for that very narrow. Like if you were going to do the trajectory to Jupiter or if we wanted to send a probe to Jupiter or something, I think we're sending something out there now from NASA, and so forth, then you need to process all the variables, but it's got one trajectory. It's going one place only. VICTORIA: Gotcha. Well, that's so interesting. I'm glad I asked you that question. And speaking of rockets going off to space, have you ever seen a SpaceX launch from LA? LEONARD: Actually, I saw one land but not a launch. I need to go over there. It's not too far from me. But you got to give credit where credit's due and Elon has a reusable rocket. See, that's where technology is solving real-world problems. Because NASA and I have, you know, my chairman, his name is Alexander Nawrocki, you know, he's Ph.D., but I call him Rocki. He goes by Rocki like I go by LS. But it's just we talk about this like NASA's budget. [laughs] How can you reduce this? And Elon says they will come up with a reusable rocket that won't cost this much and be able to...and that's the key. That was the kind of Holy Grail where you can reuse the same rocket itself and then add some little variables on top of it. But the core, you wouldn't constantly be paying for it. And so I think where the world is going...and let me be clear, Elon pushes a lot out there. He's just very good at it. But I'm also that kind of guy that I know that Tesla itself was started by two Stanford engineers. Elon came on later, like six months, and then he invested, and he became CEO, which was a great investment for Elon Musk. And then CEO I just think it just fit his personality because it was something he loved. But I also have studied for years Nikola Tesla, and I understand what his contributions created where we are today with all the patents that he had. And so he's basically the father of WiFi and why we're able to communicate in a lot of this. We've perfected it or improved it, but it was created by him in the 1800s. VICTORIA: Right. And I don't think he came from as fortunate a background as Elon Musk, either. Sometimes I wonder what I could have done born in similar circumstances. [laughter] And you certainly have made quite a name for yourself. LEONARD: Well, I'm just saying, yeah, he came from very...he did come from a poor area of Russia which is called the Russian territory, to be very honest, Eastern Europe, definitely Eastern Europe. But yeah, I don't know once you start thinking about that [laughs]. You're making me laugh, Victoria. You're making me laugh. VICTORIA: No, I actually went camping, a backpacking trip to the Catalina Island, and there happened to be a SpaceX launch that night, and we thought it was aliens because it looked wild. I didn't realize what it was. But then we figured it was a launch, so it was really great. I love being here and being close to some of this technology and the advancements that are going on. I'm curious if you have some thoughts about...I hear a lot about or you used to hear about Silicon Valley Tech like very Northern California, San Francisco focus. But what is the difference in SoCal? What do you find in those two communities that makes SoCal special? [laughs] LEONARD: Well, I think it's actually...so democratizing AI. I've been in a moment like that because, in 2015, I was in Dubai, and they were talking about creating silicon oasis. And so there's always been this model of, you know, because they were always, you know, the whole Palo Alto thing is people would say it and it is true. I mean, I experienced it. Because I was in a two-year program, post-graduate program executive, but we would go up there...I wasn't living up there. I had to go there maybe once every month for like three weeks, every other month or something. But when you're up there, it is the air in the water. It's just like, people just breathe certain things. Because around the world, and I would travel to Japan, and China, and other different parts of Asia, Vietnam, et cetera and in Africa of course, and let's say you see this and people are like, so what is it about Silicon Valley? And of course, the show, there is the Hollywood show about it, which is pretty a lot accurate, which is interesting, the HBO show. But you would see that, and you would think, how are they able to just replicate this? And a lot of it is a convergence. By default, they hear about these companies' access because the key is access, and that's what we're...like this podcast. I love the concept around it because giving awareness, knowledge, and access allows other people to spread it and democratize it. So it's just not one physical location, or you have to be in that particular area only to benefit. I mean, you could benefit in that area, or you could benefit from any part of the world. But since they started, people would go there; engineers would go there. They built company PCs, et cetera. Now that's starting to spread in other areas like Southern Cal are creating their own innovation hubs to be able to bring all three together. And those three are the engineers and founders, and idea makers and startups. And you then need the expertise. I'm older than 42; I'm not 22. [laughs] So I'm just keeping it 100, keeping it real. So I'm not coming out at 19. I mean, my son's 18. And I'm not coming out, okay, this my new startup, bam, give me a billion dollars, I'm good. And let me just write off the next half. But when you look at that, there's that experience because even if you look at Mark Zuckerberg, I always tell people that give credit where credit is due. He brought a senior team with him when he was younger, and he didn't have the experience. And his only job has been Facebook out of college. He's had no other job. And now he's been CEO of a multi-billion dollar corporation; that's a fact. Sometimes it hurts people's feelings. Like, you know what? He's had no other job. Now that can be good and bad, [laughs] but he's had no other jobs. And so that's just a credit, like, if you can surround yourself with the right people and be focused on something, it can work to the good or the bad for your own personal success but then having that open architecture. And I think he's been trying to learn and others versus like an Elon Musk, who embraces everything. He's just very open in that sense. But then you have to come from these different backgrounds. But let's say Elon Musk, Mark Zuckerberg, let's take a guy like myself or whatever who didn't grow up with all of that who had to make these two ends meet, figure out how to do the next day, not just get to the next year, but get to the next day, get to the next week, get to the next month, then get to the next year. It just gives a different perspective as well. Humanity's always dealing with that. Because we had a lot of great engineers back in the early 1900s. They're good or bad, you know, you did have Nikola Tesla. You had Edison. I'm talking about circa around 1907 or 1909, prior to World War I. America had a lot of industries. They were the innovators then, even though there were innovations happening in Europe, and Africa, and China, as well and Asia. But the innovation hub kind of created as the America, quote, unquote, "industrial revolution." And I think we're about to begin a new revolution sort of tech and an industrial revolution that's going to take us to maybe from 20...we're 2022 now, but I'll say it takes us from 2020 to 2040 in my head. VICTORIA: So now that communities can really communicate across time zones and locations, maybe the hubs are more about solving specific problems. There are regional issues. That makes a lot more sense. LEONARD: Yes. And collaborating together, working together, because scientists, you know, COVID taught us that. People thought you had to be in a certain place, but then a lot of collaboration came out of COVID; even though it was bad globally, even though we're still bad, if people were at home, they start collaborating, and scientists will talk to scientists, you know, businesses, entrepreneurs, and so forth. But if Orange County is bringing together the mentors, the venture capital, or at least Southern California innovation and any other place, I want to say that's not just Silicon Valley because Silicon Valley already has it; we know that. And that's that region. It's San Jose all the way up to...I forgot how far north it's past San Francisco, actually. But it's that region of area where they encompass the real valley of Silicon Valley if you're really there. And you talk about these regions. Yes, I think we're going to get to a more regional growth area, and then it'll go more micro to actually cities later in the future. But regional growth, I think it's going to be extremely important globally in the very near term. I'm literally saying from tomorrow to the next, maybe ten years, regional will really matter. And then whatever you have can scale globally anyway, like this podcast we're doing. This can be distributed to anyone in the world, and they can listen at ease when they have time. VICTORIA: Yeah, I love it. It's both exciting and also intimidating. [laughs] And you mentioned your son a little bit earlier. And I'm curious, as a founder and someone who spent a good amount of time in graduate and Ph.D. programs, if you feel like it's easy to connect with your son and maintain that balance and focusing on your family while you're building a company and investing in yourself very heavily. LEONARD: Well, I'm older, [laughs] so it's okay. I mean, I've mentored him, you know. And me and his mom have a relationship that works. I would say we have a better relationship now than when we were together. It is what it is. But we have a communication level. And I think she was just a great person because I never knew my real father, ever. I supposedly met him when I was two or one; I don't know. But I have no memories, no photos, nothing. And that was just the environment I grew up in. But with my son, he knows the truth of everything about that. He's actually in college. I don't like to name the school because it's on the East Coast, and it's some Ivy League school; that's what I will say. And he didn't want to stay on the West Coast because I'm in Orange County and his mom's in Orange County. He's like, "I want to get away from both of you people." [laughter] And that's a joke, but he's very independent. He's doing well. When he graduated high school, he graduated with 4.8 honors. He made the valedictorian. He was at a STEM school. VICTORIA: Wow. LEONARD: And he has a high GPA. He's studying computer science and economics as well at an Ivy League, and he's already made two or three apps at college. And I said, "You're not Mark, so calm down." [laughter] But anyway, that was a recent conversation. I won't go there. But then some people say, "LS, you should be so happy." What is it? The apple doesn't fall far from the tree. But this was something he chose around 10 or 11. I'm like, whatever you want to do, you do; I'll support you no matter what. And his mom says, "Oh no, I think you programmed him to be like you." [laughs] I'm like, no, I can't do that. I just told him the truth about life. And he's pretty tall. VICTORIA: You must have -- LEONARD: He played basketball in high school a lot. I'm sorry? VICTORIA: I was going to say you must have inspired him. LEONARD: Yeah. Well, he's tall. He did emulate me in a lot of ways. I don't know why. I told him just be yourself. But yes, he does tell me I'm an inspiration to that; I think because of all the struggles I've gone through when I was younger. And you're always going through struggles. I mean, it's just who you are. I tell people, you know, you're building a company. You have success. You can see the future, but sometimes people can't see it, [laughs] which I shouldn't really say, but I'm saying anyway because I do that. I said this the other night to some friends. I said, "Oh, Jeff Bezo's rocket blew up," going, you know, Blue Origin rocket or something. And then I said Elon will tell Jeff, "Well, you only have one rocket blow up. I had three, [laughter] SpaceX had three." So these are billionaires talking to billionaires about, you know, most people don't even care. You're worth X hundred billion dollars. I mean, they're worth 100 billion-plus, right? VICTORIA: Right. LEONARD: I think Elon is around 260 billion, and Jeff is 160 or something. Who cares about your rocket blowing up? But it's funny because the issues are still always going to be there. I've learned that. I'm still learning. It doesn't matter how much wealth you have. You just want to create wealth for other people and better their lives. The more you search on bettering lives, you're just going to have to wake up every day, be humble with it, and treat it as a new day and go forward and solve the next crisis or problem because there will be one. There is not where there are no problems, is what I'm trying to say, this panacea or a utopia where you personally, like, oh yeah, I have all this wealth and health, and I'm just great. Because Elon has had divorce issues, so did Jeff Bezos. So I told my son a lot about this, like, you never get to this world where it's perfect in your head. You're always going to be doing things. VICTORIA: That sounds like an accurate future prediction if I ever heard one. [laughs] Like, there will be problems. No matter where you end up or what you choose to do, you'll still have problems. They'll just be different. [laughs] LEONARD: Yeah, and then this is for women and men. It means you don't give up. You just keep hope alive, and you keep going. And I believe personally in God, and I'm a scientist who actually does. But I look at it more in a Godly aspect. But yeah, I just think you just keep going, and you keep building because that's what we do as humanity. It's what we've done. It's why we're here. And we're standing on the shoulders of giants, and I just always considered that from physicists and everyone. VICTORIA: Great. And if people are interested in building something with you, you have that opportunity right now to invest via the crowdfunding app, correct? LEONARD: Yes, yes, yes. They can do that because the company is still the same company because eventually, we're going to branch out. My complete vision for AIEDC is using artificial intelligence for economic development, and that will spread horizontally, not just vertically. Vertically right now, just focus on just a mobile app maker digitization and get...because there are so many businesses even globally, and I'm not talking only e-commerce. So when I say small to midsize business, it can be a service business, car insurance, health insurance, anything. It doesn't have to be selling a particular widget or project, you know, product. And I'm not saying there's nothing wrong with that, you know, interest rates and consumerism. But I'm not thinking about Shopify, and that's fine, but I'm talking about small businesses. And there's the back office which is there are a lot of tools for back offices for small businesses. But I'm talking about they create their own mobile app more as a way to communicate with their customers, update them with their customers, and that's key, especially if there are disruptions. So let's say that there have been fires in California. In Mississippi or something, they're out of water. In Texas, last year, they had a winter storm, electricity went out. So all of these things are disruptions. This is just in the U.S., And of course, I won't even talk about Pakistan, what's going on there and the flooding and just all these devastating things, or even in China where there's drought where there are these disruptions, and that's not counting COVID disrupts, the cycle of business. It literally does. And it doesn't bubble up until later when maybe the central banks and governments pay attention to it, just like in Japan when that nuclear, unfortunately, that nuclear meltdown happened because of the earthquake; I think it was 2011. And that affected that economy for five years, which is why the government has lower interest rates, negative interest rates, because they have to try to get it back up. But if there are tools and everyone's using more mobile apps and wearables...and we're going to go to the metaverse and all of that. So the internet of things can help communicate that. So when these types of disruptions happen, the flow of business can continue, at least at a smaller level, for an affordable cost for the business. I'm not talking about absorbing costs because that's meaningless to me. VICTORIA: Yeah, well, that sounds like a really exciting project. And I'm so grateful to have this time to chat with you today. Is there anything else you want to leave for our listeners? LEONARD: If they want to get involved, maybe they can go to our crowdfunding page, or if they've got questions, ask about it and spread the word. Because I think sometimes, you know, they talk about the success of all these companies, but a lot of it starts with the founder...but not a founder. If you're talking about a startup, it starts with the founder. But it also stops with the innovators that are around that founder, male or female, whoever they are. And it also starts with their community, building a collective community together. And that's why Silicon Valley is always looked at around the world as this sort of test case of this is how you create something from nothing and make it worth great value in the future. And I think that's starting to really spread around the world, and more people are opening up to this. It's like the crowdfunding concept. I think it's a great idea, like more podcasts. I think this is a wonderful idea, podcasts in and of themselves, so people can learn from people versus where in the past you would only see an interview on the business news network, or NBC, or Fortune, or something like that, and that's all you would understand. But this is a way where organically things can grow. I think the growth will continue, and I think the future's bright. We just have to know that it takes work to get there. VICTORIA: That's great. Thank you so much for saying that and for sharing your time with us today. I learned a lot myself, and I think our listeners will enjoy it as well. You can subscribe to the show and find notes along with a complete transcript for this episode at giantrobots.fm. If you have questions or comments, email us at hosts@giantrobot.fm. You can find me on Twitter @victori_ousg. This podcast is brought to you by thoughtbot and produced and edited by Mandy Moore. Thanks for listening. See you next time. ANNOUNCER: This podcast was brought to you by thoughtbot. thoughtbot is your expert design and development partner. Let's make your product and team a success. Special Guest: Leonard S. Johnson.

Stále to nie je hothatch, ale na jazdu je veľmi fajn. A spracovanie interiéru je na niektorých miestach extrémne dobré #dsautomobiles #ds4 #automobilovypodcast

Die Abkürzung SW bei Automobilen ist eine von vielen Bezeichnungen für einen Kombi. Bei Peugeot bedeutet SW Station Wagon. Warum das so ist, weiß ich ehrlich gesagt nicht, aber ich habe mal bei einem Station Wagon behauptet, das SW stehe für „Schöner Wohnen!“ Beim aktuellen Peugeot 308 SW stimmt das auch jeden Fall. Es ist dann ein „automobiles Schöner Wohnen!“ Darum geht es diesmal!Selbst unter dem Blick auf übliche automobile Lebenszyklen ist der Peugeot 308 SW ein Jungspund. Seinen Markteintritt erlebte er am 11. Juni 2022, also quasi vorgestern! SW steht bei Peugeot für die Kombiversion und die ist optisch gelungen! Wir testen ihn als 308 SW 225 e-EAT8 GT Plug-In Hybrid. Das Outfit!Optisch ist der neue Peugeot 308 SW absolut gelungen. Die Motorhaube ist langezogen, die Windschutzscheibe nach hinten versetzt. Insgesamt wirkt die Linienführung der Karosserie athletisch und katzenartig und besonders schlank und dynamisch. Das Emblem mit dem neuen Löwen-Logo der Marke ist prominent in der Mitte des neuen, vertikal ausgerichteten Kühlergrills angebracht.   Power und Drive!    Als 308 SW Käufer hat man die Wahl zwischen reinen Benzin, - Diesel- und Hybridmotorisierungen. Einstiegsmotorisierung ist der 1.2 l PureTech mit 96 kW/131 PS. Die gleiche Leistung hat auch das BlueHDi Dieselaggregat, es zieht diese Leistung allerdings aus 1.5 l Hubraum. Und schließlich kann man unter zwei Hybridmotorisierungen mit Systemleistungen von 133 kW / 180 PS und 165 kW / 225 PS wählen. Wir hatten die letztgenannte Variante im Testfuhrpark. Dieser Motor beschleunigt den 308 SW in 7,6 Sekunden von 0–100 km/h. Da der Wagen auch rein elektrisch unterwegs sein kann, gibt es zwei Höchstgeschwindigkeiten. Die Höchstgeschwindigkeit im Elektromodus liegt bei 135 km/h, das ist schon recht komfortabel. Mit Unterstützung des Benziners sind es hundert Kilometer mehr, also 235 km/h. Apropos komfortabel: Das Schalten erledigt ein elektrifiziertes 8-Stufen-Automatikgetriebe, also genau richtig für schaltfaule Fahrer wie mich! Die Kosten! Werfen wir noch schnell einen Blick auf die Preise. Die bewegen sich zwischen 31.450, -- € und 46.500, -- € für die von uns getestete Version Peugeot 308 SW 225 e-EAT8. Beide Plug-in-Hybride gibt es übrigens nur in der Topausstattung GT. Wenn Sie sich mal die Mühe machen, die einzelnen Ausstattungen zu betrachten, dann werden Sie feststellen, dass es fast überall ein „S“ für serienmäßig gibt! Somit ist der Preis absolut gerechtfertigt!  Alle Fotos: ©  Peugeot Deutschland GmbH / Stellantis   Diesen Beitrag können Sie nachhören oder downloaden unter:

Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg.   TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024   Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo

Citroën Kompaktlimousinen schreiben seit mehr als Jahren eine Erfolgsgeschichte. Bereits 1928 gab es erstmals einen C4. Er wurde im Oktober 1928 auf dem Automobilsalon in Paris vorgestellt und 1932 gebaut. Der damalige C4 erreichte eine Höchstgeschwindigkeit von 90 km/h. Darüber kann der aktuelle C4 nur lächeln! Darum geht es diesmal!Vor gut zwei Jahren feierten gleich zwei neue Citroën Modelle ihre Weltpremiere: Zum einen der neue - 100% elektrisch angetriebene - Citroën ë-C4, zum anderen der neue Citroën C4 mit effizienten Verbrennungsmotoren. Wir beschäftigen uns heute mal intensiver mit dem Citroen C4 PureTech 130, also mit einem der verbrennergetriebenen Modelle. Power und Drive!    Neben dem schon genannten rein elektrischen Antrieb hat man beim C4 die Wahl zwischen effizienten und leistungsstarken Benzin- und Dieselmotoren.  Bei den Dieselantrieben kann man zwischen Leistungsstufen von 81 KW/110 PS und 96 KW/131 PS wählen, zudem hat man die Auswahl zwischen Sechsgang-Schaltgetriebe oder Achtgang-Automatikgetriebe. Bei den Benzinern muss man sich zwischen 74 KW/101 PS und 96 KW/131 PS entscheiden. Auch hier kann man zwischen Sechsgang-Schaltgetriebe oder Achtgang-Automatikgetriebe wählen. Unser Testkandidat war der PureTech 130 Stop&Start mit 8-Gang Automatik und 96 KW/131 PS. Ein Blick auf die Daten zeigt, dass dieser in 10,2 Sekunden von 0 auf 100 km/h beschleunigt und glatte 200 Kilometer schnell ist. Der kombinierte Kraftstoffverbrauch beträgt 5,8 – 5,9 Liter auf 100 Kilometer, die entsprechenden CO2-Emissionen betragen 130 bis 133 g/km.  Die Kosten!Der Blick in die Preisliste zeigt, dass der Citroën C4 PureTech 130 zu den bezahlbaren Autos gehört! Los geht es beim C4 mit dem benzinbetriebenen PureTech 100 Stop&Start in der Ausstattungslinie LIVE PACK für 22.790, – Euro. Die teuerste Version bei den Verbrennern ist der 34.290, – Euro teure BlueHDi 130 Stop&Start EAT8. Bei den Ausstattungen muss man sich zwischen LIVE PACK, FEEL, FEEL PACK, C-SERIES und SHINE entscheiden. Unser Testkandidat, der PureTech 130 Stop&Start EAT8, schlägt in der von uns getesteten höchsten Ausstattungslinie Shine mit 32.010, – Euro zu Buche. Der Vollständigkeit halber will ich gerne noch die Preise der rein elektrischen Version ë-C4 erwähnen. Die liegen zwischen 36.140, – Euro und 38.840, – Euro.Alle Fotos: ©  Citroën Deutschland GmbH / Stellantis   Diesen Beitrag können Sie nachhören oder downloaden unter:

Notre essai de la Citroën C5 X hybride rechargeable nous avait convaincus mais laissait en suspens certaines interrogations : que vaut ce modèle avec un moteur de "seulement" 130 ch ? Le poids moins élevé des versions thermiques joue-t-il sur le comportement routier ? La consommation de carburant est-elle forcément plus intéressante en hybride ? Et surtout... le confort se confirme-t-il sur de longs trajets, même sans la suspension adaptative exclusive aux PHEV ? La solution pour répondre à cette dernière question, ainsi que les autres : faire l'aller-retour Paris-Lisbonne à bord d'une C5 X 1.2 PureTech 130 ch ! Si vous n'avez pas encore pris vos congés estivaux ou si ceux-ci vous manquent déjà, on vous emmène en roadtrip à bord de la nouvelle routière de Citroën !

Notre essai de la Citroën C5 X hybride rechargeable nous avait convaincus mais laissait en suspens certaines interrogations : que vaut ce modèle avec un moteur de "seulement" 130 ch ? Le poids moins élevé des versions thermiques joue-t-il sur le comportement routier ? La consommation de carburant est-elle forcément plus intéressante en hybride ? Et surtout... le confort se confirme-t-il sur de longs trajets, même sans la suspension adaptative exclusive aux PHEV ? La solution pour répondre à cette dernière question, ainsi que les autres : faire l'aller-retour Paris-Lisbonne à bord d'une C5 X 1.2 PureTech 130 ch ! Si vous n'avez pas encore pris vos congés estivaux ou si ceux-ci vous manquent déjà, on vous emmène en roadtrip à bord de la nouvelle routière de Citroën !

Notre essai de la Citroën C5 X hybride rechargeable nous avait convaincus mais laissait en suspens certaines interrogations : que vaut ce modèle avec un moteur de "seulement" 130 ch ? Le poids moins élevé des versions thermiques joue-t-il sur le comportement routier ? La consommation de carburant est-elle forcément plus intéressante en hybride ? Et surtout... le confort se confirme-t-il sur de longs trajets, même sans la suspension adaptative exclusive aux PHEV ? La solution pour répondre à cette dernière question, ainsi que les autres : faire l'aller-retour Paris-Lisbonne à bord d'une C5 X 1.2 PureTech 130 ch ! Si vous n'avez pas encore pris vos congés estivaux ou si ceux-ci vous manquent déjà, on vous emmène en roadtrip à bord de la nouvelle routière de Citroën !

Dr. John LaMattina, Ph.D. (https://www.johnlamattina.com), is an independent non-executive director at PureTech, a biotechnology company with a mission to discover, develop and commercialize new therapies for devastating diseases, where limited or no treatment options currently exist for patients, and has served as a member of their board of directors since 2009. Dr. LaMattina was previously President of Pfizer Global Research and Development and held positions of increasing responsibility during his 30-year career at Pfizer, including vice president of US Discovery Operations in 1993, senior vice president of Worldwide Discovery Operations in 1998 and senior vice president of Worldwide Development in 1999. During Dr. LaMattina's leadership tenure, Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft, Selzentry and Lyrica, along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. Dr. LaMattina serves on the board of directors of Ligand Pharmaceuticals, Zafgen, Inc., Immunome Inc. and Vedanta Biosciences, Inc. He also serves on the Scientific Advisory Board of Frequency Therapeutics and is a trustee associate of Boston College. Dr. LaMattina is the author of numerous scientific publications and US patents. In addition, Dr. LaMattina is the author of the recently released Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices (https://www.amazon.com/Pharma-Profits-Balancing-Innovation-Medicine-ebook/dp/B0B33V6B7Y), as well as Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image, Drug Truths: Dispelling the Myths About Pharma R&D, and an author of the Drug Truths blog at Forbes.com (https://www.forbes.com/sites/johnlamattina/?sh=4ea8dc042b0d). Dr. LaMattina was awarded an Honorary Doctor of Science degree from the University of New Hampshire in 2007 and in 2010 was the recipient of the American Chemical Society's Earle B. Barnes Award for Leadership in Chemical Research Management. Dr. LaMattina received a BS in chemistry from Boston College in 1971 and received a PhD in organic chemistry from the University of New Hampshire in 1975. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.

Can a video game help improve attention skills in kids with ADHD? According to Akili Interactive in Boston, the answer is yes. They've created an action game called EndeavorRx that runs on a tablet and uses adaptive AI  to help improve focus, attentional control, and multitasking skills in kids aged 8 to 12. And it's not just Akili saying that: In 2020 the U.S. Food and Drug Administration agrees cleared EndeavorRx as a prescription treatment for ADHD, based on positive data from a randomized, controlled study of more than 600 children with the disorder. It was the first video game ever approved as a prescription treatment for any medical problem, and Harry's guest this week, Akili co-founder and CEO Eddie Martucci, says  it opens the way for a new wave of so-called digital therapeutics. Even as Akili works to tell the world about EndeavorRx and get more doctors to prescribe the game for kids with ADHD (and more insurance companies to pay for it), it's testing whether its approach can help to treat other forms of cognitive dysfunction, including depression, the cognitive side effects of multiple sclerosis, and even Covid-19 brain fog.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.TranscriptHarry Glorikian: Hello. I'm Harry Glorikian, and this is The Harry Glorikian Show, where we explore how technology is changing everything we know about healthcare.Can a video game help improve attention skills in kids with ADHD?According to Akili Interactive in Boston, the answer is yes. They've created an action game called EndeavorRx that runs on a tablet and uses adaptive AI  to help improve focus, attentional control, and multitasking skills in kids aged 8 to 12.And it's not just Akili saying that.The U.S. Food and Drug Administration agrees.In 2020 the FDA cleared EndeavorRx as a prescription treatment for ADHD, based on positive data from a randomized, controlled study of more than 600 children with the disorder. It's the first video game ever approved as a prescription treatment for any medical problem.Kids are advised to play the game for 25 minutes a day, five days a week. After two months of play, two-thirds of parents of kids in the controlled study said they saw a meaningful change in their children's day-to-day impairments. The FDA's approval of EndeavorRx opens the way for a new wave of so-called digital therapeutics, designed to treat all kinds of problems with cognitive functioning, including depression, the cognitive side effects of multiple sclerosis, and even Covid-19 brain fog.Akili is busy telling the world about EndeavorRx and working to get more doctors to prescribe the game for kids with ADHD and more insurance companies to pay for it. And here today to tell us about all of that is Akili's co-founder and CEO Eddie Martucci.Harry Glorikian: Eddie, welcome to the show.Eddie Martucci: Thanks, Harry.Harry Glorikian: So I'm dying to get into the company and all the things you guys are doing. But, like, before we jump into the company, I'd love our audience to get to know you a little bit. Right, because you're a long time health entrepreneur. You got your PhD at Yale in the departments of pharmacology and molecular biophysics and biochemistry, where you studied structure based drug design. But how did your personal path lead you from molecular biology, which is near and dear to my heart, to video games to treat cognitive impairment? I mean, that that's not exactly the Venn diagram I would see that somebody would just put together.Eddie Martucci: No, it's not. And there is no there is no path for this. Right. Because this is so different and so new. I would say my personal passion is just new science findings. Like I just love brand new science. I was a researcher for a short stint while I did a PhD. I think I had some pretty cool research. But really, if I zoom back, it's new science and new discoveries that are moving the health world forward. And that can be whether it's insights about some part of our biology that we didn't know before, that leads us to understand the human body better. Or in the case of what I've really done from a professional perspective, it's scientific insights that can lead to new treatment modalities. And so that's really what got me most excited. I think the path that was most impactful for me, you know, I was a biochemist at Providence College and a biochemist and biophysicist at Yale, and I love proteins and structural biology and all that. I still do. But I came out of my PhD and and worked with a group called PureTech Health in Boston. And Puretech is really just this unique new health care company where they've done everything from, they have research and development and discovery, but they also have in many ways nailed down a process of starting new companies off of groundbreaking science. And so while I was in grad school, I was exposed to a couple entrepreneurs that really put a light bulb in my head that, wow, this is something I should look into. And then I got training at PureTech in Boston. And that's what kind of got me thinking about brand new medicine and brand new modalities that were never considered medicine before. And the rest is history. Once you get a framework where you can start thinking like that, then it's just work.Harry Glorikian: Yeah. I mean, I knew Daphne, I think when she started PureTech and her advisory board was like, I mean, Nobel Prize winning, who's who sort of. Right. Just watched it evolve over time. But, you know, when you were at PureTech, I think one of their focuses was neurophysiological disorders. I mean, is that the real bridge that helped start Akili? Because I remember that came out of Adam Gazzaley's lab at UCSF, if I remember correctly.Eddie Martucci: Yeah. Adam Gazzaley is where we found the core technology that which we call SSME, which has gone on to power our products, including our FDA approved product. But yes, what I was working on at PureTech, including directly with Daphne, who's really brilliant in helping and bringing new big ideas to life and board members, including people like Ben Shapiro, who used to be at Merck. And he was one of my longest term board members. It doesn't hurt to have folks like Bob Langer in the room once every quarter to bounce ideas off of as well. So like, a very privileged place to start a company. But yes, I was working on novel CNS technologies, in fact. In fact I was working on a few and one in particular that was new devices, new devices for various neurological conditions. And it was really from that effort in thinking about what are the newest modalities of medical devices that we leaped one big bridge further and said in 2010 or about or maybe 2009, could we go further from a user experience perspective now that the whole world is carrying cell phones and tablets every day? Could we go further? Could we could we think about digital? And that was right around the time when everyone and their mother was talking about digital helping medicine. And because we were in the headspace of novel therapeutic modalities, I think it was a natural leap to say, what about digital being the medicine? And then we had to find the science. And that's where I found Adam Gazzaley and, and, and we got off to the races with that technology from UCSF.Harry Glorikian: Yeah. I mean this whole area of digital therapeutics, I've been talking about it for years now and trying to convince people and they look at me really weird when I say digital therapeutics and I try to explain it to them. But so but the game you have built is called EndeavorRx. If I got that correctly. And can you tell? Me more about the game itself. Like, what are the operative features or game mechanics that are thought to increase attention in kids who play the game?Eddie Martucci: You kind of have to back up to the core technology. So the way we build the business is not building one product or one game. We're building a platform technology, meaning a technology that is not made for a single disorder. But instead the problem we're going after and that we started with all of those years ago, about a decade ago, is cognitive functioning. Cognitive dysfunction in medicine is not targeted well by molecular pharmacology. That is the problem statement. We don't target cognition very well in medicine, if at all. And so our whole theory and thesis for the business was, if we could bring in the best technologies in the world, that through software could actually target cognitive functioning directly, then we would be bringing a pillar of medicine that does something much, much different than what medicine does today. So the technology out of UCSF that we started the company around, that we have branded the Selective Stimulus Management Engine, the way this technology works, which will then help you understand how the products in for ADHD children works. The way this technology works is it is giving constant stimulus, both visual and motor. So it's creating conflicting and overwhelming stimulus to activate the part of the brain that controls attention, which is the midline prefrontal cortex. So the front part of the brain that really controls attention and speed of processing and integration, this technology is patented to be able to activate that part of the brain very strongly, but also enhance what's called long range coherence. So as you're using this technology, not only is the front part of the brain activating much more, so you can apply your attention downwards.Eddie Martucci: And I'll get to exactly how this manifests, I promise. It is also more seamlessly based on the neurological data we have. It appears to more seamlessly be helping the brain communicate to the sensory processing regions. And so the way this manifests in ADHD children, when they're using our product EndeavorRx, which is meant for children 8 to 12 years old with ADHD who struggle with the attentional issues. This product is basically experienced like a racing video game where children are running a little alien figure down a course that is ever adapting. And they're getting information, meaning things that fly up to the screen that they have to make decisions on. And that's ever adapting because we have these deep, personalized algorithms so that everyone gets their own experience. So basically what people feel is they're using this technology that feels like a game, and it's just constantly challenging them in different ways. What's happening in the brain and this is how it's designed, is that the game is presenting very specific stimuli for each user that is pushing them at the edge of their processing ability. And that's part of the IP we have, is how to do that in a really seamless way so that by the end of using a game you haven't just been using a game, you have been essentially taxing the weak link in your attentional processing every single second for hours.Harry Glorikian: I think every CEO of that we may know mutually needs to be prescribed this game.Eddie Martucci: You know, CEOs and investors have been probably the most common people that in meetings will stop me and say, hey, I think I need this.Harry Glorikian: Yes. So how did you ideate and test the game mechanics?Eddie Martucci: Yeah. This is this is really a tenet of the business where we decided early on that to truly—we want to disrupt medicine and we want to create and integrate our type of medicine into mainstream medicine. Far too often, digital is kind of left to early adopters or on the sidelines of real medicine, excuse me. And our whole thesis was you have to run real validated and literally gold standard, rigorous clinical research. So when we had done this, no one had done a well designed trial before to study something that looks like a video game. And so that's really where we spent the first handful of years of our existence is after we built the kind of data infrastructure, which we can talk about, and the adaptive algorithms. We then invested years in how to run good clinical trials with this type of product that's an experiential product. So our goal all along was being able to run the same or better rigor of randomized controlled trials that you'd expect from a drug for this same disease area. Obviously, as an interactive product that you can see and you interact with, that means you have to take a little bit of a different approach.Eddie Martucci: So we had to do a lot of work with some of our advisors and with places like Duke University on how to blind the protocol. Because it has to blind very differently. And how to how to have a control, an active controller sham that is actually controlled. And there's many nuances like that. But at the end of the day, the trials we run are meant to replicate or be analogous to drug trials, where you have really strong controls up front, that you're not biasing individuals and that the outcomes—and this is the differentiator in digital—that the outcomes are gold standard accepted outcomes for whatever you're studying. And so that was what we've done. What we did the first time we were in a trial, we were like, it took a lot of work and we were nervous about it. But we have a clinical ops team now and we've run a few dozen trials across, I think, nine or ten disease populations, so we've become pretty good at it.Harry Glorikian: Yeah, I was going to say, I mean, coming up with the first one, everybody's probably scratching their head trying to figure out, are we doing the right thing? But, and I have this discussion with some of the people I work with all the time, what's the proprietary special sauce in the case of digital therapy? I mean, is there a defensible algorithm or insight at the heart of something like EndeavorRx that would be comparable to a patented small molecule in the you know, in the traditional drug industry?Eddie Martucci: In our case, yes. And I'll tell you about that. I think what this really comes down to, though, that question about digital therapeutics, it's like a business question for the industry. To answer that question, it's important to recognize there's nuance in the industry. So the vast majority of digital approaches, I think, are tough to protect because they're taking well known human practices and putting them into an app. Right. So there's 90 percent of the digital therapy companies or products out there are using different forms of behavioral therapy or disease management techniques or strategies, and they're bringing them into an app that is not bad. It's hopefully very, very good for patients. There's a few validated products there that are, no question, good for patients. I think it does make those types of products harder to protect. We've taken a bit of a different tack. We're a little bit, I guess, iconoclastic within the industry in that what gets us excited is software that even though it's software, it's more drug like in that it's directly targeting and activating the dysfunctional physiology in the body. You can measure that and by virtue of that, you're having a really unique effect. Eddie Martucci: The second big difference is we are using algorithms that have not been ever reported on before. So we take much more of a drug lens where we actually do protect we patent our technology. So we call this whole class “physiologically activating digital therapeutics.” Some people have referred to them as mechanistic digital therapeutics or disease modifying. There's different phrases, but this idea of unique algorithms that you actually can protect with patents and copyrights, which we do. So we have about 50 issued patents for the technology that underlies EndeavorRx and another 100 that are filed on our various technologies. And you can demonstrate this has a real, unique physiological effect. I think what it enables, at least for these types of products is a feeling from the health care world that this is much more what I'm used to seeing in my traditional medicine where it's unique. I can't just go get this anywhere because I trust that this one product is the only one that has this unique technology. And by the way, it's been proven to work. And I trust that they're a stable company that's going to be around for a while. Those things are really important to our model.Harry Glorikian: Well, it's a good thing that I've been explaining it to people the right way. So at least now that we've talked, you know, my explanation is aligning correctly. So I'm happy about what I'm reading is correct. Let's take a step back. So, there's a lot of kids with ADHD who have no problems concentrating on something for hours if they're really interested in it. But it strikes me the key feature of the of the product is not just keeping kids engaged. It's supposed to build or improve those skills. Is that the key thing that makes the game special or unusual or different from any other pastime, say, building LEGO spaceships?Eddie Martucci: Yes, absolutely. So the engagement is critical, but the differentiator is the challenging and improving of that core cognitive functioning. And you don't get that just by engaging in something. And actually, the vast majority of entertainment products you engage with will allow you to either passively engage, meaning you could watch YouTube videos for hours and hours, but you're not actually challenging your brain or actively engage, but in a way that you don't really have to challenge what you don't do well. So in most video games, you can choose what most of us do in life, choose the path of least resistance, because we like certain ways of using a product. Our product is unique in that this this patented algorithm forces you—it's essentially measuring second by second where you're weak and processing the various streams of information and it is forcing you to work on those areas where you are weakest. But it's doing it naturalistically. It feels like you're using a treatment, but it's really that level of focus on, for lack of a better word, it's really that level of focus of delivery of that algorithm that's actually going to stress you where it, for lack of a better word, hurts the most. That is the differentiator. The other big differentiator is, is the personalized algorithms that that we built in. And this is where, frankly, technology and data rich medicine has never gone before. But within seconds of using the experience, this product is tailoring to each individual user. And this is true whether we're talking about kids with ADHD or some of our trials and products and adults with depression or MS, these products can actually tailor to your functional level and then move you along from there. So those two those two bits of how the algorithm works are critically important. The engagement is really the delivery vehicle to make sure you're getting that level of medicine.Harry Glorikian: Yeah, definitely, if this was available to people in a larger age range, there are people that I definitely need to recommend this to when well then that becomes available.Eddie Martucci: But well, that's the interesting thing about cognitive dysfunction, right? The way I talk about it sometimes is cognitive functioning and or problems with cognitive functioning go across disease, right? They're in many ways disease agnostic. Almost anything that touches the brain results in some level of cognitive dysfunction or at least some proportion of patients that have longer term cognitive dysfunction. But it also goes above and below disease, meaning subclinical. So there are people that are not diagnosed with issues that, you know, that probability-wise there's 20 or 30 percent that are significantly below the mean they're struggling with these things. So this is a this is a basic human function that rears its head in a really nasty way in many diseases, but is actually relatable to all of us.Harry Glorikian: Yeah. So. I mean, there's a lot of challenges when you're trying to design something like this. A ten year old will not spend much time playing a mobile game unless it's it's just as compelling as, you know, anything that they could download as a mobile app. So. How did you guys, what steps did you guys take? You know, it's almost like game design and, you know, therapeutic outcome, you know, together in one package. And so how did you guys, what steps did you guys take to make sure this thing was fun?Eddie Martucci: Correct. Yeah. And it does depend on the population. Right. So we have products, obviously a marketed product in for children with ADHD, but we're developing products and have trials and data and adults of various ages. The I think you're right. If you focus on children, there's a there's an engagement bar that is not easy. Right. Kids are highly discerning. They know a good game and a bad game. And what we like to say is we have no delusions that we're going to come out with the next blockbuster entertainment game. That is not how we built the company. However, we do want to have a game that looks and feels like the type of games that you actually like to play. So it has to be worlds better than edutainment, as people call it, educational software, because kids know. And so the way we did that is this is one thing that makes Akili very unique. Instead of outsourcing or kind of outsourcing game development or adding game development at the end of our development cycle, we actually have built the company to have cognitive science, clinical science, and game development fully integrated from the earliest days. And data science, for what it's worth, is really a kind of foundational thread for all of those. And it's hard. It's really hard. I mean, developing a product that has both these things, the strong science and the engagement, is really hard, but it's also really hard for people from all these different industries to, you know, be speaking the same language and work together because the development processes are different, the language you use is different. Your mindset of how you think about developing is different. And so for us, what I always talk about is it's literally daily attention. I'm unwilling to sacrifice or give up on it. We have to do both. Well, I think where we are today with EndeavorRx as our first product out of the platform, it's a really good product. It was built to show clinical efficacy and engage people to a minimal degree. It does that. Some kids love it. They will play for months at a time, you know, five days a week for four months. But yeah, there's a lot of people that kind of get through it and then plenty of kids that say, I really don't want to use this. So we've built features around the edges, things like an app for parents to allow them to track and monitor and incentivize their children. And we try to educate our users on why you're doing this. And so it's got to be a mix of the engagement itself, but also a little bit of inherent motivation that, hey, your doctor's in the loop, this is your medicine. It's important to put the work in and accomplish it.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's leave a rating and a review for the show on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing a lot to help other listeners discover the show.And one more thing. If you like the interviews we do here on the show I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is now available in print and ebook formats. Just go to Amazon or Barnes & Noble and search for The Future You by Harry Glorikian.And now, back to the show.[musical interlude]Harry Glorikian: What makes you optimistic? Because I've been, you know, enamored with this space for a while now and trying to watch like where it's going to grow and what's going to get in its way. And so what makes you optimistic about digital therapeutics, either as a venture scale business or a public company. Because I know you guys are thinking about that. Tell me what you're thinking.Eddie Martucci: Yeah, a couple of things that make me very optimistic. I think the foundational groundwork is now done and we've shown it can be done. So we know that these products now can be developed, they can be protected, they can be brought through clinical trials and actually help patients. That's the most important thing. They can undeniably with strong clinical data, help patients and they can be brought through the FDA and now being prescribed by docs. So these prescription digital therapeutics, there's only a couple of them on the market. But literally at this point there's been now thousands of docs, not merely tens or hundreds, but we're talking now about thousands of docs who have prescribed prescription digital therapeutics to patients, where a couple of years ago that would have been essentially zero. So the foundations are there more. Every month that goes on, it becomes a a self-fulfilling cycle where doctors and patients hear about it, they're aware of it. They know someone who's tried it. And it's becoming a little bit common nature to think, wait, isn't there something digital that I've heard about for this? I think that will flip in the coming years to I expect to have a digital treatment or I expect to be told the digital option for my doc. So that makes me that makes me optimistic is that the groundwork is there. We know it can be done.Eddie Martucci: The second thing is, frankly, society is demanding better medicine in many different ways. They're demanding, and mainly I'm talking about patients in many respects, they're demanding more accessible medicine. They're obviously…we all got the efficiency bug of telemedicine during COVID. And while I've seen the data that that has significantly receded, I don't think the concept of online or digital in medicine has receded from anyone's mind. I think we all know that it's far more efficient and we should expect to see more products that are digital in nature, whether that's scheduling with a doc or taking a treatment. And so I think there's this kind of wave in society that is that is pushing people to recognize that we should be open to these types of products. The other thing is, whereas docs and patients years ago when we did market research, there was a level of skepticism that was pretty healthy. I now see a level of openness where if there's good data and there's especially in our case, things like FDA approval and strong clinical data, there's a better chance than not that both patients and doctors are going to be not only acceptable or accepting, but they're going to want to at least try something like this. So all the groundwork is there. We've just got to keep keep plugging away because it's new.Harry Glorikian: I talk about the whole digital therapeutic space in my book. And I always tell people look, if a product like this works for you, you're not going to have a side effect profile the way you have with some of the small molecule drugs that I've seen. It's trial and error with those things. And sometimes things don't go as well as you want them to and you end up with a very angry child if the drug doesn't do what it's supposed to do.Eddie Martucci: It's egregious. It's egregious. I mean, medicines, pharmacological medicines for neurological conditions are critically important. Don't get me wrong, I think they're critically important. And EndeavorRx is not meant to be an alternative to medication, especially if it's working well for for a child. But the problem is, there are many components of these conditions that are just not well addressed. And so you're left as a clinician to try to use these blunt instruments, these molecules which weren't delivered for these problems or rather weren't designed for these problems. You're trying to use them, but you're fighting the side effect profile as much as you're fighting the efficacy the whole time. And so you're right. Trial and error is the right phrase. Like the fact that we're still doing trial and error in CNS conditions all these years later is crazy. And there's a better way because we now can have these more targeted products that are part of the patient's toolbox.Harry Glorikian: Yeah, and we need more of them, so. Yeah, great. But let's talk about the business model, right? I mean, this is, you know, feels like fresh territory, right? And if I think about mobile games generally don't make money unless you sell millions of copies. Right. So you have you must have a different business model in mind from the beginning. I suspect this business model revolved around, you know, selling Akili games as a prescription based therapeutic at a cost that would be more typical for a drug than a mobile game.Eddie Martucci: Right. Right. So the concept here is we want the products to get to the patients that really need them and we want to involve the doctor in the loop and we want to have products that are proven. And so all of that to me says a core medicine model, meaning prescription treatment, as you said, covered ideally by insurance largely, but with a little bit of out-of-pocket burden from the patient. You're right, the general cost is a little bit more in line with pharmacology, although the good news in mental health and behavioral health is that's that's relatively inexpensive. We're not talking about multi-thousand-dollar therapies here. We're talking about something that is in the low hundreds per month. And for the patient, really more like $30 to $50 a month. So these are the cost structures that we think are tenable and have been working well in behavioral medicine. And that's really where we're starting. But we're in the early days. I think one of the beauties of digital is we don't have to just stay there, meaning that is the core of the model, a prescription that scales and is paid for by both insurance and patient.Eddie Martucci: But I think there's a lot of potential to evolve and iterate the model that has more consumer elements to it. For instance, like your best technology products, we can adapt the product itself to grow with you. Like your best technology products. We can serve, you know, services and help on the side beyond or in between your use of the actual treatment. So there's a level of connectivity with our end user and consumer that is that actually looks a lot more like best in class consumer software where you can have a long term relationship with a patient. Now, we have not pulled any of those levers yet, but I think what we're most excited about is the bringing both of those models to bear. A medical model, but that has some aspects to it that can actually grow and extend more like software. I actually think that's where the field will go. But it is early days. We'll have to see how this we'll have to see how this shakes out.Harry Glorikian: Well, that's why I always I always tell people, like, you know, once you digitize something like you get to have a broader imagination about what is possible in that realm as opposed to, you know, sticking to exactly what we did before.Eddie Martucci: Exactly.Harry Glorikian: But taking a step back here, no one has ever marketed a prescription based video game or won marketing approval from the FDA for such a product. Right. So how did you frame yourself? You walk in there and you say, “Hey, here, play this. And you're going to like it.” What were the hurdles? What did you have to overcome to get regulatory approval for this? What was it like dealing with the FDA?Harry Glorikian: No, it's a great question. Yeah, the FDA process is fascinating. We know it is rigorous, it's long, it's mostly collaborative. Right. The FDA wants to learn and help. But I think, number one, most importantly, there's unfortunately a myth out there today that digital therapeutics are actually medical devices generally don't have to go through efficacy analysis by the FDA. So I see this myth all the time. People say, well, you know, on the medical device side, they only look at safety. And so, unfortunately, with broad brushes, people have painted digital therapeutics as part of that. They've said, well, digital therapeutics may or may not have evidence, but the FDA looks at safety. I can unequivocally tell you that could not be farther from the truth. I would say 95 percent of our interactions with the FDA, which took the better part of two years because our product was so novel, you can imagine we were not only innovating the delivery mechanism, it's a video game. We were innovating the target, which is cognitive functioning, which there are no products labeled for cognitive functioning. And we were trying to look at what are the endpoints that, you know, that read on cognitive functioning. All of this is new, but not 95 percent of the questions we had, and that's—please don't quote me on the specifics, this is not a deposition—but in that range, were about efficacy. And we went through every little bit of our efficacy data so that the FDA could understand it, so that they could audit it.Eddie Martucci: We even, midway through our regulatory process, brought on a fifth study. So we have five studies in our FDA label package. So we brought on the most recent study to show to address some questions FDA had around efficacy in the longer run or efficacy along with medication. So this was a very rigorous process. I always tell people the good news about this is you can trust it when it comes out because this is something that looks and feels a lot like the drug process, right? There's a lot of scrutiny put on the trials and the legitimacy of the trials. So so it looked a lot like that. It's highly iterative. From a business side, the one tough part with FDA is when you're when you have a new classification for a product, so a 510K de novo, so they're creating a classification, there is no hard timeline on the review. And so when you're a startup and you're building a business, you kind of just keep iterating until you get to a label or not, right? And luckily in our case, we did. But yeah, I mean, as a startup, you're going through a nearly two-year approval. It's stressful. It's stressful, but it's good for the industry, I believe, because it's really forcing a high bar of science.Harry Glorikian: Well, no. And I mean, that's what you want. You don't want a low bar and then things go wrong, like you want it to be held to a higher standard. And usually when the FDA is taking on something new, they've also got to take the time to catch up to where you are. Right. They can't just walk in the room and be ready for this. So you're sort of paving the path for everybody that's coming behind you, which is a I guess there's a good part of that and a bad part of that.Eddie Martucci: Yes. Yes.Harry Glorikian: So there's a lot of stakeholders and gatekeepers in this space that we're talking about, right. Patients, parents, physicians, payers. I mean, each one of them needs to be persuaded that digital therapy or digital therapeutics are, you know, beneficial and worth prescribing or worth paying for. So, anything special you're doing to sort of win them all over?Eddie Martucci: Well, we're doing the work to put time and attention towards it. So you're right. Just because it's digital does not mean people will use it or understand it. So you've got to sit with patients and educate. Just because docs have a new tool doesn't mean they'll trust it. So you've got to spend time to make sure they understand the data and more importantly, understand where we're trying to play in the treatment paradigm. Right. Because, again, we're not … the easy answer for a digital is, “Oh, this is supposed to be a digital equivalent of a drug.” No. It's more nuanced than that. This is supposed to help in a very specific way. And insurers are probably the biggest barrier because it's so new for them. Right. This is this is very new. They don't really, they're not really built to be able to adjudicate digital products. Right. And unfortunately, we've got some of these types of myths floating around, like the FDA medical device myth, which understandably makes insurers uncomfortable. Right. If they if that's what they've heard, they say, well, how in the world am I supposed to adjudicate efficacy if the FDA doesn't? I guess I'll look at this with all the other hundreds of wellness apps out there.Eddie Martucci: So it's education time. Honestly, it's education time to unravel these myths, to really sit and make sure these stakeholders understand the data and the utility of the product. In terms of special things, one of the one of the nice things about growing a company, especially with digital company in this day and age, is you can test and iterate really quickly on all of these fronts. And so when we test you've got to have the meetings and you've got to fit into their review cycles. But for patients and docs, you know, we, we take a very clear test and learn approach. We are releasing certain types of educational content or certain types of marketing messages in pilot phase. Right now we see what works, we see what doesn't. We adapt. We do the same thing with the distribution infrastructure, frankly. Like how in the world do you get a video game therapeutic from your doctor? We built the infrastructure. We tested, we changed, we scrapped half of it and started again. So that is the beauty of living in a digital world. We can we can do that type of testing and learning.Harry Glorikian: And good old AB testing on what works and what doesn't.Eddie Martucci: Totally.Harry Glorikian: All right, let's step out of ADHD for a minute. You've been talking about other neurophysiological sort of conditions. And I think the website, if I'm not mistaken, mentions depression, cognitive dysfunction, multiple sclerosis, autism spectrum disorder, and a few other future treatments is. Is there something about the EndeavorRx platform or the proprietary adaptive algorithm that gives you the ability to sort of generalize? And I think you mentioned that earlier, but sort of to dig into that a little bit.Eddie Martucci: Yeah. So it really starts with what technology are looking for. And so we don't source technologies that are meant for any one condition. That is more common in the behavioral therapy space where there's behavioral therapy for disease X because it's a tried and true technique specific to the disease. The way we work is looking for technologies that actually activate specific brain regions and have data that they do that well. And so the interesting thing that we found about cognitive functioning, and we knew a little bit about this, but you know, I don't like to have revisionist history and say we we knew it all, with cognitive dysfunction and disease, independent of the etiology or the cause of why the brain is having issues, the downstream manifestation actually tends to bucket into very similar issues. And so our theory was, and so far it's proven true, is if you could bring technologies that are meant for the neurological processing issues, not the disease, not specifically the disease, then any condition that results in similar issues, you should be able to have a functional impact on. Because we're not we're not targeting, you know, dopamine reuptake and a dopamine driven disorder. We're not targeting myelination in am anti-myelinating disorder. We are targeting the end result, which is how well the brain is communicating. So we've because we start there, we, we theoretically have the ability to go across disease, and we've actually shown it now. So the same technology that has a treatment label for ADHD has been able to power two studies, including a larger randomized controlled study in multiple sclerosis adults, and showed clinically meaningful, large changes in speed of processing and related cognitive functions. That's the same technology under the ADHD product. ADHD and MS could not be farther from each other in terms of cause, but because the resulting functionally in the same in the same area, that's then you get that benefit. So that's our theory and that's how we're going to continue to develop products and take a functional and a neural network approach, if you will. And, and ideally, we have a much more efficient product pipeline because of it.Harry Glorikian: So. In your mind, like what are the biggest unanswered questions, either for EndeavorRx or for the Akili business. Is it more product? Is it more market? I mean, for example, do you worry about whether it'll work, you know, in the real world, as well as it did in your initial studies, whether doctors will prescribe the game, whether payers will cover it. There's all these issues. And so I'm just wondering where you think the biggest hurdles lie?Eddie Martucci: Sure. Yeah, I think I think my number one is not about the product. It's really systemic to the to the health care system and industry, which is it's important to me that the insurance industry, the doctors write prescriptions, but more importantly, the insurance industry and broader we could call it the payer industry. Right. Anyone that should be paying for medicine pays for digital therapeutics. Right. I don't think this should be the only class of medicine where patients bear the entire cost. That makes no sense. So we are not there yet for sure. Right. We're in such the early days that I think some payers are waiting, but I think we're starting to see a turn. We're beyond skepticism, beyond intrigue, probably into early acceptance. And I think the work needs to be done. And frankly, we need we need a couple folks in this industry and by folks, I mean both people, but also organizations to step up as the early pioneers for their patients. I think that's really important. Now, again, I have empathy for why that part of the industry moves slower. They're trying to protect patients. There's obviously cost arguments as well. And there are some of these myths or misconceptions out there about the industry. But I think when education is done right and when payers really engage, we're going to start to see a broader payer ecosystem adopting this like they would any other medicine. So I think that's kind of the biggest near-term barrier. And slightly longer term, I think the business model is a question. Which no one likes to hear, no investor likes to hear. And we're a company that's going to go public. I don't mean the business model is a question in that we don't know if we can make money or build a business. I just mean, what is…so, the foundations we know are there. Doctors will prescribe, patients will pay, payers are starting to pay. It has a benefit in people's lives. So the foundations are there. The business will grow. What the eventual business model is, is TBD, frankly. What is the top end business model that's going to allow a company to thrive at scale? I think we have to invest to learn that. And I'd say the same thing about the product. In terms of the product, it's not whether it will work, it's not whether it can help patients on the market. We've shown all of that. It's at this point, how well can you develop that product on the market so that it engenders long term compliance so that engenders loyalty and use in the future? And so I think in both those scenarios, I guess the health care system's got to get there. Which is a secondary priority, more like an opportunism. We don't want to miss the opportunity to find the best business model or to iterate on the products because we have the ability to do so. I don't want to miss that opportunity to grow the best business model we possibly can.Harry Glorikian: So you mentioned going public once or twice, and so I saw that there's paperwork with the SEC to go through a public filing with a special purpose entity backed by Chamath, whose I think it was Social Capital, through his venture fund. What's the thinking behind becoming public? Why now?Eddie Martucci: Yeah. I think I always had a mantra and I didn't come up with it. This is from advisors to me and mentors: Stay private as long as you possibly can for the business to be able to adapt and iterate and a little bit more of a clean way. But I think that time has come, and the reason I say that is we have a product that is being prescribed by doctors now and we have a pipeline where I've already talked about it. We could help potentially up to dozens of different populations who are struggling today. On top of that, the need and urgency around mental health and behavioral health has had a step function change in the last year. Right. We know that President Biden talked about it at the State of the Union. The surgeon general has put out a national state of emergency on youth mental health. So the time is right for a real investment here and the time is right for the company to fill that need. We know all the all the foundations are right. So I've always wanted to wait till that moment why we chose this specific entry point and vehicle, which we hope is kind of middle of this year, that Akili becomes a publicly listed company is, I think, the opportunity to not only have capital and the type of flexible capital that the public markets gives you, but in the case of a special purpose acquisition company, the expertise of that acquiring entity, in this case, Chamath Palihapitiya, who's extremely well known and amazing at building disruptive technologies for different industries that scale to ubiquity using technology and data.Eddie Martucci: But actually that the SPAC vehicle here is Social Capital Suvreta. Suvreta being a well known biotech hedge fund who specializes in early commercial biotech companies. So rarely do you get to become public with the right amount of capital, but also some new expertise around the table, strategic expertise in a disruptive business. And I think we get both of those with this deal. So we're still, it's too early to tell if the whole thing will go through. We're certainly crossing our fingers and hopefully if people listen to this in the longer future, Akili is already a public company and thriving.Harry Glorikian: Well, I mean, it's a good thing I spoke to you now so that we could speak a little bit more freely than when you're under that public rubric.Eddie Martucci: But oh, no, I'm already I'm already watching my words. It is important. It's a level of maturity as a business. Now, we have we've grown for about a decade. We grew methodically and slowly. We have over 100 employees now. And, you know, businesses change and mature. And I think it's the right time for us to do it.Harry Glorikian: Oh, yeah. I mean, a lot of the companies that I interact with as an investor, I mean, when we're going to go public, it's like, “Oh, we got to do this, we've got to get that ready. We got to get accounting ready. We got it.” I mean, you've got to go through it methodically because being public is is not for the faint of heart for sure. So, well, I wish you the greatest success. I look forward to staying in touch and, you know, keeping up to date on how things are going with the company. And, you know, I hope a ton of people listen to this because it's easier for them to hear it from you than hear it from me.Eddie Martucci: Thanks, Harry. This is a lot of fun. And thanks for your focus in innovation and these new areas that are really going to transform patients' lives. So I'm hoping we're doing our part there.Harry Glorikian: Thanks.Harry Glorikian: That's it for this week's episode. You can find a full transcript of this episode as well as the full archive of episodes of The Harry Glorikian Show and MoneyBall Medicine at our website. Just go to glorikian.com and click on the tab Podcasts.I'd like to thank our listeners for boosting The Harry Glorikian Show into the top three percent of global podcasts.If you want to be sure to get every new episode of the show automatically, be sure to open Apple Podcasts or your favorite podcast player and hit follow or subscribe. Don't forget to leave us a rating and review on Apple Podcasts. And we always love to hear from listeners on Twitter, where you can find me at hglorikian.Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview.

Die Automobillandschaft ist im Umbruch. Damit ist weniger das Thema Elektromobilität gemeint, sondern mehr das Zusammenachsen von Konzernen. Mittlerweile haben Sie bestimmt schon von Stellantis gehört. Stellantis ist 2021 als Holding aus der Fusion von Fiat Chrysler Automobiles (FCA) und Groupe PSA (PSA) hervorgegangen. Nach verkauften Fahrzeugen ist der Konzern mit seinen 14 Marken der viertgrößte Automobilhersteller der Welt. Die deutsche Niederlassung wird von Rüsselsheim am Main aus, dem Stammsitz von Opel, gesteuert, Opel gehört seit einiger Zeit zur Groupe PSA. Ein Fahrzeug dieser Groupe PSA schauen wir uns heute mal genauer an. Darum geht es diesmal!Heute werfen wir mal einen automobilen Blick ins Nachbarland, nach Frankreich und schauen in das Modellangebot von Citroën. Das ist ja quasi Verwandtschaft, denn seit einiger Zeit gehört auch Opel, genauso wie Peugeot, zum PSA-Konzern, der wiederum mit weiteren Marken mittlerweile unter Stellantis fungiert! Doch wir fokussieren uns auf Citroën und hier auf den C4 PureTech 130  EAT8 Shine. Power und Drive!    Den Citroën C4 gibt es natürlich in mehreren Versionen und Motorisierungen. Los geht es bei den Benzinern mit dem PureTech 100 Stop&Start mit manuellem 6-Gang-Schaltgetriebe und 74 kW (101 PS). Weiter geht es mit der PureTech 130 Version, alternativ mit 6-Gang-Schaltgetriebe oder 8-Gang Automatik. In beiden Fällen sprechen wir jetzt über 96 kW (131 PS). Die Spitze der Motorenreihe ist beim PureTech 155 mit 114 kW (155 PS) erreicht. Der ist generell mit der 8-Gang Automatik kombiniert. Bei den Dieselaggregaten können Sie wählen zwischen dem BlueHDi 110 mit 81 kW (110 PS) und dem BlueHDi 130 mit 96 kW (131 PS). Den Erstgenannten gibt es NUR mit Handschaltung, den zweiten NUR mit Automatik.  Und für die E-Auto-Fans gibt es noch den ë-C4 mit 100 kW (136 PS). Sie haben also die Qual der Wahl. Die Innenausstattung!Wo wir grade bei der Qual der Wahl sind. Sie müssen sich natürlich auch noch für eine Ausstattungslinie entscheiden. Diese heißen bei Citroën Live, Feel, Feel Pack, C-Series und Shine. Die letztgenannte Ausstattung hatten wir im Test! Ein Schwerpunkt davon ist das Drive-Assist-Paket: Es enthält unter anderem das Sicherheitspaket Plus, den aktiven Geschwindigkeitsregler, den Toter-Winkel-Assistenten, den Fernlichtassistenten, die Einparkhilfe vorne und hinten inkl. Rückfahrkamera mit Top Rear Vision und seitlichen Parksensoren.  Und auch eine 180-Grad Rundumsicht ist gegeben. Die Kosten!Die Preise des Citroën C4 starten aktuell bei 19.990, – Euro, sie enden bei 37.340, – Euro. Aus dem reichhaltigen Füllhorn der Modelle hatten wir uns für den C4 PureTech 130 Stop&Start EAT8, also mit der 8-Gang Automatik als Shine zum Preis von 30.490, – Euro entschieden.   Alle Fotos: ©  CITROËN DEUTSCHLAND GmbH   Diesen Beitrag können Sie nachhören oder downloaden unter:

Thema heute:    Neuer PEUGEOT 308 ab sofort bestellbar   Foto: PEUGEOT DEUTSCHLAND GMBH Ab sofort ist der neue 308 bestellbar. PEUGEOT präsentiert die nächste Generation des 308 im charaktervollen Design und mit neuesten Fahrassistenzsystemen. Getreu dem Motto "Power of Choice", bietet das Unternehmen seinen Kundinnen und Kunden die Wahl zwischen aufladbaren Hybrid- und Verbrennungsmotoren. Der neue 308 ist in der Ausstattungsvariante Active Pack ab 23.200 Euro UVP für den PureTech 110 mit 81 kW (110 PS) erhältlich. Die Kompaktlimousine der Löwenmarke wurde bereits mehrfach ausgezeichnet, unter anderem zum „Car of the Year 2014“. Foto: PEUGEOT DEUTSCHLAND GMBH Erstes Serienfahrzeug mit neuem Logo Als erstes Serienfahrzeug zeigt sich der neue 308 mit dem neuen Logo, dem Wappen, das auf dem Kühlergrill sitzt und durch das Kühlergrillmuster besonders hervorgehoben wird. Der neue 308 wird in sieben Fahrzeugfarben angeboten. In den Ausstattungsniveaus GT und GT Pack sind die Full-LED-Scheinwerfer noch schmaler und verfügen über die PEUGEOT Matrix LED-Technologie, die für mehr Effizienz und Sicherheit im Alltag sorgt. Sicherheit und Komfort dank moderner Fahrerassistenzsysteme Das PEUGEOT i-Cockpit® wurde für den neuen 308 weiterentwickelt und modernisiert. Das digitale Kombiinstrument verfügt über mehrere Anzeigemodi wie Navigation, Radio, Fahrerassistenzsysteme und ist ab der Ausstattungsvariante Active Pack mit einem 10-Zoll-High-Definiton-Digitalpanel (25,4 cm) ausgestattet. Ab dem Niveau GT ist das digitale Kombiinstrument in 3D erhältlich und lässt sich individuell konfigurieren und anpassen. Foto: PEUGEOT DEUTSCHLAND GMBH Das neue Infotainmentsystem PEUGEOT i-Connect® Advanced ist mit dem TomTom® Echtzeitnavigationssystem ausgestattet, das über den 10-Zoll-HD-Touchscreen (25,4 cm) bedient werden kann. Für zusätzliche Sicherheit beim Fahren sorgen unter anderem die Rückfahrkamera, der Kollisionswarner, der Toterwinkelassistent mit einer Reichweite von 75 Metern, der Notbremsassistent und der aktive Spurhalteassistent mit Lenkeingriff. Verbesserte Luft im Innenraum des neuen 308 bringt das AQS (Air Quality System). Es überwacht die Qualität der in das Fahrzeug einströmenden Luft und kann aktiv das Luftrecycling aktivieren. Ab dem Ausstattungsniveau GT wird dies durch Clean Cabin ergänzt, ein Luftaufbereitungssystem, das umweltschädliche Gase und Partikel herausfiltert.   Diesen Beitrag können Sie nachhören oder downloaden unter:

Facelift spravil autu dobre. Alebo nie? Ja nevijem uš, ale je to príjemné SUV so športovými vizážami, ktorému automobilka už vychytala chyby. #Peugeot #3008 #autoroka #automobilovypodcast

Enfin une marque Française lance une vraie berline haut de gamme. J'ai eu envie d'essayer cette auto et de savoir si, enfin DS était de retour. Même si la DS7 est déjà un bon début. A retrouver sur https://www.histo-auto.com/fr/actualite/1187/essai-ds-ds9-2021

Hemos creado un set de radio especial, desde casa, para poderte acercar, las últimas noticias del motor. Para todas las emisoras FM de REC Radio y las plataformas de Podcast. Analizamos las siguientes noticias: • Mini será solo eléctrica en 2030 • Volkswagen despedirá a 5.000 trabajadores • MG vuelve a España, con vehículos eléctricos. • Volvo solo fabricara SUV • Nuevo BMW i4 • Nuevo logotipo de Renault • Nuevo Toyota Aygo X Prologue • Toyota avisa a Apple que no es tan sencillo fabricar un coche eléctrico. • Prueba Peugeot 2008 Puretech 130 CV gasolina • Fabrica de baterías en España de Volkswagen • La posición al volante, a gran olvidada de la seguridad. El equipo de gala que ha acompañado en este programa especial ha sido: Fernando Rivas, José Lagunar, Alberto Martínez, Eduardo Lausin y Victor Delgado. Intentando dirigir a estos profesionales del motor, Antonio R. Vaquerizo. Esperamos que os guste este programa especial de AutoFM. El programa de radio del motor líder en España. Puedes seguirnos en nuestra web: https://autofm.es/ Twiter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ Youtube: https://www.youtube.com/channel/UC57czZy-ctfV02t_PeNXCAQ

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Daphne Zohar, Founder and CEO of PureTech. Daphne sheds light on how their unique and innovative business model looks to solve unmet needs and problem areas across the industry, how they differ from your typical biotech and the benefit of their problem centric approach. She explores how they're constantly innovating their internal pipeline and adapting to the needs of the market, such as using LYT-100, an existing program, to treat post-recovery complications from COVID-19. Daphne also shares her excitement at how the industry is becoming more open to new ideas and new models for developing medicines.  See acast.com/privacy for privacy and opt-out information.

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Eric Elenko, Chief Innovation Officer of PureTech. Eric provides a unique insight into how they use a problem centric approach to identify and build out treatment programs, both internally and through their own founded entities. Eric also explains how this model has inspired them to repurpose one of their existing programs, LYT-100, to help solve the issue of pulmonary complications in recovering COVID-19 patients. He also talks about the affect social distancing has had on the industry, stating his expectation that telemedicine and digital health is here to stay and will gather momentum going forward. See acast.com/privacy for privacy and opt-out information.

PureTech Health is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline that includes multiple post human proof-of-concept studies and pivotal stage programs. PureTech’s rich research and development pipeline has been advanced in collaboration with some of the world’s leading scientific experts, who along with PureTech’s team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. Ms. Zohar created PureTech Health, assembling a leading team to help implement her vision for the Company. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT’s Technology Review, the Boston Globe, and Scientific American. She sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston, is an Editorial Advisor to Xconomy, and is on the Board of Advisors of Life Science Care 

PureTech Alliance of reps tells CE Pro why the wellness trend is ready to take off, and which categories are set for growth.

PureTech Alliance of reps tells CE Pro why the wellness trend is ready to take off, and which categories are set for growth.

Auto roka 2020 je výborné. Titulu však vo veľkom pomohla elektrická verzia #Caroftheyear #Peugeot #208 #automobilovypodcast

Cactus prišiel o Airbumpy. Ale stále má megapohodlné kreslá miesto sedadiel a odklápacie zadné okná. #citroen #c4cactus #automobilovypodcast

The DIA Europe 2020 Keynote Address will focus on the intersections of science and business as explored by a scientist turned investor, Mr. Joep Muijrers, who currently serves as CFO of PureTech, a listed biopharmaceutical company that focuses on developing medicines for devastating diseases including cancer, CNS disease, and immunological disorders. “What is the value of a product that, quite often against the odds in this sector, makes it and gets to patients and then doesn't make a dent whatsoever – it's not being used. What's the relevance of that?” he asks. “Put it this way: In this industry, we tell the end user what's good for them. Isn't that crazy?”

On Cyrus Says this week, Cyrus is joined by Prashant Deorah, MD and CEO, Puretech Digital. They talk about how Prashant got into the digital marketing space, and pushed governmental institutions to start '.in' domains and build infrastructure to host websites in India in the late 90's-early 2000's, which kind of made him a pioneer in the field. Also, a lot of talk about living and growing up in Napean Sea Road in South Mumbai, plus tons more.Follow Prashant on Twitter @prashant125Do send in AMA questions for Cyrus by tweeting them to @cyrussaysin or e-mailing them at whatcyrussays@gmail.comDon't forget to follow Cyrus Broacha on Instagram @BoredBroachaIn case you're late to the party and want to catch up on previous episodes of Cyrus Says you can do so at: www.ivmpodcasts.com/cyrussaysYou can listen to this show and other awesome shows on the new and improved IVM Podcasts App on Android: https://ivm.today/androidor iOS: https://ivm.today/ios

Show #634   Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily for Thursday 7th November 2019. It’s Martyn Lee here and I go through every EV story to save you time.   Thank you to MYEV.com for helping make this show, they’ve built the first marketplace specifically for Electric Vehicles. It’s a totally free marketplace that simplifies the buying and selling process, and help you learn about EVs along the way too.   PORSCHE IS SETTING UP ELECTRIC CAR INSURANCE FOR THE TAYCAN "With the launch of the Taycan, Porsche Financial Services is now offering not only established motor vehicle insurance but also a policy specially tailored to electric cars." reports electrive: "According to the press release, the new policy supplements the existing Porsche CarPolicy with, for example, special protection for the battery and charging station as well as mobility protection. Porsche did not give any information on the policy’s costs or detailed conditions in the press release."   “A highlight of ‘E-Cover’ is the original price protection for the battery in the event of damage. Extensive cyber protection is another innovative component of the product”.   https://www.electrive.com/2019/11/07/porsche-is-setting-up-electric-car-insurance-for-the-taycan/   MAERSK TO PILOT 600 KWH CONTAINERIZED BATTERY SYSTEM ON CONTAINER SHIP "A containerized 600 kWh marine battery system will be installed in a trial on board the Maersk Cape Town in December 2019 to improve vessel performance and reliability while reducing CO2 emissions." says Green Car Congress: "Propelling marine vessels with battery power alone is still years away from being a technically- and economically-viable option, Maersk says. However marine battery systems can be used to improve the efficiency of a vessel’s onboard electrical systems such as the Maersk Cape Town’s generators. By maintaining the vessel’s auxiliary generators at a more optimal load, and avoiding running generators when not needed, overall fuel consumption can be reduced."   https://www.greencarcongress.com/2019/11/20191107-maersk.html   PRICES AND SPECS REVEALED FOR CITROËN C5 AIRCROSS HYBRID "Citroën has launched a plug-in hybrid version of its C5 Aircross SUV, bringing CO2 emissions of 39g/km and a 31-mile electric-only range to aid fleets looking to go greener." according to Fleetworld:" Priced from £35,340 and starting deliveries in mid-2020, the C5 Aircross Hybrid combines a PureTech 180hp petrol engine, a 109hp electric motor and an ë-EAT8 automatic gearbox. with a 100% electric range of up to 31 miles / 50km, The 13.2kWh battery is covered by an eight-year / 100,000 mile warranty to guarantee up to 70% of its charge capacity, and can be charged in less than two hours thanks to the standard 7.4KW on board charger."   https://fleetworld.co.uk/prices-and-specs-revealed-for-citroen-c5-aircross-hybrid/   DTM REVEALS A 1,000 HP CONCEPT FOR AN ALL-ELECTRIC RACING SERIES DTM—also known as Deutsche Tourenwagen Masters—has introduced a 1,000 horsepower concept of the future for what will inevitably be an all-electric (or an all-hydrogen) series. That’s a pretty massive upgrade from the series’ current 600 HP combustion engines." reports Jalopnik: "A press release makes it very clear that this newer, more eco-friendly series will run alongside DTM without actually replacing it just yet. DTM’s promoter ITR is pretty keen on keeping both series around as long as possible."   MERCEDES-BENZ CHIEF CONFIRMS ALL-ELECTRIC G-CLASS WAGON IN THE WORKS "Ola Källenius, chairman of Daimler and head of Mercedes-Benz, confirmed today that the company will produce an all-electric version of the iconic G-Class wagon." says Fred at Electrek: "The introduction of a G-Class wagon — rated at 14 miles per gallon ­— would transform one of Mercedes’ biggest gas guzzlers into a zero-emissions vehicle. Källenius mentioned that there had been discussions to eliminate the iconic model. Apparently, instead, it will be electrified."   https://electrek.co/2019/11/07/mercedes-benz-chief-confirms-all-electric-g-class-wagon-in-the-works/   ELECTRIFICATION FOR TRUCKING FROM TEVVA "On Wednesday, electric commercial vehicle pioneer Tevva unveiled its Electrify initiative, aiming to drive the electrification of medium-duty HGVs through the deployment of up to 50 electric trucks across the United Kingdom and Europe over the next six months." according to GreenBiz: "Tevva has developed a package of EV technologies tailored for HGV vehicles, including battery packs, fleet management systems and advanced cloud-based software that uses geofencing capabilities to autonomously control a range extender and ensure vehicles can switch to zero-emissions mode to optimize efficiency and minimize air pollution in built-up areas."   https://www.greenbiz.com/article/poo-and-power-electrification-and-manure-offer-competing-paths-decarbonize-hgvs     2020 HYUNDAI IONIQ ELECTRIC RANGE BOOSTED TO 170 MILES FOR VERY EFFICIENT EV "The 2020 Hyundai Ioniq Electric gets a big range boost—up to 170 EPA-rated miles, according to results posted Tuesday by the federal agency." says Green Car Reports: "The pack goes up from 28 kwh in the 2019 model to about 38 kwh in the 2020 model.  EPA test info also confirm that the U.S.-spec Ioniq Electric will get the same motor upgrade given to versions in other markets—raising output to 134 hp (100 kw), from 118 hp (88 kw)."   https://www.greencarreports.com/news/1125897_2020-hyundai-ioniq-electric-range-boosted-to-170-miles-for-very-efficient-ev   FORD MUSTANG-INSPIRED ELECTRIC CROSSOVER CAUGHT ALMOST CAMO FREE "The Ford Mustang-inspired electric SUV unveiling is scheduled for November 17, ahead of the LA Auto Show, but we already obtained photos of a barely disguised prototype." says InsideEVs: "It seems that the new long-range electric Ford is more like a crossover than an actual SUV. Size and shape probably will put it in the same segment as the Tesla Model Y."   https://insideevs.com/news/381083/ford-mustang-inspired-mach-e-bev/   FORMER DAIMLER CEO PRAISES TESLA, BUT SAYS GERMANS REMAIN PERMANENTLY AHEAD Former Daimler CEO Dieter Zetsche recently shared his thoughts on the electric car revolution and the part played by American electric car maker Tesla. Now retired and without commitments to a specific automaker, Zetsche freely praised Elon Musk, stating that he adores the daring Tesla CEO." says Simon Alvarez at Teslarati: "Thus, despite his admiration for Elon Musk, Zetsche believes that established automakers will be permanently ahead. Volkswagen, BMW, and Daimler are all making big moves on electromobility."   https://www.teslarati.com/tesla-vs-daimler-electric-vehicle-race-dieter-zetsche/     QUESTION OF THE WEEK The MYEV.com Question Of The Week…   What do you prefer, the carrot or the stick? Ie incentives for EVs or penalties for polluters   I want to say a heartfelt thank you to the 254 patrons of this podcast whose generosity means I get to keep making this show, which aims to entertain and inform thousands of listeners every day about a brighter future. By no means do you have to check out Patreon but if it’s something you’ve been thinking about, by all means look at patreon.com/evnewsdaily     PHIL ROBERTS / ELECTRIC FUTURE (PREMIUM PARTNER) BRAD CROSBY (PREMIUM PARTNER) AVID TECHNOLOGY (PREMIUM PARTNER)   DAVID ALLEN (PARTNER) OEM AUDIO OF NEW ZEALAND AND EVPOWER.CO.NZ (PARTNER) PAUL O’CONNOR (PARTNER) TRYEV.COM (PARTNER) GARETH HAMER eMOBILITY NORWAY HTTPS://WWW.EMOBILITYNORWAY.COM/  (PARTNER) ALAN ROBSON (EXECUTIVE PRODUCER) ALAN SHEDD (EXECUTIVE PRODUCER) ALEX BANAHENE (EXECUTIVE PRODUCER) ALEXANDER FRANK @ https://www.youtube.com/c/alexsuniverse42 ANDERS HOVE (EXECUTIVE PRODUCER) ASHLEY HILL (EXECUTIVE PRODUCER) BÅRD FJUKSTAD (EXECUTIVE PRODUCER) BARRY PENISTON (EXECUTIVE PRODUCER) BRENT KINGSFORD (EXECUTIVE PRODUCER) BRIAN THOMPSON (EXECUTIVE PRODUCER) BRIAN WEATHERALL (EXECUTIVE PRODUCER) BRUCE BOHANNAN (EXECUTIVE PRODUCER) CESAR TRUJILLO (EXECUTIVE PRODUCER) CHARLES HALL (EXECUTIVE PRODUCER) CHRIS HOPKINS (EXECUTIVE PRODUCER) COLIN HENNESSY (EXECUTIVE PRODUCER) CRAIG COLES (EXECUTIVE PRODUCER) CRAIG COOPER (EXECUTIVE PRODUCER) CRAIG ROGERS (EXECUTIVE PRODUCER) DAMIEN DAVIS (EXECUTIVE PRODUCER) DAN FAIRS (EXECUTIVE PRODUCER) DARREN BYRD (EXECUTIVE PRODUCER) DARREN SANT FROM YORKSHIRE EV CLUB (EXECUTIVE PRODUCER) DAVE DEWSON (EXECUTIVE PRODUCER) DAVID BARKMAN (EXECUTIVE PRODUCER) DAVID FINCH (EXECUTIVE PRODUCER) DAVID PARTINGTON (EXECUTIVE PRODUCER) DAVID PRESCOTT (EXECUTIVE PRODUCER) DEREK REILLY FROM THEEFFECT.NET (EXECUTIVE PRODUCER) DIRK RUTSATZ (EXECUTIVE PRODUCER) DON MCALLISTER / SCREENCASTSONLINE.COM (EXECUTIVE PRODUCER) ENRICO STEPHAN-SCHILOW (EXECUTIVE PRODUCER) FREDRIK ROVIK (EXECUTIVE PRODUCER) FREEJOULE AKA JAMES (EXECUTIVE PRODUCER) GENE RUBIN (EXECUTIVE PRODUCER) GEOFF LOWE (EXECUTIVE PRODUCER) GEORGE CLARGO (EXECUTIVE PRODUCER) IAN GRIFFITHS (EXECUTIVE PRODUCER) IAN SEAR (EXECUTIVE PRODUCER) JACK OAKLEY (EXECUTIVE PRODUCER) JAMES STORR (EXECUTIVE PRODUCER) JEFF ERBES (EXECUTIVE PRODUCER) JERRY ALLISON (EXECUTIVE PRODUCER) JIM MORRIS (EXECUTIVE PRODICERS) JOHN BAILEY (EXECUTIVE PRODUCER) JOHN LACEY FROM CLICK CLACK VIDEO NZ (EXECUTIVE PRODUCER) JON AKA BEARDY MCBEARDFACE FROM KENT EVS (EXECUTIVE PRODUCER) JON KNODEL (EXECUTIVE PRODUCER) JUAN GONZALEZ (EXECUTIVE PRODUCER) KEN MORRIS (EXECUTIVE PRODUCER) KEVIN MEYERSON (EXECUTIVE PRODUCER) KYLE MAHAN (EXECUTIVE PRODUCER) LARS DAHLAGER (EXECUTIVE PRODUCER) LAURENCE D ALLEN (EXECUTIVE PRODUCER) LESZEK GRZYL (EXECUTIVE PRODUCER) LEE BROWN (EXECUTIVE PRODUCER) LUKE CULLEY (EXECUTIVE PRODUCER) MARCEL LOHMANN (EXECUTIVE PRODUCER) MARCEL WARD (EXECUTIVE PRODUCER) MARLIN SCHELL (EXECUTIVE PRODUCER) MARTIN CROFT (EXECUTIVE PRODUCER) MATT PISCIONE (EXECUTIVE PRODUCER) MATTHEW ELLIS (EXECUTIVE PRODUCER) MAZ SHAR (EXECUTIVE PRODUCER) MIA OPPELSTRUP (EXECUTIVE PRODUCER) MICHAEL PASTRONE (EXECUTIVE PRODUCER) MICHEAEL KYFFIN (EXECUTIVE PRODUCER) MIKE ROGERS (EXECUTIVE PRODUCER) MIKE WINTER (EXECUTIVE PRODUCER) NATHAN GORE-BROWN (EXECUTIVE PRODUCER) NEIL E ROBERTS FROM SUSSEX EVS (EXECUTIVE PRODUCER) NORTHERN EXPLORERS (EXECUTIVE PRODUCER) OHAD ASTON (EXECUTIVE PRODUCER) PAUL RIDINGS (EXECUTIVE PRODUCER) PAUL SHELLEY ((EXECUTIVE PRODUCER) PAUL STEPHENSON (EXECUTIVE PRODUCER) PERRY SIMPKINS (EXECUTIVE PRODUCER) PETE GLASS (EXECUTIVE PRODUCER) PETE GORTON (EXECUTIVE PRODUCER) PETER & DEE ROBERTS FROM OXON EVS (EXECUTIVE PRODUCER)  PHIL MOUCHET (EXECUTIVE PRODUCER) PONTUS KINDBLAD (EXECUTIVE PRODUCER) RAJEEV NARAYAN (EXECUTIVE PRODUCER) RALPH JENSON (EXECUTIVE PRODUCER) RENÉ SCHNEIDER (EXECUTIVE PRODUCER) ROB COOLING / HTTP://WWW.APPLEDRIVING.CO.UK/ (EXECUTIVE PRODUCER) ROB HERMANS (EXECUTIVE PRODUCER) ROBERT GRACE (EXECUTIVE PRODUCER) ROBIN TANNER (EXECUTIVE PRODUCER) RUPERT MITCHELL (EXECUTIVE PRODUCER) SABBY THE CAT (EXECUTIVE PRODUCER) SARAH MCCANN (EXECUTIVE PRODUCER) SARI KANGASOJA (EXECUTIVE PRODUCER) SEIKI PAYNE (EXECUTIVE PRODUCER) STEVE JOHN (EXECUTIVE PRODUCER) STUART HANNAH (EXECUTIVE PRODUCER) THE LIMOUSINE LINE SYDNEY (EXECUTIVE PRODUCER) THE PLUGSEEKER – EV YOUTUBE CHANNEL (EXECUTIVE PRODUCER) TIM GUTTERIDGE (EXECUTIVE PRODUCER) WILLIAM LANGHORNE (EXECUTIVE PRODUCER) ZACK HURST (EXECUTIVE PRODUCER)   You can listen to all 633 previous episodes of this this for free, where you get your podcasts from, plus the blog https://www.evnewsdaily.com/ – remember to subscribe, which means you don’t have to think about downloading the show each day, plus you get it first and free and automatically. It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast. And if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing. Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, I’ll catch you tomorrow and remember…there’s no such thing as a self-charging hybrid.   CONNECT WITH ME! EVne.ws/itunes EVne.ws/tunein EVne.ws/googleplay EVne.ws/stitcher EVne.ws/youtube EVne.ws/iheart EVne.ws/blog EVne.ws/patreon   Check out MYEV.com for more details: https://www.myev.com

Invest Alongside Boston's Top Angels: Our Syndicates Scientist and intrapreneur Gillian Isabelle, PhD, founded Enlivity (https://enlivity.com/) to make chemotherapy more bearable for cancer patients. The first product is a supplement invented by an oncologist that helps prevent sores from forming in the mouths and digestive tracts of patients receiving chemotherapy, a problem that can delay life-saving treatment. A fun interview with an infectiously affable guest. Gillian Isabelle studied material science at UC Berkeley and received her PhD from MIT. Worked at Corning and then at PureTech Health, the remarkable promising new pharma company started in Boston. At the Broad Institute she set up and ran the business development office to bring is licensing revenue from the Broad’s research. Gillian Isabelle is the founder of Enlivity, a startup dedicated to improving the lives of patients receiving chemotherapy. Radiation and chemotherapy have serious side effects that include sores in the mouth and the digestive tract. Such sores can cause treatment to be reduced or suspended, lowering the chances of the patient surviving the cancer. Patients with mouth sores may need to be administered opioids to help them endure treatment. These side effects also have economic consequences. Patients with sores may need to be admitted to a hospital in order to continue receiving therapy. Providers have an economic incentive to help to prevent hospitalization due to side effects from therapy. Value-based reimbursement for treatments, which is now the rule among payors, increases the incentive of managing side effects from treatment. Supporting the health of the oral and digestive mucosa allows patients to eat and drink normally and to maintain a healthy weight. Gillian observed a gap in cancer care. Great work is being done in developing new therapies but those can take decades before they help patients. Little is being done to help patients endure current therapies. If we can help patients better tolerate existing therapies, we can achieve better treatment outcomes and lower cost of care in the short run. She sees dealing with side effects as relatively low-hanging fruit. Gillian’s research, including talking to a lot of doctors, nurses and patients, showed that the most likely path to improving outcomes was to work on making nutrients that are known to support the health of tissues more bio-available. She speculated that using technology for targeted released of compounds in the body could help make these nutrients more available. The first product, Healios, is a compound of glutamine. Glutamine has been known to provide amino acids, the building blocks of protein, that support tissue health and immune function. Unfortunately, glutamine by itself is not bio-available. A pediatric oncologist at MD Anderson, a leading cancer clinic in Houston, invented a compound of glutamine with sugars which is readily absorbed by the body. This patented formulation is licensed exclusively to Enlivity. Gillian intends Healios to be the first of a whole stable of products that support patients receiving treatment. Gillian met her co-founder Jill Tobacco via LinkedIn. Jill brings marketing experience and to complement Gillian’s technical background. Gillian was looking for a nutritionist who was good at marketing. Jill bought into the vision. Looking for a co-founder displays self-awareness on the part of Gillian Isabelle for knowing what she needed help with. Before asking Gillian how she plans to go to market, Sal talks a bit about his portfolio company Akili Interactive which expects to be the first company to get approval from the FDA to market a video game to treat ADHD or attention deficit. Akili’s approach is to actually train the young person’s brain to make it easier to pay attention. It’s meant to be a therapy for the underlying cause of the problem, not just a treatment for the symptoms. This is a link to an article in the Financial Times about the founder Eddie Martucci, PhD and the company: https://www.ft.com/content/1f2bc488-8c5a-11e9-a1c1-51bf8f989972 Sal mentions Akili to highlight the type of opportunity he sees in Boston’s startup ecosystem. Accredited investors should contact AngelInvestBoston.com to learn more. Chemotherapy targets the fastest growing cells in the body because cancer cells are fast-growing. Cells in the lining of the mouth and throat are also fast-growing so they are susceptible to chemotherapy which is what leads to sores. Radiation releases free radicals which also attack the lining of the mouth and throat. Enlivity plans to market its products directly to the care providers who are the most familiar with the problems of cancer therapy. There is also growing inbound interest from care providers. Conversion is high when patients try samples. Sold via their own website. By the end of 2020 Gillian hopes Enlivity will have a strategic partnership for distribution and to be launching their second product, a treatment for people who lose the ability to make saliva due to radiation therapy. Gillian describes working at PureTech Health when it was a startup starting startups. The company partnered with faculty members seeking to commercialize technologies. Gillian told us how exciting it was to work with Daphne Zohar, the founder of PureTech. PureTech has shown a remarkable ability to define important problems to address and to bring capable resources to bear on their area of focus. When Gillian went to the Broad Institute it was still managed as a department within MIT. As the Broad spun out from MIT, it needed to have its own technology transfer office which handled licenses and collaboration with strategic players such as the large pharmaceutical companies. Big pharma is reducing in-house research and contracting it out to universities. Watching a friend die from cancer at age 42 changed Gillian’s focus from long-term cures to what could be done in the short run to improve the lives of cancer patients. Gillian did not see anyone else addressing the gap she noticed so she decided she was the person to do it. Gillian’s mother was a nurse practitioner who was an early social entrepreneur creating a program for disabled children which was copied all over Jamaica. She is a model for Gillian. Gillian’s husband is very supportive of her venture. Gillian emphasized the importance of finding allies to support you early on because the journey is very lonely. Advice to entrepreneurs: don’t go it alone. Important allies: MIT Venture Mentoring Services (VMS), co-founder, and other mentors and friends. Gillian reveals that she’s a listener to the Angel Invest Boston podcast and that she has left a review on iTunes. I’m honored!

Wenn ein bestimmtes Produkt mit dem Namen einer Marke fast untrennbar verbunden ist, dann ist das schon fast ein Ritterschlag. Da wird bei der Frage nach einem Papiertaschentuch wie selbstverständlich ein Tempo verlangt, transparentes Klebeband wird in der Regel als Tesa beschrieben und ein Geländewagen fast immer als Jeep, auch wenn im jeweiligen Fall ein anderer Hersteller dahintersteht. Citroën hat das Kunststück geschafft, dass der Name Berlingo in einigen Ländern sogar als Synonym für ein Familien- und Freizeitauto verwendet wird. Gratulation! Darum geht es diesmal!ER war der Begründer des Segments der Hochdachkombis. 1996 gestartet wurden bisher vom Citroën Berlingo weltweit über 1,7 Millionen Fahrzeuge verkauft. Jetzt hat Citroën den Berlingo nicht nur im Design, sondern auch in Komfort und Modularität weiterentwickelt: Erstmals gibt es ihn in zwei Längen und wahlweise als Fünf- und als Siebensitzer. Dazu kann man 19 Fahrerassistenzsysteme, vier Konnektivitätstechnologien sowie leistungsstarke Benzin- und Dieselmotoren ordern. Diese erfüllen natürlich schon jetzt die zukünftige Abgasnorm Euro 6d-TEMP. Power und Drive!    Beim Antrieb kann man aktuell zwischen 1.2 Liter - PureTech Benzinmotoren mit 81 kW /110 PS und 96 kW /131 PS und Dieselantrieben mit 75 kW /110 PS und 96 kW /131 PS  wählen. Je nach Modell ist auch das 8-Gang-Automatikgetriebe EAT8 verfügbar. Unser Testkandidat ging mit dem mit 81 kW /110 PS PureTech Benzinmotor mit Sechs-Gang-Schaltgetriebe ans Werk. Damit konnten wir folgende Fahrwerte erzielen. Die Beschleunigung von 0 auf Tempo 100 dauert 13 Sekunden, beim Siebensitzer dauert es mit 13,6 Sekunden etwas länger. Die Spitze erreichen beide aber bei 175 km/ h.  Die Verbrauchswerte liegen mit 5,4 Liter auf 100 km im kombinierten Verbrauch gleich, im CO2-Ausstoß ist es mit 124 zu 125 g / km  kombiniert nur ein unbedeutender Unterschied. Die Innenausstattung!Wer sich die Ausstattungsliste eines Citroën Berlingo anschaut wird sehen, dass schon die Basisversion, die lustigerweise den Namen START trägt, ordentlich ausgestattet ist. Das sind neben vielen Selbstverständlichkeiten auch erfreuliche Features wie ein Sicherheitspaket, bestehend aus Spurassistent, Verkehrszeichenerkennung und einem aktiven Notbremsassistenten mit Kollisionswarner. Das sind weiterhin angenehme Hilfsmittel wie der Berganfahrassistent oder elektrische Fensterheber vorn. Mit steigender Ausstattungslinie wird auch die Ausstattung umfangreicher. Genaueres sagt Ihnen die Preisliste. Trotzdem gibt es auch noch eine Optionsliste, mit der man den Wagen nochmal aufpeppen kann. Wenn es denn unbedingt sein muss! Die Kosten!Reden wir über Geld. Den Citroën Berlingo gibt es ja nach Modell zwischen 19.090,– und 30.690,– Euro. Der Berlingo PureTech mit 81 kW /110 PS  und 6-Gang-Schaltgetriebe kostet in der SHINE-Ausstattung 24.640,– Euro. Das ist ein ausgewogener Preis für einen gut ausgestatteten Hochdachkombi.   Diesen Beitrag können Sie nachhören oder downloaden unter:

Der neue Peugeot 508 setzt neue Maßstäbe im Segment der Mittelklassefahrzeuge und zahlt damit auf die Höherpositionierung der Marke ein, wie man in Marketingkreisen zu sagen pflegt. Die Rechnung dürfte aufgehen. Ein markant-elegantes Design, die jüngste Version des Peugeot i-Cockpits® sowie neueste Fahrerassistenzsysteme und Euro 6d-TEMP-sprechen eine klare Sprache. Darum geht es diesmal!Seit dem vergangenen Oktober ist die aktuelle Version der sportlichen Limousine Peugeot 508 auf den Straßen unterwegs. Das ist ein Fahrzeug, dass durch eine Linienführung auffällt, die gleichermaßen elegant und sportlich ist. Zudem ist es eine ausgesprochen gute Mischung, die auch unterschiedliche Zielgruppen anspricht. Das Outfit!Die sportliche Ausstrahlung wird unter anderem durch eine aufwendig konstruierte Motorhaube erzeugt. Dazu kommen ausdrucksstarke Full-LED-Scheinwerfer und eine klare und markante Linienführung. Mit knapp 1,40 Metern Höhe ist der neue 508 besonders flach designt und damit sechs Zentimeter niedriger als der Vorgänger.  Power und Drive!    Antriebsseitig kann man zwischen zwei Benzin- und drei Dieselmotoren mit Leistungen zwischen 130 PS (96 kW) und 225 PS (165 kW) wählen. Wir haben uns mal verwöhnen lassen und den PureTech 225 zum Test geordert.  EAT8 steht für das neue Achtgang-Automatikgetriebe, das wahlweise eine ausgesprochen sportliche oder gemütliche Fahrweise erlaubt.  Es ist übrigens serienmäßig an Bord. Tempo 100 erreicht man beim beherzten Tritt aufs Gaspedal nach 7,3 Sekunden, die Maximalgeschwindigkeit beträgt 250 km/h. Die wird man auf deutschen Straßen aber eher selten fahren können. Der Verbrauch liegt im kombinierten Zyklus bei 5,7 Litern Super auf 100 Kilometer Fahrstrecke, umgerechnet vom WLTP-Meßverfahren auf NEFZ-Standard. Das entspricht kombiniert 131 g CO2-Emissionen pro Kilometer. Die Innenausstattung!Von den drei Ausstattungslinien ACTIVE, ALLURE und GT ist die letztgenannte die umfangreichste. Hier ist fast alles vorhanden, was man sich so wünscht, was wir hier aber auch Zeitgründen leider nicht aufzählen können. Eine interessante Option will ich aber erwähnen. Die Night Vision. Das ist ein Nachtsicht-System mit Darstellung der Straßensituation bei Nacht im Kombiinstrument.  Eine Infrarot-Kamera erkennt Lebewesen, die sich nachts oder bei eingeschränkter Sicht in einer Entfernung von bis zu 250 Metern im Bereich vor dem Fahrzeug befinden. Die Kosten!Von 31.850,-- Euro bis 47.050,-- Euro reicht die Preisliste des Peugeot 508, unser Testkandidat, der 508 PureTech 225 EAT8 GT liegt mit 46.400,-- Euro knapp unter dem teuersten Modell. Das ist durchaus angemessen, denn die GT – Version ist die umfangreichste Ausstattungslinie beim 508.   Diesen Beitrag können Sie nachhören oder downloaden unter:

Can You Help Me Fight The Fossils? Read More About Patreon here EVne.ws/patreon   Read today’s show notes on https://www.evnewsdaily.com   Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily for Friday 25th January 2019. It’s Martyn Lee here and I’ve been through every EV story I can find today, and picked out the ones I think you need to know about.   Thank you to MYEV.com for helping make this show, they’ve built the first marketplace specifically for Electric Vehicles. It’s a totally free marketplace that simplifies the buying and selling process, and help you learn about EVs along the way too. And welcome to the community on Patreon it’s a new Producer of the show MIA OPPELSTRUP!   CARLOS GHOSN QUITS AS RENAULT BOSS "Renault on Thursday announced that Ghosn resigned from his top spot as chairman and CEO of that automaker too, throwing into doubt the now-shaky alliance Ghosn helped forge between all three automakers" says Green Car Reports: "Under Ghosn, Nissan built and sold the first mass-market, fully electric vehicle sold around the world. In eight years on sale, Nissan has reportedly sold more than 386,000 Leafs according to the automaker, which makes it the world's best-selling electric car. Ghosn told CNBC in 2017 that the automakers he collectively ran profited on electric vehicles, which has been elusive for many automakers so far. In 2009, Ghosn spearheaded Nissan's efforts to produce the Leaf and sell it across the world. He committed billions of dollars to the Leaf's development, battery production, and marketing, and committed billions more to building and selling electric cars in China, the biggest opportunity market for automakers in the world."   https://www.greencarreports.com/news/1121126_carlos-ghosn-electric-car-proponent-and-embattled-executive-quit-as-renault-boss   FIRST TESLA MODEL 3 DEMO CARS ARRIVED IN EUROPE "In Norway during during the course of this month 17 Tesla Model 3 cars were already registered. These units are most likely all demo cars that will be available at the 12 Tesla Stores in Norway." says Pedro Lima at PushEVs: "The arrival of demo units happens just few weeks before first deliveries start to Norwegian customers. I’m curious to see how many units of long and mid-range will Tesla sell before making the standard range variant available. I think that most Europeans will wait for the cheapest and more efficient variant, since it will have enough range for European customers." I’ve seen three different posts on Twitter with photo’s of car carriers transporting Performance models.   https://pushevs.com/2019/01/24/first-tesla-model-3-demo-cars-arrived-in-norway/   2020 OPEL CORSA SPIED UP CLOSE WITH PRODUCTION BODY "Sticking to General Motors underpinnings would’ve meant paying a license fee, which is why PSA decided to go back to the drawing board and start development of the new Opel/Vauxhall Corsa from scratch. As a result, the new supermini will ride on the same Common Modular Platform (CMP) as the next-gen Peugeot 208" reports Adrian Padeanu for Motor1.com: "While conventionally powered versions will likely employ PSA’s latest turbocharged three-cylinder PureTech engine with a 1.2-liter displacement, there will also be a zero-emissions variant that will go by the name of eCorsa. The electric hatch will ride on the e-CMP platform set to be used by an assortment of EVs within the PSA Group."   https://www.motor1.com/news/302447/2020-opel-corsa-spy-photos/   POLESTAR 2 ELECTRIC CAR PLANS TO OFFER 'TRULY FUTURE-PROOF SOFTWARE SETUP' Inverse have taken a look at the Polestar 2 and how connected it will be: "In a wide-ranging description of the software, Polestar explains that the car will come with an “Android-based that’s always connected to the internet and receives over-the-air updates just like your smartphone.” The system will come bundled with “apps, services, and technologies that people already use every day on their smartphones,” including Google Maps, that are “designed and adapted specifically for an in-vehicle experience.” The car will also offer an embedded Google Assistant that supports car-based actions like changing the temperature. If these apps aren’t to the driver’s liking, the system will also support the Google Play Store."   https://www.inverse.com/article/52702-polestar-2-electric-car-plans-to-offer-truly-future-proof-software-setup   FREMONT, CALIF. TO PILOT A TESLA MODEL S POLICE CRUISER "Police in Fremont, Calif. are turning to a novel solution to get in line with the city's broader goal of lowering greenhouse gas emissions by preparing to launch a pilot program to use a zero-emission Tesla Model S fitted for police duty in daily operation." reports Autoblog: "Last year, the department purchased a used 2014 Model S 85 for $61,478.50, including taxes and fees, as a replacement for a more standard cop-issue 2007 Dodge Charger that was scheduled to be taken out of service. The department says it's working with vendors to install equipment like the light bar, a digital computer, rear flasher and a push bumper, with total modifications so far running $4,447 and expected to climb."   https://www.autoblog.com/2019/01/24/fremont-tesla-model-s-police-cruiser/   TESLA MODEL S AND MODEL X PRODUCTION AFFECTED BY LAYOFFS As per the CNBC i mentioned yesterday: "According to an ex-employee who was involved in Tesla’s delivery operations, and a current employee who works for Tesla in Fremont, the layoffs appear to have impacted workers across every department and region from factory workers to recruiters and receptionists. But deep cuts apparently hit Tesla’s delivery, sales and Model S and X production teams." Tesla replied: "“We recently announced that we are no longer taking orders for the 75 kWh version of Model S and X in order to streamline production and provide even more differentiation with Model 3. As a result of this change and because of improving efficiencies in our production lines, we have reduced Model S and X production hours accordingly. At the same time, these changes, along with continuing improvements, give us the flexibility to increase our production capacity in the future as needed. We’ll be providing more details on our earnings call next week.”   https://electrek.co/2019/01/23/tesla-model-s-model-x-production-most-affected-layoffs-report/   FORMULA E RACES THIS SATURDAY IN SANTIAGO, CHILE "Formula E hits the track again this Saturday, January 26th in Santiago, Chile, just two weeks after the last race in a racing series historically more accustomed to month-long breaks between races." says Jameson Dow for Electrek: "For those of us in the EV world, BMW driver Alexander Sims is someone to keep an eye on. He’s been a professional racing driver for several years now, but unlike many of the other drivers in Formula E, Sims also drives an electric car in his daily life.  He was an early Tesla Roadster owner and also has a BMW i3 as a daily driver."   https://electrek.co/2019/01/24/formula-e-races-this-saturday-in-santiago/   CHARIN: CCS COMBO STANDARD TO OFFER V2G BY 2025 "CharIN e.V. has released the roadmap for grid integration (V2H, V2G) of charging systems based on the Combined Charging System (CCS)." reports Mark Kane for InsideEVs.com: "Initially, the organization was busy with the popularization of CCS around the world and increasing the power output, which is now set at 350 kW (or even more). The standard will also include grid integration features, but the timeframe is some 7 years from now before it will be ready, on par with CHAdeMO.   There are five levels of grid integration specified: Today: Grid-compliant Charging Till 2020: Level 1 – V1G Controlled Charging Till 2020: Level 2 – V1G/H Cooperative Charging Till 2025: Level 3 – V2H Bidirectional Charging Around 2025: Level 4 – V2G Aggregated (bidirectional) charging"   https://insideevs.com/ccs-combo-standard-v2g-2025/   TESLA TO ROLL OUT “SENTRY MODE” SECURITY SYSTEM "With the recent increase in Tesla vehicle break-ins and vandalism popping up across social media and online forums, CEO Elon Musk’s recent hint at an upcoming “Sentry Mode” feature for Model S, Model X, and Model 3 vehicles that are equipped with Enhance Autopilot hardware is both welcome and timely." says AstroJane for Teslarati: "The reveal comes via Twitter and in response to a customer’s complaint about a large dent found on his Model 3. “Tesla Sentry Mode coming soon for all cars with Enhanced Autopilot.” said Musk. Enhanced Autopilot (EAP), Tesla’s driver-assist software enabled in February 2017 with the version 8.0 software update, utilizes 8 surround cameras and 12 ultrasonic sensors and radar. "   https://www.teslarati.com/tesla-sentry-mode-security-enhanced-autopilot-2-hardware-cars/   BP INVESTS IN CHINESE EV CHARGING OUTFIT POWERSHARE "BP Ventures' first direct investment in China sees the energy giant step up its interest in electric vehicle infrastructure" reports Business Green today: "P has underlined its growing interest in the fast-expanding global electric vehicle (EV) market with the announcement it has invested in Chinese charging technology specialist PowerShare. The oil and gas giant's venture arm, BP Ventures, confirmed today it has invested an undisclosed sum in the company after leading A Series A funding round with support from Chinese private equity firm DETONG Capital Partners. PowerShare provides an online platform that connects EV drivers, charge point operators and power suppliers, streamlining the charging experience from locating a charge point through to paying for the power supply, BP said."   https://www.businessgreen.com/bg/news/3069886/bp-invests-in-chinese-ev-charging-outfit-powershare   COMMUNITY And thanks to MYEV.com they’ve set us another Question Of The Week. Keep your comments coming in on email and YouTube…   What’s the best way to your to get your first experience of driving an EV? Test drive, hire, experience centre? And if you are already an EV driver, how would have liked to have gotten your first experience of driving an EV if you could do it again?   I want to say a heartfelt thank you to the 178 patrons of this podcast whose generosity means I get to keep making this show, which aims to entertain and inform thousands of listeners every day about a brighter future. By no means do you have to check out Patreon but if it’s something you’ve been thinking about, by all means look at patreon.com/evnewsdaily     PHIL ROBERTS / ELECTRIC FUTURE (PREMIUM PARTNER) ELECTRICMOTORING.NET (PREMIUM PARTNER) BRAD CROSBY (PREMIUM PARTNER)   DAVID ALLEN (PARTNER) OEM AUDIO OF NEW ZEALAND AND EVPOWER.CO.NZ (PARTNER) SASCHA PALLENBERG (PARTNER) JON BEARDY MCBEARDFACE (PARTNER) ALAN ROBSON @SCOTTISHEVOWNER (EXECUTIVE PRODUCER) ARILD GEIR SKAALSVEEN (EXECUTIVE PRODUCER) ASHLEY HILL (EXECUTIVE PRODUCER) BÅRD FJUKSTAD (EXECUTIVE PRODUCER) BOB MUIR / GINGERCOMPUTERS.COM IN DUNDEE (EXECUTIVE PRODUCER) BORISLAV BORISOV (EXECUTIVE PRODUCER) BRENT KINGSFORD (EXECUTIVE PRODUCER) BRIAN WEATHERALL (EXECUTIVE PRODUCER) BRYAN YOUNG / CONFT.SHOW PODCAST (EXECUTIVE PRODUCER) CESAR TRUJILLO (EXECUTIVE PRODUCER) CHRIS BENSON (EXECUTIVE PRODUCER) CHRIS HOPKINS (EXECUTIVE PRODUCER) DAMIEN DAVIS (EXECUTIVE PRODUCER) DARREN BYRD (EXECUTIVE PRODUCER) DARREN SANT (EXECUTIVE PRODUCER) DAVE DEWSON (EXECUTIVE PRODUCER) DAVID FINCH (EXECUTIVE PRODUCER) DAVID PARTINGTON (EXECUTIVE PRODUCER) DAVID PRESCOTT (EXECUTIVE PRODUCER) DIRK RUTSATZ (EXECUTIVE PRODUCER) DON MCALLISTER / SCREENCASTSONLINE.COM (EXECUTIVE PRODUCER) FREDRIK ROVIK (EXECUTIVE PRODUCER) GEORGE CLARGO (EXECUTIVE PRODUCER) JACK OAKLEY (EXECUTIVE PRODUCER) JASON FAN (EXECUTIVE PRODUCER) JEFF ERBES (EXECUTIVE PRODUCER) JERRY ALLISON (EXECUTIVE PRODUCER) JOHN BAILEY (EXECUTIVE PRODUCER) JON KNODEL (EXECUTIVE PRODUCER) JON TIMMIS (EXECUTIVE PRODUCER) KEN MORRIS (EXECUTIVE PRODUCER) KEVIN MEYERSON (EXECUTIVE PRODUCER) LARS DAHLAGER (EXECUTIVE PRODUCER) LAURENCE D ALLEN (EXECUTIVE PRODUCER) LOUIS HOPKIN (EXECUTIVE PRODUCER) LUKE CULLEY (EXECUTIVE PRODUCER) MARCEL LOHMANN (EXECUTIVE PRODUCER) MARCEL WARD (EXECUTIVE PRODUCER) MARTIN CROFT (EXECUTIVE PRODUCER) MATTHEW ELLIS (EXECUTIVE PRODUCER) MATTHEW GROOBY (EXECUTIVE PRODUCER) MAZ SHAR (EXECUTIVE PRODUCER) MIKE ROGERS (EXECUTIVE PRODUCER) NEIL E ROBERTS FROM SUSSEX EVS (EXECUTIVE PRODUCER) PAUL SEAGER-SMITH (EXECUTIVE PRODUCER) PAUL STEPHENSON (EXECUTIVE PRODUCER) PETE GLASS (EXECUTIVE PRODUCER) PHILIPPE CALVE (EXECUTIVE PRODUCER) RAJ BADWAL (EXECUTIVE PRODUCER) RENÉ SCHNEIDER (EXECUTIVE PRODUCER) ROD JAMES (EXECUTIVE PRODUCER) RUPERT MITCHELL (EXECUTIVE PRODUCER) SARAH MCCANN (EXECUTIVE PRODUCER) SCOTT CALLAHAN (EXECUTIVE PRODUCER) SEIKI PAYNE (EXECUTIVE PRODUCER) THE LIMOUSINE LINE SYDNEY (EXECUTIVE PRODUCER) WALTER MACVANE (EXECUTIVE PRODUCER) ZACK HURST (EXECUTIVE PRODUCER)   You can listen to all 367 previous episodes of this this for free, where you get your podcasts from, plus the blog https://www.evnewsdaily.com/ – remember to subscribe, which means you don’t have to think about downloading the show each day, plus you get it first and free and automatically. It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast. And if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing. Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, and I’ll catch you tomorrow.   CONNECT WITH ME! EVne.ws/itunes EVne.ws/tunein EVne.ws/googleplay EVne.ws/stitcher EVne.ws/youtube EVne.ws/iheart EVne.ws/blog EVne.ws/patreon   Check out MYEV.com for more details:

Wissen Sie aus dem Stehgreif, welches Auto 85 Gestaltungsmöglichkeiten außen und fünf Ausstattungsvarianten innen bietet und dennoch mühelos bezahlbar ist? Ich gebe Ihnen einen Tipp. Man nennt den Hersteller auch „Die Marke mit dem Doppelwinkel!“. Richtig! Es ist der neue C3 Aircross von Citroën. Darum geht es diesmal!Im Oktober 2017 hatte er seine Markteinführung, schon im Februar 2018 hat er in Europa die 50.000er Marke bei den Verkäufen geknackt. Die Rede ist von einem ausgesprochen auffälligen Fahrzeug aus dem Hause Citroën, dem neuen Compact SUV C3 Aircross.  Genau den haben wir uns zum Test ins Haus geholt.  Das Outfit!Also eines ist quasi amtlich. Wenn ein Auto so richtig ins Auge fällt, dann ist es der Citroën C3 Aircross. Viel auffälliger geht kaum noch, aber das macht auch den Reiz des knackigen Franzosen aus. Auf Anhieb fallen seine kurze, hohe Haube, horizontale Linien und großzügige Flächen auf. Am auffälligsten ist er sicher in Anthrazit mit dem 200 Euro teuren Style-Paket Orange, bei dem Dachreling, Scheinwerferumrandung, Außenspiegelgehäuse und Radnabenumrandung in einem knackigen Orange gehalten sind. Extrem auffällig ist dabei ein orangefarbener Jalousieeffekt auf den Seitenscheiben ganz hinten. Power und Drive!    Den Citroën C3 Aircross gibt es mit Benzinmotoren von 60 kW (82 PS), 81 kW (110 PS) und 96 kW (130 PS), dazu kommen Dieselantriebe mit 73 kW (99 PS) und 88 kW (120 PS). Wer wie ich ein Fan des absolut schaltfaulen Fahrens ist, also mithilfe einer Automatik, der hat nicht ganz so viel Auswahl, denn es gibt nur den C3 Aircross PureTech 110 Stop&Start mit der EAT6 genannten 6-Gang Automatik. Aber das ist kein Grund, Trübsal zu blasen, mit 81 kW (110 PS) kommt man durchaus zügig voran. Der 1,2 Liter Dreizylinder beschleunigt den Wagen in 11,8 Sekunden auf Tempo 100 und garantiert eine Spitze von 183 km/h. Mit 5,5 Liter bleifreiem Benzin kommt er im kombinierten Verbrauch 100 Kilometer weit, das entspricht einem CO2-Ausstoß von 124 g/km. Die Kosten!Der Blick auf die Preisliste des Citroën C3 Aircross wird Ihnen keinen erhöhten Blutdruck verschaffen. Es geht bei 15.290,-- Euro los und endet bei 23.540,-- Euro. Wer mit dem PureTech 110 Stop&Start mit dem 6-Gang Automatik-Getriebe EAT6 und 81  kW(110 PS) liebäugelt, muss alternativ 20.440,– Euro für die Ausstattungslinie Feel auf den Tisch des Citroën-Händlers legen, 22.840,– Euro sind es beim Shine. Das sind absolut ordentliche Preise. Alle Fotos :  © Citroën Kommunikation  Diesen Beitrag können Sie nachhören oder downloaden unter:

Today in FirstWord:

Listen to Andrew chat with Alan about his experience with the Peugeot 5008. He will discuss how impressed he was with the car and how it was much better than he was expecting.

Akili Interactive – a start-up growing out of the PureTech Health group – may pick up where pharmaceuticals have left off in developing new treatments for behavioral health disorders.

Te presentamos el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Luis Mazarracin, Alejandro Arostegui, Juan Ávila, Iván Vicario director de Clásicos Populares y Patxi del Periodico ABC. Como invitados especiales: Gabriel López Ruiz. Director de desarrollo de Negocios y Marketing de Total España. Pedro Beamud, Director de operaciones de Total España Intentando dirigir a estos locos en el programa del motor más divertido de las ondas, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Se presenta de manera oficial el nuevo Citroën C3 WRC • El grupo PSA ha incrementado en 2016 su producción española en un 2,6% • Nuevo BMW 530e iPerformance, el nuevo sedán híbrido enchufable • Arranca la venta del renovado Volkswagen Golf • El Kia Niro de costa a costa de Estados Unidos con un consumo de 3,07 l/100km • Ya funciona ‘EMOV’ en Madrid, el nuevo servicio de car sharing de la mano de PSA • EuroNCAP hace una lista de los coches más seguros de 2016 y nosotros lo analizamos • Los próximos Nissan Leaf y Renault Zoe utilizarán la mima plataforma En el buzón del oyente nos solicita asesoramiento Agustín Hernández desde Segovia ante la compra de un vehículo nuevo. En esta ocasión nuestro oyente nos pregunta sobre el Citroën C4 Cactus Rip Curl 1.2 Puretech de 120 CV. Nosotros la guiamos ante esta importante decisión y le acercamos nuestra opinión sobre este automóvil. Realizamos un especial sobre el aceite Total. Acercamos la importancia de un buen aceite en el motor del automóvil y descubrimos muchas características de este gran desconocido del coche. El aceite es la sangre del motor y es muy importante su función. Esta semana hemos probado uno de esos coches de ensueño, uno de esos vehículos que todos quisiéramos tener en nuestro garaje. El renovado Nissan GT-R 2017. Un superdeportivo de 570 CV y dos turbos que nos ha dejado con la boca abierta. Es un vehículo adictivo que solo te pide más vueltas en el circuito y notar su impecable comportamiento en curvas lentas y rápidas. Terminamos el programa repasando los titulares más importantes de la Fórmula 1.

Te presentamos el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Luis Mazarracin, Alejandro Arostegui, Juan Ávila, Iván Vicario director de Clásicos Populares y Patxi del Periodico ABC. Como invitados especiales: Gabriel López Ruiz. Director de desarrollo de Negocios y Marketing de Total España. Pedro Beamud, Director de operaciones de Total España Intentando dirigir a estos locos en el programa del motor más divertido de las ondas, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Se presenta de manera oficial el nuevo Citroën C3 WRC • El grupo PSA ha incrementado en 2016 su producción española en un 2,6% • Nuevo BMW 530e iPerformance, el nuevo sedán híbrido enchufable • Arranca la venta del renovado Volkswagen Golf • El Kia Niro de costa a costa de Estados Unidos con un consumo de 3,07 l/100km • Ya funciona ‘EMOV’ en Madrid, el nuevo servicio de car sharing de la mano de PSA • EuroNCAP hace una lista de los coches más seguros de 2016 y nosotros lo analizamos • Los próximos Nissan Leaf y Renault Zoe utilizarán la mima plataforma En el buzón del oyente nos solicita asesoramiento Agustín Hernández desde Segovia ante la compra de un vehículo nuevo. En esta ocasión nuestro oyente nos pregunta sobre el Citroën C4 Cactus Rip Curl 1.2 Puretech de 120 CV. Nosotros la guiamos ante esta importante decisión y le acercamos nuestra opinión sobre este automóvil. Realizamos un especial sobre el aceite Total. Acercamos la importancia de un buen aceite en el motor del automóvil y descubrimos muchas características de este gran desconocido del coche. El aceite es la sangre del motor y es muy importante su función. Esta semana hemos probado uno de esos coches de ensueño, uno de esos vehículos que todos quisiéramos tener en nuestro garaje. El renovado Nissan GT-R 2017. Un superdeportivo de 570 CV y dos turbos que nos ha dejado con la boca abierta. Es un vehículo adictivo que solo te pide más vueltas en el circuito y notar su impecable comportamiento en curvas lentas y rápidas. Terminamos el programa repasando los titulares más importantes de la Fórmula 1.

PureTech historically has focused on creating new biotech and medical device technologies. CEO and founder Daphne Zohar explains PureTech’s move into digital therapeutics, including companies that use sound and games to promote good health.

Te presentamos el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Luis Mazarracin, Juan Ávila y Alejandro Arostegui. En esta edición hemos tratado las siguientes noticias del motor: • Ford Focus y Fiesta ST-Line, los compactos estrenan acabado deportivo • Los coches anteriores a 1997 no podrán circular en París • Volkswagen Beetle Dune, en España desde 25.200 euros • Premios al motor del año 2016: Ferrari se lleva la palma • El mercado español de turismos crece en mayo un 20,9% • BMW Serie 3 Gran Turismo 2016, llega el restyling • El Citroën C4 Cactus Rip Curl ya disponible desde 20.350 euros • Opel Zafira 2016, renovación estética y más tecnología para el monovolumen • Volvo no tendrá modelos por debajo de la nueva Serie 40 • Suzuki trabaja en un Swift Sport totalmente nuevo, con motor turbo y una estética más moderna • SsangYong XLV: El monovolumen con tintes de crossover En el buzón del oyente Lourdes desde Salamanca nos solicita asesoramiento ante la compra de un vehículo nuevo. En esta ocasión nuestro oyente nos pregunta sobre el Citroën C4 Picasso con motor gasolina Puretech de 130 CV. Nosotros le guiamos ante esta importante decisión y le acercamos nuestra opinión sobre estos automóviles. La prueba de la semana la ha protagonizado el Mercedes-Benz Clase C Coupé 220d. Un ejemplo de la evolución técnica y de diseño que está sufriendo la marca de la estrella. Un modelo que nos ha gustado tanto por su comportamiento, refinamiento y su diseño.

Te presentamos el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Luis Mazarracin, Juan Ávila y Alejandro Arostegui. En esta edición hemos tratado las siguientes noticias del motor: • Ford Focus y Fiesta ST-Line, los compactos estrenan acabado deportivo • Los coches anteriores a 1997 no podrán circular en París • Volkswagen Beetle Dune, en España desde 25.200 euros • Premios al motor del año 2016: Ferrari se lleva la palma • El mercado español de turismos crece en mayo un 20,9% • BMW Serie 3 Gran Turismo 2016, llega el restyling • El Citroën C4 Cactus Rip Curl ya disponible desde 20.350 euros • Opel Zafira 2016, renovación estética y más tecnología para el monovolumen • Volvo no tendrá modelos por debajo de la nueva Serie 40 • Suzuki trabaja en un Swift Sport totalmente nuevo, con motor turbo y una estética más moderna • SsangYong XLV: El monovolumen con tintes de crossover En el buzón del oyente Lourdes desde Salamanca nos solicita asesoramiento ante la compra de un vehículo nuevo. En esta ocasión nuestro oyente nos pregunta sobre el Citroën C4 Picasso con motor gasolina Puretech de 130 CV. Nosotros le guiamos ante esta importante decisión y le acercamos nuestra opinión sobre estos automóviles. La prueba de la semana la ha protagonizado el Mercedes-Benz Clase C Coupé 220d. Un ejemplo de la evolución técnica y de diseño que está sufriendo la marca de la estrella. Un modelo que nos ha gustado tanto por su comportamiento, refinamiento y su diseño.

Aquí tienes el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Luis Mazarracin, Juan Ávila, Pabo García y Alejandro Arostegui. Como invitado especial nos acompaña José Antonio León, Director de Comunicación del grupo PSA en España. Intentando dirigir a estos “profesionales” de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor:7 • El ‘copiloto invisible’ de Toyota tomará el control del volante en caso de peligro de accidente • Nuevo Mitsubishi Space Star 2016 • Los BMW M5 y M6 dicen adiós al cambio manual • Nuevos DS3 y DS3 Cabrio Puretech 130 S&S: más dinamismo y conectividad • Audi A3 2016, llega el restyling del compacto premium • BMW M4 CS: 60 unidades solamente para España • Nuevo Volkswagen Tiguan: a la venta desde 29.560 euros En el buzón del oyente nos solicita ayuda Gabriel desde Guadalajara. Nos pide consejo ante su inminente compra de un Citroën C4 Cactus gasolina PureTech 110 S&S.El equipo de AutoFM le guía y le aconseja sobre esta futura compra. La prueba de la semana la ha protagonizado el nuevo Mazda CX-5 con motor diésel SKYACTIV-D 2.2 de 175 CV. Nos ponemos al volante de uno de los SUV mejor valorados del momento, Lanzado al mercado en 2012, el Mazda CX5 se impuso rápidamente como uno de los mejores SUV compactos del mercado. En AutoFM hemos comprobado porque es el Mazda más vendido en Europa y te contamos todos los secretos de este SUV compacto. Realizamos un especial sobre el grupo PSA, Citroën, Peugeot y DS. Repasamos las novedades más importantes del grupo y de sus tres marcas. Desde el desenfadado Citroën C4 Cactus hasta el lujoso DS5. Pasando por las últimas informaciones sobre el futuro del grupo y de sus ambiciosos proyectos. Para finalizar Juan nos acerca el nuevo proyecto de Teo Martin Motorsport.

Aquí tienes el programa de radio del motor más descargado donde analizamos de una manera amena y divertida las últimas noticias del motor. Este programa del motor es emitido en directo a través de COPE Madrid Sur y COPE Jarama. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Luis Mazarracin, Juan Ávila, Pabo García y Alejandro Arostegui. Como invitado especial nos acompaña José Antonio León, Director de Comunicación del grupo PSA en España. Intentando dirigir a estos “profesionales” de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor:7 • El ‘copiloto invisible’ de Toyota tomará el control del volante en caso de peligro de accidente • Nuevo Mitsubishi Space Star 2016 • Los BMW M5 y M6 dicen adiós al cambio manual • Nuevos DS3 y DS3 Cabrio Puretech 130 S&S: más dinamismo y conectividad • Audi A3 2016, llega el restyling del compacto premium • BMW M4 CS: 60 unidades solamente para España • Nuevo Volkswagen Tiguan: a la venta desde 29.560 euros En el buzón del oyente nos solicita ayuda Gabriel desde Guadalajara. Nos pide consejo ante su inminente compra de un Citroën C4 Cactus gasolina PureTech 110 S&S.El equipo de AutoFM le guía y le aconseja sobre esta futura compra. La prueba de la semana la ha protagonizado el nuevo Mazda CX-5 con motor diésel SKYACTIV-D 2.2 de 175 CV. Nos ponemos al volante de uno de los SUV mejor valorados del momento, Lanzado al mercado en 2012, el Mazda CX5 se impuso rápidamente como uno de los mejores SUV compactos del mercado. En AutoFM hemos comprobado porque es el Mazda más vendido en Europa y te contamos todos los secretos de este SUV compacto. Realizamos un especial sobre el grupo PSA, Citroën, Peugeot y DS. Repasamos las novedades más importantes del grupo y de sus tres marcas. Desde el desenfadado Citroën C4 Cactus hasta el lujoso DS5. Pasando por las últimas informaciones sobre el futuro del grupo y de sus ambiciosos proyectos. Para finalizar Juan nos acerca el nuevo proyecto de Teo Martin Motorsport.

Aquí tienes el primer magazine del automóvil emitido en la radio, donde analizamos de una manera amena las últimas noticias del motor. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Juan Ávila, Luis Mazarracin, Alejandro Arostegui, y por teléfono a Guillermo Alfonsín. Intentando dirigir a estos “locos” de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Analizamos el renovado Kia Cee´d • La marca sueca Volvo quiere más híbridos enchufables y un eléctrico 100% para 2019 • Porsche marca un doblete en las 6 horas de Fuji • Mazda patrocinará LaLiga 2015-2016 y aportará sus coches como vehículos oficiales • Analizamos el nuevo BMW M2 con 370 CV • Analizamos el nuevo Mercedes GLE 450 AMG • A subasta por 700.000 euros los dos Ferrari regalados al Rey Juan Carlos I • El Peugeot 2008 ahora con motor gasolina PureTech de 110 CV y cambio automático • El Nuevo Toyota RAV4, precios para España desde 24.300 euros • Nos ponemos al día de todo lo que está sucediendo con la actualidad del DieselGate En el buzón del oyente nos ha escrito Juanjo y nos pide consejo para la compra de su nuevo vehículo, esta entre tres modelos: El Seat Leon SC FR 1.8 de 180 CV TSI, el Ford Focus 1.5 EcoBoost de 182 CV y el Nissan Pulsar 1.6 de 190 CV DIG-T. Le ayudamos y le asesoramos ante esta futura compra. En la prueba de la semana el protagonista ha sido el innovador Lexus NX300h. Un modelo que nos ha dejado con muy buen sabor de boca. Sabe explotar muy bien sus cartas: Es silencioso, un diseño que no deja indiferente, buen comportamiento y gran calidad de materiales. Un SUV diferentes, distinto que mira de tú a tú a los modelos Premium alemanes como el BMW X3 o el Audi Q3. Pero el Lexus dispone de una tecnología híbrida avanzada que nos sorprenderá por su sencillez en el uso y su resultado. Para finalizar Juan Ávila nos acerca las últimas noticias de la Fórmula 1.

Aquí tienes el primer magazine del automóvil emitido en la radio, donde analizamos de una manera amena las últimas noticias del motor. Esta semana hemos tenido en el estudio a: Eduardo Lausín, Juan Ávila, Luis Mazarracin, Alejandro Arostegui, y por teléfono a Guillermo Alfonsín. Intentando dirigir a estos “locos” de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Analizamos el renovado Kia Cee´d • La marca sueca Volvo quiere más híbridos enchufables y un eléctrico 100% para 2019 • Porsche marca un doblete en las 6 horas de Fuji • Mazda patrocinará LaLiga 2015-2016 y aportará sus coches como vehículos oficiales • Analizamos el nuevo BMW M2 con 370 CV • Analizamos el nuevo Mercedes GLE 450 AMG • A subasta por 700.000 euros los dos Ferrari regalados al Rey Juan Carlos I • El Peugeot 2008 ahora con motor gasolina PureTech de 110 CV y cambio automático • El Nuevo Toyota RAV4, precios para España desde 24.300 euros • Nos ponemos al día de todo lo que está sucediendo con la actualidad del DieselGate En el buzón del oyente nos ha escrito Juanjo y nos pide consejo para la compra de su nuevo vehículo, esta entre tres modelos: El Seat Leon SC FR 1.8 de 180 CV TSI, el Ford Focus 1.5 EcoBoost de 182 CV y el Nissan Pulsar 1.6 de 190 CV DIG-T. Le ayudamos y le asesoramos ante esta futura compra. En la prueba de la semana el protagonista ha sido el innovador Lexus NX300h. Un modelo que nos ha dejado con muy buen sabor de boca. Sabe explotar muy bien sus cartas: Es silencioso, un diseño que no deja indiferente, buen comportamiento y gran calidad de materiales. Un SUV diferentes, distinto que mira de tú a tú a los modelos Premium alemanes como el BMW X3 o el Audi Q3. Pero el Lexus dispone de una tecnología híbrida avanzada que nos sorprenderá por su sencillez en el uso y su resultado. Para finalizar Juan Ávila nos acerca las últimas noticias de la Fórmula 1.

¿Quién decía que hablar de coches era aburrido? Aquí tienes el primer magazine del automóvil emitido en la radio, donde analizamos de una manera amena las últimas noticias del motor. Esta semana hemos tenido en el estudio a: Juan Ávila, Luis Mazarracin y por teléfono a Guillermo Alfonsín. Intentando dirigir a estos "locos" de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Renovación para el Citroën C5 • Renault presenta el Talisman, el sustituto del Laguna • Volkswagen confirma dos nuevos SUV, uno más pequeño que el Tiguan y otro más grande • El Hyundai i30 N estaría ya trabajando en Nürburgring • Conocemos todos los secretos del renovado Fiat 500 • Concentración nacional de Ford, Ford Fans Only, en el Circuito del Jarama En el "Buzón del Oyente" nos ha escrito un correo electrónico Pedro García y nos pido la opinión del nuevo Peugeot 308 y de su motor tricilíndrico 1.3 Puretech. Nosotros le resolvemos sus dudas y le guiamos en su posible compra de un vehículo nuevo. Esta semana el protagonista de nuestra prueba semanal ha sido el Range Rover Evoque DS4 de 190 CV. Un ejemplo de cómo se puede revolucionar el mercado con diseño y calidad. El evoque ha revolucionado una de las marcas que no hace mucho era muy “tradicional” y gracias a este modelo se ha abierto a un público hasta la fecha inexplorado por la marca inglesa. El Evoque ha sido un éxito de ventas y su fórmula es sencilla. Conseguir un diseño revolucionado donde juntan destellos de deportividad, solidez y todoterreno. Justo, lo que hoy en día el mercado pide. Y si a todo esto le añadimos el halo de exclusividad que tiene un Range Rover nos sale un vehículo perfecto para distinguirse. En la sección de Motorsport, Juan Ávila nos acerca la actualidad de la F1. Resumiendo, un programa que no debes perderte. Esperamos que te guste.

¿Quién decía que hablar de coches era aburrido? Aquí tienes el primer magazine del automóvil emitido en la radio, donde analizamos de una manera amena las últimas noticias del motor. Esta semana hemos tenido en el estudio a: Juan Ávila, Luis Mazarracin y por teléfono a Guillermo Alfonsín. Intentando dirigir a estos "locos" de la comunicación del motor, Antonio R. Vaquerizo. En esta edición hemos tratado las siguientes noticias del motor: • Renovación para el Citroën C5 • Renault presenta el Talisman, el sustituto del Laguna • Volkswagen confirma dos nuevos SUV, uno más pequeño que el Tiguan y otro más grande • El Hyundai i30 N estaría ya trabajando en Nürburgring • Conocemos todos los secretos del renovado Fiat 500 • Concentración nacional de Ford, Ford Fans Only, en el Circuito del Jarama En el "Buzón del Oyente" nos ha escrito un correo electrónico Pedro García y nos pido la opinión del nuevo Peugeot 308 y de su motor tricilíndrico 1.3 Puretech. Nosotros le resolvemos sus dudas y le guiamos en su posible compra de un vehículo nuevo. Esta semana el protagonista de nuestra prueba semanal ha sido el Range Rover Evoque DS4 de 190 CV. Un ejemplo de cómo se puede revolucionar el mercado con diseño y calidad. El evoque ha revolucionado una de las marcas que no hace mucho era muy “tradicional” y gracias a este modelo se ha abierto a un público hasta la fecha inexplorado por la marca inglesa. El Evoque ha sido un éxito de ventas y su fórmula es sencilla. Conseguir un diseño revolucionado donde juntan destellos de deportividad, solidez y todoterreno. Justo, lo que hoy en día el mercado pide. Y si a todo esto le añadimos el halo de exclusividad que tiene un Range Rover nos sale un vehículo perfecto para distinguirse. En la sección de Motorsport, Juan Ávila nos acerca la actualidad de la F1. Resumiendo, un programa que no debes perderte. Esperamos que te guste.

Una semana más, regresa el mejor programa de motor de la radio española. Nos acompaña en el estudio Juan López Frade, Director General y Comercial de Suzuki Ibérica, con quien repasamos el #CERA y probamos el nuevo #Vitara. Charlamos con los pilotos oficiales Suzuki, Joan Vinyes, Gorka Antxustegi y Santi Cañizares, analizamos el GP de Australia de F1 y la categoría en general con Joan Villadelprat, probamos el Ford Focus Ecoboost y el Peugeot 308 Puretech. Y repasamos con Juanma Fernández Pellón la portada de AutoHebdo. Nadie da tanto en 90 minutos. Dirigido y presentado por Ramón Biosca. En Gestiona Radio.